<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005415.pub3" GROUP_ID="UPPERGI" ID="564104091011344814" MERGED_FROM="" MODIFIED="2012-02-13 15:51:52 +0100" MODIFIED_BY="Karin Dearness" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.7&lt;/p&gt;&lt;p&gt;Old title: Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in unselected upper gastrointestinal bleeding&lt;/p&gt;" NOTES_MODIFIED="2010-06-02 15:12:52 -0400" NOTES_MODIFIED_BY="Karin L Dearness" REVIEW_NO="35" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2012-02-13 15:51:52 +0100" MODIFIED_BY="Karin Dearness">
<TITLE>Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding</TITLE>
<CONTACT MODIFIED="2012-02-13 15:51:52 +0100" MODIFIED_BY="Karin Dearness"><PERSON ID="19853" ROLE="AUTHOR"><FIRST_NAME>Aravamuthan</FIRST_NAME><LAST_NAME>Sreedharan</LAST_NAME><POSITION>Consultant Gastroenterologist</POSITION><EMAIL_1>Sree6sree@aol.com</EMAIL_1><EMAIL_2>Aravamuthan.Sreedharan@ulh.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Gastroenterology</DEPARTMENT><ORGANISATION>United Lincolnshire Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Lincoln County Hospital</ADDRESS_1><ADDRESS_2>Greetwell Road</ADDRESS_2><CITY>Lincoln</CITY><ZIP>LN2 2YE</ZIP><REGION>Lincolnshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1522 573416</PHONE_1><PHONE_2>+44 1522 573304</PHONE_2><FAX_1>+44 1522 573304</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-02-13 15:51:52 +0100" MODIFIED_BY="Karin Dearness"><PERSON ID="19853" ROLE="AUTHOR"><FIRST_NAME>Aravamuthan</FIRST_NAME><LAST_NAME>Sreedharan</LAST_NAME><POSITION>Consultant Gastroenterologist</POSITION><EMAIL_1>Sree6sree@aol.com</EMAIL_1><EMAIL_2>Aravamuthan.Sreedharan@ulh.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Gastroenterology</DEPARTMENT><ORGANISATION>United Lincolnshire Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Lincoln County Hospital</ADDRESS_1><ADDRESS_2>Greetwell Road</ADDRESS_2><CITY>Lincoln</CITY><ZIP>LN2 2YE</ZIP><REGION>Lincolnshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1522 573416</PHONE_1><PHONE_2>+44 1522 573304</PHONE_2><FAX_1>+44 1522 573304</FAX_1></ADDRESS></PERSON><PERSON ID="B67853EC82E26AA2005347C32B46F44C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Janet</FIRST_NAME><LAST_NAME>Martin</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>janet.martin@lhsc.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>Departments of Pharmacy, Medicine and Anesthesia &amp; Perioperative Medicine</DEPARTMENT><ORGANISATION>London Health Sciences Centre, University of Western Ontario</ORGANISATION><ADDRESS_1>Room C1-202</ADDRESS_1><ADDRESS_2>339 Windermere Road</ADDRESS_2><CITY>London</CITY><ZIP>N6A 5A5</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 519 6858500</PHONE_1><FAX_1>+1 519 6632968</FAX_1></ADDRESS></PERSON><PERSON ID="16685" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Grigorios</FIRST_NAME><MIDDLE_INITIALS>I</MIDDLE_INITIALS><LAST_NAME>Leontiadis</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>leontia@mcmaster.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine, Division of Gastroenterology</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1200 Main Street West</ADDRESS_1><ADDRESS_2>HSC 4W8B</ADDRESS_2><CITY>Hamilton</CITY><ZIP>L8N 3Z5</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 521 2100 ext 76762</PHONE_1><FAX_1>+1 905 521 4958</FAX_1></ADDRESS></PERSON><PERSON ID="63C2202382E26AA200991D5629B5ADB0" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Stephanie</FIRST_NAME><LAST_NAME>Dorward</LAST_NAME><POSITION>Clinical Research Associate</POSITION><EMAIL_1>sdorward@medvance.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>Medivance Ltd</DEPARTMENT><ORGANISATION>Medivance House</ORGANISATION><ADDRESS_1>Burn Grange, Doncaster Road</ADDRESS_1><CITY>York</CITY><ZIP>YO8 8LA</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="16669" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Colin</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Howden</LAST_NAME><POSITION>Professor of Medicine</POSITION><EMAIL_1>c-howden@northwestern.edu</EMAIL_1><ADDRESS><DEPARTMENT>Division of Gastroenterology</DEPARTMENT><ORGANISATION>Northwestern University Feinberg Medical School</ORGANISATION><ADDRESS_1>Suite 1400</ADDRESS_1><ADDRESS_2>676 N. St. Clair Avenue</ADDRESS_2><CITY>Chicago</CITY><ZIP>IL 60611</ZIP><REGION>Illinois</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 312 695 4018</PHONE_1><FAX_1>+1 312 695 3999</FAX_1></ADDRESS></PERSON><PERSON ID="7466" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Forman</LAST_NAME><EMAIL_1>formand@iarc.fr</EMAIL_1><ADDRESS><ORGANISATION>International Agency for Research on Cancer</ORGANISATION><ADDRESS_1>150 cours Albert-Thomas</ADDRESS_1><CITY>Lyon</CITY><ZIP>69372</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 4 7273 8056</PHONE_1><FAX_1>+33 4 7273 8696</FAX_1></ADDRESS></PERSON><PERSON ID="16692" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Paul</FIRST_NAME><LAST_NAME>Moayyedi</LAST_NAME><POSITION>Professor of Gastroenterology</POSITION><EMAIL_1>moayyep@mcmaster.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine, Division of Gastroenterology</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1200 Main Street West</ADDRESS_1><ADDRESS_2>Room 4W8E</ADDRESS_2><CITY>Hamilton</CITY><ZIP>L8N 3Z5</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 525 9140 Ext: 26688</PHONE_1><FAX_1>+1 905 522 3454</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-02-13 15:51:52 +0100" MODIFIED_BY="Karin Dearness">
<UP_TO_DATE>
<DATE DAY="28" MONTH="10" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="10" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="2" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2012-02-13 15:51:52 +0100" MODIFIED_BY="Karin Dearness"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-02-13 15:51:52 +0100" MODIFIED_BY="Karin Dearness"><DATE DAY="13" MONTH="2" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2012-02-13 15:51:52 +0100" MODIFIED_BY="Karin Dearness"><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-02-13 15:51:52 +0100" MODIFIED_BY="Karin Dearness">
<DATE DAY="2" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>The review is being republished to correct the citation version.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-06-02 15:08:46 -0400" MODIFIED_BY="Karin L Dearness">
<DATE DAY="28" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-28 07:44:37 -0400" MODIFIED_BY="Cathy Bennett">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-28 07:44:37 -0400" MODIFIED_BY="Cathy Bennett">
<DATE DAY="17" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>New studies sought but none found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-28 07:44:37 -0400" MODIFIED_BY="Cathy Bennett">
<DATE DAY="18" MONTH="6" YEAR="2006"/>
<DESCRIPTION>
<P>Minor update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-28 07:44:37 -0400" MODIFIED_BY="Cathy Bennett">
<DATE DAY="7" MONTH="1" YEAR="2005"/>
<DESCRIPTION>
<P>New studies found and included or excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-08-03 19:26:42 -0400" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-08-03 19:26:42 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This internal support was available for the original review period in 2004-2005&lt;/p&gt;" NOTES_MODIFIED="2009-08-03 19:26:42 -0400" NOTES_MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-08-03 19:26:01 -0400" MODIFIED_BY="[Empty name]">
<NAME>University of Leeds</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-08-03 19:24:52 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The support from NHS R&amp;amp;D HTA was available for the initial review.&lt;/p&gt;" NOTES_MODIFIED="2009-08-03 19:24:52 -0400" NOTES_MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>NHS R &amp; D Health Technology Assessment Programme (Project 03/12/03)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-11-10 09:40:33 -0500" MODIFIED_BY="Jan Lilleyman">
<SUMMARY MODIFIED="2009-10-28 07:50:21 -0400" MODIFIED_BY="Cathy Bennett">
<TITLE MODIFIED="2009-10-28 07:49:52 -0400" MODIFIED_BY="Cathy Bennett">Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding</TITLE>
<SUMMARY_BODY MODIFIED="2009-10-28 07:50:21 -0400" MODIFIED_BY="Cathy Bennett">
<P>Bleeding from lesions in the oesophagus, stomach or duodenum is a common medical emergency. Research has suggested that reducing the amount of acid in the stomach may help to control the bleeding, but it is unknown if early initiation of such treatment (that is, before endoscopic diagnosis) is beneficial for patients.</P>
<P>This review compared the effect of one type of anti-acid drug (proton pump inhibitor) with either no treatment (placebo) or with another type of anti-acid drug (an Histamine-2 receptor antagonist) initiated prior to endoscopic diagnosis. Taking proton pump inhibitors 24 to 48 hours before endoscopy significantly reduced the proportion of patients with findings of recent serious bleeding on endoscopic examination and the need for treatment during endoscopy such as injecting medicines or cauterising blood vessels to stop bleeding. However, overall there was no effect of taking a proton pump inhibitor on further bleeding, need for surgery or risk of death.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-11-10 09:40:33 -0500" MODIFIED_BY="Jan Lilleyman">
<ABS_BACKGROUND MODIFIED="2009-11-10 09:38:17 -0500" MODIFIED_BY="Jan Lilleyman">
<P>There is conflicting evidence regarding the clinical efficacy of proton pump inhibitors (PPI) initiated before endoscopy for upper gastrointestinal bleeding.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-11-10 09:38:36 -0500" MODIFIED_BY="Jan Lilleyman">
<P>To systematically review evidence from randomised controlled trials (RCTs) of PPI treatment initiated before endoscopy for upper gastrointestinal bleeding.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-11-10 09:39:05 -0500" MODIFIED_BY="Jan Lilleyman">
<P>We searched CENTRAL (<I>The Cochrane Library</I>), MEDLINE, EMBASE and CINAHL databases and major conference proceedings to September 2005, using the Cochrane Upper Gastrointestinal and Pancreatic Diseases model. Searches were re-run in February 2006 and October 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-11-10 09:39:19 -0500" MODIFIED_BY="Jan Lilleyman">
<P>We selected randomised controlled trials (RCTs), of hospitalised participants with unselected upper gastrointestinal bleeding, undergoing active treatment with a proton pump inhibitor PPI (oral or intravenous) and control treatment with either placebo, histamine-2 receptor antagonist (H2RA) or no treatment prior to endoscopy. Outcomes were assessed at 30 days and included mortality, rebleeding and surgery. Also assessed were stigmata of recent haemorrhage (SRH; active bleeding, non bleeding visible vessel or adherent clot) at index endoscopy, length of hospital stay, blood transfusion requirements and requirement for endoscopic therapy at index endoscopy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-11-10 09:35:17 -0500" MODIFIED_BY="Jan Lilleyman">
<P>At least two review authors assessed eligibility criteria and extracted data regarding outcomes and factors affecting methodological quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-11-10 09:36:22 -0500" MODIFIED_BY="Jan Lilleyman">
<P>Six RCTs comprising 2223 participants were included. There was no statistical heterogeneity among trials for dichotomous outcomes. There were no statistically significant differences in mortality, rebleeding or surgery between PPI and control treatment. Unweighted pooled mortality rates were 6.1% and 5.5% respectively (odds ratio (OR)1.12; 95% CI 0.72 to 1.73). Unweighted pooled rebleeding rates were 13.9% and 16.6% respectively (OR 0.81; 95%CI 0.61 to 1.09). Pooled rates for surgery were 9.9% and 10.2% respectively (OR 0.96 95% CI 0.68 to 1.35). PPI treatment compared to control significantly reduced the proportion of participants with SRH at index endoscopy; unweighted pooled rates were 37.2% and 46.5% respectively (OR 0.67; 95% CI 0.54 to 0.84). However, this result was not robust to sensitivity analysis. PPI treatment compared to control significantly reduced endoscopic therapy at index endoscopy; unweighted pooled rates were 8.6% and 11.7% respectively (OR 0.68; 95% CI 0.50 to 0.93). For continuous outcomes (length of hospital stay and blood transfusion requirements), quantitative analysis could not be performed.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-11-10 09:40:33 -0500" MODIFIED_BY="Jan Lilleyman">
<P>PPI treatment initiated before endoscopy for upper gastrointestinal bleeding might reduce the proportion of participants with SRH at index endoscopy and significantly reduces requirement for endoscopic therapy during index endoscopy. However, there is no evidence that PPI treatment affects clinically important outcomes, namely mortality, rebleeding or need for surgery.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-11-10 09:02:38 -0500" MODIFIED_BY="Jan Lilleyman">
<BACKGROUND MODIFIED="2009-11-10 07:47:46 -0500" MODIFIED_BY="Jan Lilleyman">
<CONDITION MODIFIED="2009-10-28 07:56:56 -0400" MODIFIED_BY="Cathy Bennett">
<P>Upper gastrointestinal haemorrhage remains the most common reason for emergency hospital admission with a gastrointestinal problem and is a major cause of morbidity, mortality and medical care costs (<LINK REF="REF-Gilbert-1990" TYPE="REFERENCE">Gilbert 1990</LINK>; <LINK REF="REF-Longstreth-1997" TYPE="REFERENCE">Longstreth 1997</LINK>). Peptic ulcer is the most frequent source of acute upper gastrointestinal haemorrhage, accounting for around 50% of all cases (<LINK REF="REF-Laine-1994" TYPE="REFERENCE">Laine 1994</LINK>; <LINK REF="REF-Silverstein-1981" TYPE="REFERENCE">Silverstein 1981</LINK>). The prevalence of upper gastrointestinal haemorrhage is reported to be approximately 170 per 100,000 adults per year (<LINK REF="REF-Blatchford--1997" TYPE="REFERENCE">Blatchford 1997</LINK>), with a total estimated cost of $750 million in the United States (<LINK REF="REF-Jiranek-1996" TYPE="REFERENCE">Jiranek 1996</LINK>) and a substantial utilisation of resources and costs for each hospitalisation (<LINK REF="REF-Gralnek-1998" TYPE="REFERENCE">Gralnek 1998</LINK>; <LINK REF="REF-Gralnek-1997" TYPE="REFERENCE">Gralnek 1997</LINK>; <LINK REF="REF-Lee-1999" TYPE="REFERENCE">Lee 1999</LINK>; <LINK REF="REF-Longstreth-1995" TYPE="REFERENCE">Longstreth 1995</LINK>).</P>
<P>The mortality rates due to upper gastrointestinal haemorrhage have remained unchanged despite enormous advances in endoscopic and pharmacotherapy over the last 30 years. Epidemiological studies have shown a decrease in the incidence of peptic ulcer related upper gastrointestinal haemorrhage but without a significant decrease in rebleeding or mortality rates in recent years. This could be explained by the increased incidence in patients with advanced age, significant co-morbid illness and the increasing use of non-steroidal anti-inflammatory drugs (<LINK REF="REF-van-Leerdam-2003" TYPE="REFERENCE">van Leerdam 2003</LINK>; <LINK REF="REF-Higham-2002" TYPE="REFERENCE">Higham 2002</LINK>; <LINK REF="REF-Paimela-2002" TYPE="REFERENCE">Paimela 2002</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-10-28 07:50:59 -0400" MODIFIED_BY="Cathy Bennett">
<P>Current management of bleeding ulcers includes fluid replacement, drug therapy with acid inhibitors, early endoscopic haemostasis and surgery. The cessation of bleeding from a peptic ulcer is inhibited by gastric acid by two mechanisms: firstly, inhibition of clot formation and promotion of clot lysis; and secondly, by ongoing tissue damage (<LINK REF="REF-Kolkman-1996" TYPE="REFERENCE">Kolkman 1996</LINK>). Drug therapy aimed at inhibition of gastric acid secretion increases gastric pH, facilitates clot formation, stabilises the clot and perhaps hastens the healing of lesions (<LINK REF="REF-Barkun-2006" TYPE="REFERENCE">Barkun 2006</LINK>). This is based on data from in vitro studies that observed that an increase in pH &gt; 6 would be required to inactivate pepsin and inhibit fibrinolysis (<LINK REF="REF-Green-1978" TYPE="REFERENCE">Green 1978</LINK>; <LINK REF="REF-Low-1980" TYPE="REFERENCE">Low 1980</LINK>). An open label randomised controlled trial (<LINK REF="STD-Brunner-1990" TYPE="STUDY">Brunner 1990</LINK>) comparing omeprazole with ranitidine in critically ill patients with bleeding ulcers (Forest 1b) reported that significantly more patients stopped bleeding after omeprazole (84%) compared to ranitidine (15%).</P>
</INTERVENTION>
<THEORY MODIFIED="2009-11-10 07:47:46 -0500" MODIFIED_BY="Jan Lilleyman">
<P>A number of meta-analyses have assessed RCTs that studied the clinical effectiveness of PPI treatment in acute upper gastrointestinal bleeding (<LINK REF="REF-Khuroo-2005" TYPE="REFERENCE">Khuroo 2005</LINK>) and in acute peptic ulcer bleeding (<LINK REF="REF-Andriulli-2005" TYPE="REFERENCE">Andriulli 2005</LINK>; <LINK REF="REF-Bardou-2005" TYPE="REFERENCE">Bardou 2005</LINK>; <LINK REF="REF-Khuroo-2005" TYPE="REFERENCE">Khuroo 2005</LINK>; <LINK REF="REF-Leontiadis-2005" TYPE="REFERENCE">Leontiadis 2005</LINK> ). These did not analyse RCTs that studied the clinical effectiveness of proton pump inhibitor (PPI) treatment initiated prior to endoscopy.<BR/>
<BR/>Evidence from recent cost-effectiveness studies suggests that PPI treatment after endoscopic haemostatic therapy reduces rebleeding rates and the requirement for surgery in patients with peptic ulcer haemorrhage (<LINK REF="REF-Barkun-2004" TYPE="REFERENCE">Barkun 2004</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="REF-Spiegel-2003" TYPE="REFERENCE">Spiegel 2003</LINK>). Guidelines on management of non variceal upper gastrointestinal bleeding from the British Society of Gastroenterology and, more recently, from ICON-UGIB multi-society consensus group, recommend the use of high dose intravenous PPI in peptic ulcer bleeding with high risk stigmata on endoscopy (<LINK REF="REF-Barkun-2003" TYPE="REFERENCE">Barkun 2003</LINK>; <LINK REF="REF-Barkun-2010" TYPE="REFERENCE">Barkun 2010</LINK>; <LINK REF="REF-Palmer--2002" TYPE="REFERENCE">Palmer 2002</LINK>).</P>
<P>Empirical acid suppression treatment using PPI or an H2RA is often used in clinical practice for patients presenting with upper gastrointestinal haemorrhage even before endoscopic confirmation of the cause of the bleed. Although empirical PPI treatment in this situation is regarded by many clinicians as reasonable, it appears to be a major challenge for formularies when judicious use of medications is required based on the evidence of benefit. In the absence of strong evidence, the indiscriminate use of PPIs could not be recommended for all patients presenting with upper gastrointestinal bleeding. The largest randomised study evaluating the role of PPI in acute, unselected upper gastrointestinal bleeding included 1147 patients. The authors found no significant difference in mortality, rebleeding rates or requirement for surgery between the PPI and control groups. The only significant difference between the groups was the reduction in endoscopic stigmata of haemorrhage in patients treated with PPI (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>). In a more recent randomised controlled study, Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>), randomised 631 patients to either high dose intravenous omeprazole or placebo before endoscopy in patients with acute unselected upper gastrointestinal bleeding. The authors found no significant difference in clinically relevant outcomes such as mortality, rebleeding or requirement for surgery between the omeprazole and the control groups. This study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) however, confirmed the observation that proton pump inhibitor treatment reduces the incidence of stigmata of recent haemorrhage and the requirement for endoscopic therapy on index endoscopy.</P>
<P>Previous studies have demonstrated some evidence that empirical PPI treatment before endoscopic confirmation could be cost effective (<LINK REF="REF-Enns-2003" TYPE="REFERENCE">Enns 2003</LINK>; <LINK REF="REF-Gagnon-2003" TYPE="REFERENCE">Gagnon 2003</LINK>). A more recent cost effectiveness study (<LINK REF="STD-Tsoi-2008" TYPE="STUDY">Tsoi 2008</LINK>) constructed a data analysis model of treatment pathways based on the data from their original randomised controlled trial (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). The authors (<LINK REF="STD-Tsoi-2008" TYPE="STUDY">Tsoi 2008</LINK>) observed that pre-emptive PPI treatment reduces the need for endoscopic therapy by 7.4% and hence resulted in a lower cost per endoscopic therapy averted in the PPI group (US $3561) compared to placebo group (US $4117). Another study (<LINK REF="STD-Al_x002d_Sabah-2008" TYPE="STUDY">Al-Sabah 2008</LINK>) evaluated the cost effectiveness of high dose IV PPI before endoscopy in preventing rebleeding. The authors observed that this strategy was more cost effective than PPI use after endoscopy in the United States and in Canada. This strategy was more effective and less costly if the period of hospitalisation for high risk ulcer patients increased to more than 6 days or if the period of hospitalisation for low risk ulcer patients reduced to less than 3 days in Canadian hospitals.</P>
<P>Guidelines from the recent consensus group statement recommend the use of empirical PPI treatment in patients waiting for endoscopy. Although only 40% of the consensus panel agreed to this recommendation without any reservations (<LINK REF="REF-Barkun-2003" TYPE="REFERENCE">Barkun 2003</LINK>), the more recent ICON-UGIB consensus considered the updated evidence for use of PPI prior to endoscopy and the consensus was near unanimous (<LINK REF="REF-Barkun-2010" TYPE="REFERENCE">Barkun 2010</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-11-04 17:22:25 -0500" MODIFIED_BY="[Empty name]">
<P>This is an update of a systematic review previously published in 2006, which aimed to ascertain the role of PPI therapy initiated prior to endoscopic diagnosis in reducing mortality in unselected upper gastrointestinal haemorrhage. By systematically reviewing all studies in which a PPI has been directly compared with another acid-lowering agent (that is, an H2RA), placebo or no treatment in unselected patients with upper gastrointestinal bleeding prior to endoscopy, we aimed to assess whether PPIs show any overall benefit in reducing adverse clinical outcomes including mortality, rebleeding, requirement for surgery and endoscopic outcomes including stigmata of recent haemorrhage and requirement for haemostatic treatment during index endoscopy.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-10-28 07:57:23 -0400" MODIFIED_BY="Cathy Bennett">
<P>This project aimed to assess the clinical effectiveness of PPI treatment initiated prior to endoscopy in acute upper gastrointestinal bleeding by systematic review and meta-analysis of randomised controlled trials.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-11-09 18:17:32 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-11-04 17:30:49 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-10-28 07:54:57 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomised controlled trials (RCTs) that compared the relative effectiveness of pre-endoscopic PPI versus placebo or an H2RA were eligible for inclusion in this review. Published and unpublished studies, full articles and abstracts were considered for inclusion in this review. Only studies that evaluated PPI initiated prior to endoscopy upon presentation with upper gastrointestinal (GI) bleeding were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-11-04 17:28:01 -0500" MODIFIED_BY="[Empty name]">
<P>Trials were eligible for inclusion in the review if they recruited participants admitted to hospital with upper GI tract bleeding or inpatients who developed upper gastrointestinal bleeding after having been admitted for other reasons. The only studies included were those which enrolled unselected patients with upper GI bleeding before the cause of bleeding was ascertained by endoscopy, and those in which treatment groups were treated similarly regardless of the active therapies being compared.. Allocation to PPI or comparator treatment had to have been made before diagnostic upper endoscopy. Steps were taken to clarify whether participants with variceal bleeding had been excluded from the primary trials. <U>
<BR/>
</U>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-11-04 17:30:26 -0500" MODIFIED_BY="[Empty name]">
<P>To be included in the review, the tested regimen had to meet the following criteria:<BR/>The treatment group had to have received a PPI; the control group had to have received either placebo, an H2RA or no treatment prior to endoscopy and otherwise, the control group had to have been managed similarly to the active treatment group. The method of delivery of PPI and control treatment included both intravenous and oral routes of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-11-04 17:30:49 -0500" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-10-14 16:41:17 -0400" MODIFIED_BY="[Empty name]">
<P>The primary outcome measure in this review was all cause mortality, defined as any death occurring within 30 days (or mortality at the time point closest to 30 days) after the acute bleed.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-11-04 17:30:49 -0500" MODIFIED_BY="[Empty name]">
<P>The secondary outcome measures were as follows:</P>
<OL>
<LI>rebleeding within 30 days;</LI>
<LI>surgery for continued or recurrent bleeding within 30 days of randomisation;</LI>
<LI>length of hospital stay, where available, expressed and compared as the mean and standard deviation;</LI>
<LI>transfusion requirements, where available, expressed and compared as mean number of units transfused per participant and standard deviation;</LI>
<LI>proportion of participants with high-risk stigmata at the time of endoscopy.</LI>
<LI>proportion of participants receiving endoscopic treatment at index endoscopy.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-11-09 18:17:32 -0500" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-11-09 18:17:32 -0500" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (<I>The Cochrane Library)</I>, MEDLINE, EMBASE and CINAHL databases up to September 2005 (using the search terms: (bleed or rebleed or haemorrhage or hemorrhage) and any of the generic names of proton pump inhibitors), using the Cochrane Upper Gastrointestinal and Pancreatic Diseases (UGPD) model (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). We also searched the National Research Register (NRR) and the UGPD trials register. The search strategy was then re-run in February 2006 and in October 2008. </P>
<P>The search provided a comprehensive list of primary studies, both published and unpublished, that complied with the inclusion criteria. Free-text searches and medical subject headings were combined to identify papers concerned with PPIs and upper gastrointestinal bleeding.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-11-04 17:37:11 -0500" MODIFIED_BY="[Empty name]">
<P>Reference lists from trials selected by electronic searching were handsearched to identify further relevant trials. Published Abstracts from Digestive Disease Week, United European Gastroenterology Week, American College of Gastroenterology annual meeting, World Congress of Gastroenterology and British Society of Gastroenterology annual meeting were also handsearched (1997 to October 2008). Authors of trial reports published only as abstracts were contacted and asked to contribute full data sets or completed papers. We handsearched the reference lists of identified articles for further relevant trials.</P>
<P>The following web based resources were also searched:</P>
<UL>
<LI>http://www.controlledtrials.com</LI>
<LI>http://www.cancer.gov/cancerinformation</LI>
<LI>http://clinicaltrials.gov</LI>
<LI>http://www.eortc.be</LI>
<LI>http://www.swog.org</LI>
<LI>http://www.ctg.queensu.ca</LI>
<LI>http://www.CenterWatch.com/</LI>
</UL>
<P>In addition, members of the Cochrane UGPD Group and experts in the field were contacted and asked to provide details of outstanding clinical trials and any relevant unpublished materials.</P>
<P>
<B>Correspondence</B>
</P>
<P>Experts in the field who were registered with the Cochrane Collaboration Upper Gastrointestinal and Pancreatic Disease (UGPD) Review Group were contacted for leads on unpublished studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-06 17:24:44 -0500" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-10-14 16:43:54 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors (AS and SD) independently checked trials and abstracts identified from the search for fulfilment of pre-defined inclusion criteria. One of the review authors (AS) was an expert in content matter. A third review author (GL) adjudicated in the event of discrepancies and a consensus view was taken. During the update of the review in 2008 two review authors (AS and JM) independently evaluated the studies for quality, methodology and collection of data. The full text of all relevant studies was obtained wherever possible. If it was not clear from the information presented whether the trial met the inclusion criteria, further information was sought from the original author. The inclusion of trials and grading of methodological quality were determined, and reasons for exclusion were documented. Authors were contacted to provide the relevant unpublished and missing data wherever required.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-11-06 17:24:44 -0500" MODIFIED_BY="[Empty name]">
<P>Data regarding the above-mentioned outcomes were extracted independently by two review authors (AS and SD for the initial version of the review; AS and JM during the update of the review in 2008). The data were collected using a pre-abstracted proforma. By a <I>post hoc</I> decision, a third review author (GL) independently extracted data. In the event of discrepancies a consensus view was taken. In the end, the agreement was 100% among the three authors.</P>
<P>Studies were summarised and, if appropriate, meta-analysis was undertaken.</P>
<P>The following features were also recorded:<BR/>
</P>
<UL>
<LI>setting: single centre versus multicentre;</LI>
<LI>geographical location;</LI>
<LI>name of PPI;</LI>
<LI>high dose PPI (equivalent to a dose of omeprazole or pantoprazole 80 mg bolus intravenous followed by an intravenous infusion of 8 mg/hr for 72 hours) versus lower dose PPI;</LI>
<LI>intravenous PPI versus oral PPI;</LI>
<LI>control group treatment - H2RA versus placebo;</LI>
<LI>concomitant treatment - therapeutic endoscopy (subdivided by intervention - injection, thermal, injection plus thermal, clips, other) versus no therapeutic endoscopy;</LI>
<LI>adverse reactions - actively sought versus not actively sought;</LI>
<LI>proportion of participants eventually found to be bleeding from peptic ulcers.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-10-28 09:05:06 -0400" MODIFIED_BY="Cathy Bennett">
<P>Assessment of risk of bias was based on the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). Each included study was assessed regarding sequence generation, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting and other potential sources of bias.<BR/>Other validity criteria used to assess studies included the following:</P>
<UL>
<LI>baseline comparability of treatment groups;</LI>
<LI>criteria for participant inclusion and exclusion;</LI>
<LI>interventions described in detail;</LI>
<LI>definition of outcomes;</LI>
<LI>stated time for outcome assessment;</LI>
<LI>stated indications for repeat endoscopy, initial and subsequent endoscopic treatment, surgery and transfusion;</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-10-28 09:05:08 -0400" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<P>The primary outcome was mortality rate, defined as death from any cause within 30 days of randomisation. We expected dichotomous data for mortality and this was expressed as odds ratio (OR) with 95% confidence intervals (CI).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>We expected dichotomous data for secondary outcome measures including rebleeding rate, requirement for surgery within 30 days and proportion of participants with stigmata of recent haemorrhage (active bleeding, non bleeding visible vessel or adherent clot). These were also expressed as OR or with 95% CI.</P>
<P>We expected continuous data for secondary outcome measures including length of hospital stay and blood transfusion requirement. These were expressed as means and compared between the intervention groups. However, length of hospital stay was expected to be skewed and we admit that mean and standard deviation are not the ideal summary measures to express this outcome.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-11-04 17:41:30 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Studies with multiple treatment groups</HEADING>
<P>A decision was made <I>a priori</I> to include such studies in the review, provided the study satisfied the inclusion criteria and the inclusion was limited to the interventions eligible to be included in this review, i.e., participants treated with PPI in the treatment group and participants either treated with H2RA, placebo or no-treatment in the control group. The other subgroups were excluded from this review.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-10-28 08:05:58 -0400" MODIFIED_BY="Cathy Bennett">
<P>Details of missing values were requested from authors. Analyses were performed with an intention to treat basis. In the event of missing data such as standard deviation, these data were requested from authors in order to perform meta-analysis for continuous outcomes.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-10-28 08:06:36 -0400" MODIFIED_BY="Cathy Bennett">
<P>Heterogeneity was assessed using the Chi-squared test, I<SUP>2</SUP> statistic as a heterogeneity indicator along with visual inspection of the forest plots. A significance level less than 0.10 was interpreted as evidence of heterogeneity. We looked for an explanation for any heterogeneity and have reported this in the review. Sensitivity analysis was performed using the potential sources of heterogeneity to test the robustness of the overall results. Where no significant heterogeneity was observed among study results, the fixed-effect model was used. Otherwise, the random-effects model was used.</P>
<P>The potential reasons for heterogeneity hypothesized a priori include:</P>
<OL>
<LI>study quality (open trial versus blinded trial);</LI>
<LI>study setting (multi centre versus single centre);</LI>
<LI>geographical location (Asian versus Western study);</LI>
<LI>PPI treatment (intravenous versus oral; conventional versus high dose PPI);</LI>
<LI>concomitant treatment (therapeutic endoscopy versus no therapeutic endoscopy);</LI>
<LI>control treatment used (H2RA versus placebo);</LI>
<LI>outcome measure for bleeding (recurrent bleeding versus persistent bleeding);</LI>
<LI>outcome measure of mortality, criteria stated (bleed-related mortality versus non bleed related mortality).</LI>
</OL>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-10-28 08:06:44 -0400" MODIFIED_BY="Cathy Bennett">
<P>The review was designed to include published and unpublished studies in all languages. Specialist translation help was sought to obtain data during data collection. Publication bias was explored using funnel plots (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-10-28 08:06:54 -0400" MODIFIED_BY="Cathy Bennett">
<P>All trials included in the systematic review were entered into Review Manager 5 (RevMan). An intention-to-treat approach was used in all analyses. Meta-analysis was performed only if two or more trials with similar comparisons and outcome measures were found.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-10-28 09:05:10 -0400" MODIFIED_BY="Cathy Bennett">
<P>We decided to perform sub group analyses <I>a priori </I>in the following categories:</P>
<UL>
<LI>According to degree of allocation (A vs Non-A)</LI>
<LI>According to control treatment (H2RA vs placebo vs no treatment)</LI>
<LI>According to route of PPI administration</LI>
<LI>According to the PPI used</LI>
<LI>According to report of using endoscopic haemostatic treatment</LI>
<LI>Restricted to participants to peptic ulcer bleeding</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-10-14 16:56:44 -0400" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses for all outcomes were performed by excluding each study to assess the robustness of the results of the meta-analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-11-10 08:46:57 -0500" MODIFIED_BY="Jan Lilleyman">
<STUDY_DESCRIPTION MODIFIED="2009-11-04 17:52:55 -0500" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2009-11-04 17:42:41 -0500" MODIFIED_BY="[Empty name]">
<P>The search strategy used for CENTRAL, MEDLINE, EMBASE and CINAHL databases identified 94 articles. 33 further articles were identified during the update of the search strategy in October 2008. Handsearching reference lists from these articles and searching major conference proceedings identified no further trials. No further trials were identified by contacting members of the Cochrane UGPD Group, experts in the field of gastroenterology and pharmaceutical companies marketing PPIs.</P>
<P>After reviewing the abstracts of the above articles, 69 were excluded as they were clearly not relevant and three due to inadequate data. The main reason for exclusion was not being a RCT. We retrieved the full articles for the remaining 54 trials and obtained translations for those published in languages other than English. One trial was published only in the abstract form (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>). Of these trials, 49 did not meet the eligibility criteria and were excluded for the following reasons: randomisation had taken place after endoscopy, or the study had been restricted to peptic ulcer bleeding only (see table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>').</P>
<P>The remaining six trials were included in our systematic review (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>; ) (see table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>').</P>
<P>Of these, five were full peer-reviewed publications (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>;<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK> <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) and one was published as an abstract only (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>). Five of the trials were published in the English language and one in Turkish (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>). We were provided with additional information from the authors of two of the trials (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>).<BR/>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-11-04 17:52:55 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>All included studies were RCTs with a parallel-group design.<BR/>Other aspects of trial design are discussed in '<LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>Four of the studies had been conducted in a single centre (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>;) and two had been conducted in two centres (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>, <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). All studies took place in a hospital setting.</P>
<P>Four trials had been conducted in Europe (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>, <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>;) and two in Asia (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>). (The trial by Hulagu et al had been conducted in the Asian part of Turkey).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>All trials included participants with clinical signs of upper gastrointestinal bleeding. Three studies defined these as haematemesis or melaena or both (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>).</P>
<P>The number of participants per trial ranged from 58 (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) to 1147 (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>). In one trial (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>), we included only two of the four treatment groups, the PPI-only group and the placebo group, in our analysis. One trial (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) did report stigmata of haemorrhage only in the subgroup of participants with peptic ulcer disease and hence this study was not included in the main analysis for this outcome. Another study (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) did not report requirement for surgery and hence was excluded from the analysis for this outcome.</P>
<P>The six trials that were included in the main analysis (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) comprised a total of 2223 participants. Of these, 1114 were randomised to PPI treatment and 1109 to control treatment.</P>
<P>The mean age of participants was reported in three trials: 58.4 years with a standard deviation of 19.9 years (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>), 59.5 years with a standard deviation of 19 years (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) and 54 years (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>). Two trials reported only median age per treatment group: 54 years for PPI group and 56 years for the control group in one trial (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) and 58.1 years for the PPI group and 49.5 years for the control group in the other trial (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>). One trial (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported mean age with standard deviation per treatment group, 61.7 (SD 17.9) in the PPI group and 62.3 (SD 17.5) in the control group.</P>
<P>Five studies reported the gender of participants; in all five there was a male predominance. The male to female ratios were 74/28 (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>), 729/418 (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>), 251/163 (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>), 409/222 (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) and 52/28 (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>).</P>
<P>One trial specifically excluded participants who developed bleeding after being admitted to hospital for other reasons (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>). It was not clear whether such participants had been excluded from the other studies.</P>
<P>None of the studies was confined to participants with peptic ulcer bleeding, although one only reported outcomes of stigmata of haemorrhage for participants with peptic ulcer bleeding (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). The percentage of participants with peptic ulcer bleeding per trial was as follows: 43.9% (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>), 42.4% (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>), 75.5% (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>), 60.7% (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) and 77.6% (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>).<BR/>
<BR/>Two of the studies did not exclude participants with bleeding from oesophageal varices. Such participants comprised 2.5% of total participants in one trial (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) and 3.9% of total participants in another trial (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). One other trial attempted to avoid the inclusion of such patients by excluding patients with existing hepatic insufficiency (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>). Hulagu et al did not state whether participants with variceal bleeding were deliberately excluded although no such patients were included in the study (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>). Lau et al did not exclude participants with varices and reported variceal bleeding in 3.2% of the PPI group and 4.4% in the control group (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). Naumoski et al did not state any exclusion of variceal bleeding but mentioned that lesions considered were erosive gastritis, gastric and duodenal ulcers.</P>
<P>Co-morbidity was reported in detail in only one of the trials (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). Lau et al reported co-morbid medical illness per treatment group. Of the 314 participants in the PPI group, 17 had cirrhosis, 32 had cancer, 18 had cardiovascular disease and two had chronic renal failure. In the control group, out of 317 participants, 19 had cirrhosis, 23 had cancer, 25 had cardiovascular disease and three participants had chronic renal failure. None of the other trials used a standardised grading system of co-morbidity. From information stated in the exclusion criteria, we presume that three of the trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) did not include severely ill participants (terminal illness and malignancy stated as examples). Naumovski et al (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) reported eleven participants with renal and six participants with hepatic dysfunction in participants admitted to the Intensive Care unit. Wallner et al (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) did not include participants with hepatic insufficiency or malignancy. It is not possible to make comparisons about co-morbidity among the trials.</P>
<P>Two trials (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) reported data on the haemodynamic condition of patients on admission: Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported a mean systolic blood pressure of 116.2 (SD 20.4) in the PPI group and 117.3 (SD 21.9) in the placebo group. The number of participants (%) with a systolic blood pressure of less than 90 mm Hg was 30 (9.6) in the PPI group and 28 (8.8) in the control group. In Wallner et al (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>), 8.8% of total participants had haemodynamic shock, defined as systolic blood pressure &lt; 80 mm Hg; 29.5% of participants had systolic blood pressure below 100 mm Hg or heart rate &gt; 100 beats/min. One other study (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) stated the mean and standard deviation of systolic blood pressure and pulse rate per treatment group but did not report percentage of participants with shock.</P>
<P>Two trials (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) reported the proportion of participants on non-steroidal antiinflammatory drugs (NSAIDS). In the Lau study, 70 (22.3%) participants in the PPI group and 74 (23.3) in the placebo group were on NSAIDS. In the Wallner study, 35% of all randomised participants used NSAIDS. Another trial (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) reported that 62% of participants used such medications.</P>
<P>None of the trials reported Helicobacter pylori (H <I>pylori</I>) status of all randomised participants. One study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported 95/178 participants with peptic ulcer disease in the PPI group and 109/182 participants in the placebo group to be positive for <I>H pylori</I> either by biopsy urease (CLO test) or histology.</P>
<P>One study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported the proportion of participants using PPI or H2RA in the 4 weeks before admission. In the PPI group 38 (12.1%) had taken acid suppressant treatment compared to 40 (12.6%) in the placebo group.</P>
<P>Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported 80 (25.5%) to have had previous peptic ulcer disease in the PPI group compared to 80 (25.2%) participants in the placebo group. In the same study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>), 68 (21.7%) participants had a previous GI bleed compared to 66 (20.8%) in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Baseline comparability of treatment groups</HEADING>
<P>Hulagu et al (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) reported baseline comparability of treatment groups regarding haemoglobin values, presentation with haematemesis and melaena, past history of peptic ulcer disease, past history of upper gastrointestinal bleeding, anti-ulcer therapy, cigarette smoking, alcohol abuse, postural haemodynamic compromise and use of NSAIDS.</P>
<P>Daneshmend et al (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) reported baseline comparability among the following characteristics for which raw data were provided: male to female ratio, age, systolic blood pressure, pulse, haemoglobin, presentation with haematemesis and melaena, history of peptic ulcer disease, history of previous upper gastrointestinal bleeding, previous gastric surgery and endoscopic haemostatic treatment.</P>
<P>In the trial of Hawkey et al (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>), both groups were well balanced for age, sex, past history of peptic ulcer disease and use of non-steroidal anti-inflammatory drugs. More participants had been receiving ulcer-healing medication on admission in the control group compared to the PPI group (14/55 versus 8/58). Also, fewer participants were classified as high risk (as classified in a non-standardised way by the admitting team) in the control group compared to the PPI group (7/55 versus 11/58).</P>
<P>In the study by Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>), the two groups were comparable for age, gender, ASA status, haemodynamic status, comorbidity and proportion of participants with history of previous peptic ulcer disease or previous bleed. The two groups were similar for previous history of NSAIDS, warfarin use and the proportion of peptic ulcer participants with positive <I>H pylori</I> status.</P>
<P>Naumovski et al (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) did not provide baseline characteristics in their abstract publication.</P>
<P>Wallner et al (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) reported that the two treatment groups were well balanced with respect to mean age, sex, haemodynamic shock and haemoglobin. There was a larger proportion of participants older than 65 years in the control group (18/52) compared to the PPI group (12/50).</P>
<P>Overall, there was good baseline comparability for the four trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) that reported raw data and were available as full publications.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Presence of inclusion and exclusion criteria</HEADING>
<P>All trials had well-defined inclusion criteria. Five trials also reported exclusion criteria in detail. The sixth trial, published as abstract only (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>), did not specify any exclusion criteria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention described in detail</HEADING>
<P>Five trials provided detailed descriptions of the type, route and method of administration, dose and duration of medication used in both study groups. The fifth trial (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) was unclear regarding the dosing of both PPI and control treatment; three different dosage regimens were for each group but it was not clear how participants were allocated to each dose.</P>
<P>Also see table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' for details of intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Active treatment</HEADING>
<P>Four trials used intravenous omeprazole as active treatment (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>; ). One study used oral lansoprazole (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). Another study (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) used intravenous pantoprazole. Only the Lau study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) used a high dose regimen as predefined in the methods of the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Control treatment</HEADING>
<P>Three of the trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) used placebo as control treatment. Of these, one stated that placebo treatment consisted of intravenous mannitol (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>). Two trials compared active treatment to an H2RA; Hulagu et al (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) used intravenous ranitidine followed by oral famotidine, while Wallner et al (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) used intravenous ranitidine. The remaining study (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) used no treatment in the control group as the study design was pre and post endoscopy PPI treatment. In this study (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>), participants in the control group were treated with IV pantoprazole 40mg IV bolus after endoscopy followed by 40mg tid for five days. Of note, Hawkey et al (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) also randomised participants to an additional two treatment arms (four in total): tranexamic acid alone, and tranexamic acid plus lansoprazole. As mentioned above, these latter treatment arms were not included in our analysis.</P>
<P>Also see table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' for details of intervention including dose and duration of use.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Co-interventions</HEADING>
<P>Endoscopic haemostatic treatment was offered in selected participants in three of the trials. Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported the mean duration between admission and index endoscopy to be 14.7 (SD 6.3) hours in the PPI group compared to 15.2 (SD 6.2) hours in the placebo group and administered endoscopic haemostatic treatment with adrenaline injection and heater probe thermocoagulation to participants with active bleeding, non-bleeding visible blood vessel or clots. Variceal bleeding was treated with cyanoacrylate glue or variceal ligation as decided appropriate by the treating endoscopist. In this study, 60 out of 314 participants underwent endoscopic therapy in the PPI group compared to 90 /317 in the control group. Daneshmend et al (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) reported performing the index endoscopy generally within 24 hours of admission and applied endoscopic haemostatic treatment to a minority of high risk participants (37 participants out of 164 participants with active bleeding or non-bleeding visible vessels, i.e. 22.5%). Hawkey et al (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) reported performing index endoscopy on the morning following admission, or earlier if clinically indicated, and applied endoscopic haemostatic treatment only for actively bleeding lesions, which amounted to 40% of all participants with stigmata of haemorrhage. The remaining two trials (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) did not mention the use of endoscopic haemostatic treatment. Hulagu et al (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) reported performing the index endoscopy generally within 24 hours of admission and Wallner et al (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) reported performing the index endoscopy within the first 24 to 48 hours of admission. Information on the proportion of participants scoped before 24 hours from the onset of bleeding or admission, and the average duration of treatment with a PPI prior to index endoscopy were not available for either the whole study population or each study group from the published data or further unpublished data provided by the authors. Naumovski et al (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) did not describe details of endoscopy or endoscopic treatment.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-10-28 09:07:04 -0400" MODIFIED_BY="Cathy Bennett">
<P>49 did not meet the eligibility criteria and were excluded. The main reasons for exclusion included randomisation after endoscopy, or study restricted to peptic ulcer bleeding participants (see table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>').</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-11-10 07:51:41 -0500" MODIFIED_BY="Jan Lilleyman">
<ALLOCATION MODIFIED="2009-10-28 08:12:53 -0400" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">Sequence generation</HEADING>
<P>Two trials (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) adequately described the method of sequence generation. These have been described in the Risk of bias tables in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>One trial (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) had adequate concealment (Grade A) and the remaining five trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1994" TYPE="STUDY">Hulagu 1994</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) had uncertain concealment (Grade B).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2009-09-01 02:40:43 -0400" MODIFIED_BY="[Empty name]">
<P>Three trials were doubled blinded (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>), one trial was described as unblinded (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>), and another trial (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) provided no information regarding blinding status. The sixth trial (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) did not provide information about blinding, but was a comparison between PPI in the treatment arm and no treatment until endoscopy in the control arm.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-10-28 09:07:06 -0400" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">Description of withdrawals and dropouts, and percentage dropouts</HEADING>
<P>Five trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) described withdrawals and dropouts in detail. Of these, Wallner et al reported having no dropouts. Hawkey et al and Daneshmend et al and Lau et al (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>), clearly described the reasons for dropout for each treatment group at each stage of the study. All dropouts were assumed to have failed treatment and the clinical outcomes were analysed on an intention-to-treat basis. Hulagu et al (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) report that two participants in the H2RA group could not get scoped at 30 days and had excluded them. However, these two participants had been included in the final analysis. The authors do not report whether the outcomes were imputed or last observation carried forward (LOCF) was used at 30 days. One remaining trial (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) did not report the details of withdrawal and drop out data. The details of the withdrawals and dropouts for each study has been described in detail in the risk of bias table under characteristics of included studies</P>
</SUBSECTION>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-10-28 14:06:09 -0400" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">Stated indications for repeat endoscopy, initial and subsequent endoscopic treatment, surgery and transfusion</HEADING>
<P>Two trials (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) offered scheduled repeat endoscopy to all participants at five days and at five to six days, respectively. Three trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) offered the option of repeat endoscopy to participants with clinical suspicion of rebleeding, although the exact criteria were not specified. Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) clearly defined rebleeding which was treated with repeat endoscopy and retreatment with adrenaline injection and heater probe coagulation.</P>
<P>Wallner et al (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) stated that the indication for surgical treatment was ineffective conservative therapy or chronic ulceration with poor healing prognosis. Daneshmend et al (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) stated that participants were cared for by the admitting medical team, who made decisions about blood transfusion and surgery. In the Lau study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>), surgery was deemed indicated for rebleeding if haemostasis could not be achieved by repeat endoscopy or at the second rebleeding episode. The other three trials did not state indications for surgery.</P>
<P>Within the Hulagu et al study, transfusions were offered with the aim of keeping the haemoglobin at least 10 g/dl (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>). The remaining five trials did not clarify indications for blood transfusions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stigmata of recent haemorrhage</HEADING>
<P>Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported this outcome only for the subgroup of participants with peptic ulcer bleeding and not for all randomised participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Surgery</HEADING>
<P>Hulagu et al (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) did not report requirement for surgery.</P>
</SUBSECTION>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-11-10 07:51:41 -0500" MODIFIED_BY="Jan Lilleyman">
<SUBSECTION>
<HEADING LEVEL="4">Sample size estimation</HEADING>
<P>Three trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) estimated an <I>a priori </I>sample size of the trials. The other three trials did not state this.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Definition of outcomes</HEADING>
<P>Among the most important outcomes of the review: mortality, rebleeding and surgery, rebleeding was the only outcome that was difficult to define.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary Outcome</HEADING>
<P>Naumovski et al (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) did not define the time of assessment of mortality in their abstract. However, no mortality was found in either of the treatment groups in their study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Daneshmend et al (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) defined rebleeding by clinical or laboratory findings (fall in haemoglobin) or by endoscopic findings at repeat endoscopy. However, it was not clear if repeat endoscopy was offered to all participants with suspected rebleeding.</P>
<P>
<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK> defined rebleeding as a combination of clinical signs and a drop in haemoglobin or endoscopic evidence of rebleeding or both. However, repeat endoscopy was performed at the discretion of the managing team.</P>
<P>
<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK> did not define rebleeding. However, they did state that all participants were re-endoscoped five days following admission.</P>
<P>
<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK> did not report rebleeding as this was not one of their study outcomes. Instead, they reported time required for cessation of bleeding as determined by clinical and endoscopic criteria.</P>
<P>
<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK> defined rebleeding as vomiting of fresh blood, hypotensive shock (defined as a systolic blood pressure &#8804;90 mm Hg or a pulse &#8805;110 beats per minute) with melaena after stabilization, or a decrease in the haemoglobin level of more than 2 g per deciliter and a decrease in the haematocrit of more than 6% within 24 hours after a transfusion, resulting in a haemoglobin level of 10 g per deciliter or less. The participants were followed up for 30 days and mortality, requirement for repeat endoscopy or surgery, were assessed at 30 days.</P>
<P>
<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK> did not provide details of the outcomes or time period of outcome assessment.</P>
<P>Regarding the definition of hospital stay, two trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) reported data on hospital stay but did not distinguish between hospital stay ended by death and hospital stay ended by discharge. Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported median length of stay according to treatment group and also the proportion of participants requiring more than three days stay in hospital. <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK> reported mean length of stay in the intensive care unit for participants in both treatment groups.</P>
<P>Two studies (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>), reported mean number of blood units transfused in each group whereas the remaining trials reported the number of participants requiring blood transfusion in both treatment groups.</P>
<P>There was a wide variation of reporting hospital stay among the studies. Naumovski et al (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) measured and reported stay in intensive care unit. Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported median stay and also proportion of participants requiring stay less than three days per treatment group. Hence a pooled summary statistic could not be derived for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stated time for outcome assessment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>All trials reported mortality rates per treatment group. One trial (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) did not state the time of assessment. The four other trials reported mortality at: 40 days (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>), 30 days (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) and at both six and 30 days (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>). <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK> did not report a time period for any of the outcomes apart from lesion stabilisation by repeat endoscopy after five days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Rebleeding</HEADING>
<P>One of the trials (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) clarified that rebleeding was assessed at six and 30 days. <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK> reported rebleeding rates at 30 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Surgery</HEADING>
<P>Two trials (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported time for surgery assessment, namely at 30 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Stigmata of recent haemorrhage at index endoscopy</HEADING>
<P>Timing of index endoscopy would have significantly affected this outcome. Of the four trials that reported the proportion of participants per treatment group with stigmata of recent haemorrhage (as opposed to not having any stigmata): two (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) stated that index endoscopy took place within 24 hours of admission, one (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) stated that index endoscopy was performed within the first 24 to 48 hours of admission, and one (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported the mean time to endoscopy in the PPI and control group. We could not extract the proportion of patients per treatment group with stigmata of recent haemorrhage from the trial by Hulagu et al, who performed endoscopy within 24 hours of admission (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>). <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK> did not report timing of endoscopy or details of stigmata of haemorrhage.</P>
</SUBSECTION>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-11-10 08:46:57 -0500" MODIFIED_BY="Jan Lilleyman">
<SUBSECTION>
<HEADING LEVEL="3">Main analysis: all studies (Comparison 01)</HEADING>
<P>Unweighted pooled rates and odds ratios with 95% confidence intervals were calculated for each of the outcomes and compared between the treatment and control groups.</P>
<SUBSECTION>
<HEADING LEVEL="4">Mortality - 30 days or at point closest to 30 days</HEADING>
<P>Six trials reported mortality rates for all randomised patients (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) comprising a total of 1114 participants in the PPI group and 1109 in the control group. There was no significant heterogeneity among the trials (P = 0.60, I<SUP>2 </SUP>= 0%). Unweighted pooled mortality rates were 4.9% for PPI treatment and 4.3% for control treatment. There was no statistically significant effect of PPI treatment on mortality (OR 1.12, 95% CI (fixed-effect model) 0.75 to 1.68; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The results remained non-significant when, in a sensitivity analysis, any of the four trials was removed. Of note, in the study by Daneshmend et al (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>), all deaths occurred within 30 days although follow up was for a period of 40 days.</P>
<P>Visual inspection of a funnel plot indicated possible publication bias, missing small negative trials from the right bottom area of the plot (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rebleeding</HEADING>
<P>Rebleeding data for all randomised patients could be extracted from five trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>), comprising a total of 1064 patients in the PPI group and 1057 in the control group. There was no significant heterogeneity in this analysis (P = 0.45, I<SUP>2 </SUP>= 0%). Unweighted pooled rebleeding rates were 11% for PPI treatment and 13.1% for control treatment. There was no statistically significant effect of PPI treatment on rebleeding (OR 0.81, 95% CI (fixed-effect model) 0.62 to 1.06; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The result remained non-significant when, in a sensitivity analysis, any of the trials was removed. Although the funnel plot was asymmetrical, it was not possible to conclude if there was evidence of publication bias due to the small number of studies (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>Rebleeding rates could not be extracted from the trial by Wallner et al (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>), since it was designed to assess the time needed for bleeding cessation. This trial found that the time required for bleeding cessation was shorter on omeprazole compared to control treatment, the difference being statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Surgery</HEADING>
<P>Five trials reported surgical intervention rates for all randomised patients (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>), comprising a total of 1084 patients in the PPI treatment group and 1081 in the control treatment group. Heterogeneity among trials was not statistically significant (P = 0.53, I<SUP>2 </SUP>= 0%). Unweighted pooled rates for surgery were 7.2% for PPI treatment and 7.9% for control treatment. PPI treatment did not significantly affect requirement for surgery (OR 0.90, 95% CI (fixed-effect model) 0.65 to 1.25; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The result remained non-significant when any of the trials was removed by sensitivity analysis. The funnel plot was asymmetrical (missing small negative studies in the bottom right area of the plot), suggesting possible publication bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood transfusion requirements</HEADING>
<P>Two trials (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) reported blood transfusion requirements as a continuous outcome. Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported mean (SD) units of blood transfused in the PPI group to be 1.54 (2.41) compared to 1.88 (3.44) in the placebo group. This difference was not statistically significant (P = 0.12). Naumovski et al (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) reported mean units of blood transfused in the PPI group to be 2.5 compared to 4.2 in the placebo group and reported this to be significantly lower in the PPI group (P=0.001). However, in the absence of standard deviation for these values or raw data, a meta analysis could not be undertaken for this outcome.</P>
<P>The other trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) reported the proportion of patients requiring blood transfusion in the PPI and control groups. None of the trials found a statistically significant difference in blood requirements between the two groups. In a post hoc analysis, we were able to extract the percentage of patients per treatment group receiving blood transfusion from all four trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>). These trials comprised a total of 760 patients in the PPI treatment group and 752 in the control treatment group. There was no statistically significant heterogeneity among the trials (P = 0.36, I<SUP>2 </SUP>= 6.1%). A total of 53.2% of patients on PPI treatment and 54.5% on control treatment received blood transfusions. The proportion of patients requiring blood transfusion was not significantly affected by PPI treatment (OR 0.95, 95% CI (fixed-effect model) 0.78 to 1.16; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The result remained non-significant when, in a sensitivity analysis, any of the trials was removed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of participants with stigmata of recent haemorrhage at index endoscopy</HEADING>
<P>Four trials reported the proportion of participants per treatment group with stigmata of recent haemorrhage (active spurting or oozing, non bleeding visible vessel or adherent clot) at index endoscopy (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>). Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported this outcome only in participants with peptic ulcer disease and hence was excluded from the main analysis for this outcome. The other study (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) did not report the details of stigmata of recent haemorrhage. The trials comprised 672 participants in the PPI arm and 660 in the control arm, in total. There was no significant heterogeneity among the trials (P = 0.20 I<SUP>2 </SUP>= 35%). A total of 37.2% of participants on PPI and 46.5% of participants on control treatment had stigmata of recent haemorrhage at index endoscopy. PPI treatment significantly reduced the proportion of participants with stigmata of recent haemorrhage (OR 0.67, 95% CI (fixed-effect model) 0.54 to 0.84; P = 0.0005; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>This result was not robust, that is, it became statistically non-significant with the exclusion of one of the trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>). Furthermore, although the Chi-Square test did not show significant heterogeneity, the I<SUP>2</SUP> test indicated moderate heterogeneity; therefore a <I>post-hoc</I> sensitivity analysis was performed to assess whether the result would remain robust to the selection of the analysis model. When the random-effects model was applied, the result was rendered non significant (OR 0.80; 95% CI 0.52 to 1.21). Inspection of the funnel plot did not give any indication of publication bias (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of participants with blood in the stomach (post hoc analysis)</HEADING>
<P>Three trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) reported the proportions of participants with blood in the stomach at index endoscopy. We conducted a post hoc analysis of the proportions of participants. These three trials comprised a total of 622 participants in the PPI group and 608 participants in the control group. A total of 20.6% of participants on PPI and 27.0% of participants on control treatment were found to have blood in the stomach at index endoscopy. Since there was statistically significant heterogeneity among the three trials (P = 0.07, I<SUP>2</SUP> = 62.9%), a random-effects model was applied. There was no statistically significant effect of PPI treatment on the proportion of participants with blood in the stomach at index endoscopy (OR 0.64, 95% CI (random-effects model) 0.32 to 1.30; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). On performing a sensitivity analysis, by excluding each trial, the results remained robust.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of participants with active bleeding</HEADING>
<P>Four trials reported the proportions of participants per treatment group with active bleeding at index endoscopy (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>). The trials comprised 672 participants in the PPI arm and 660 in the control arm. There was no significant heterogeneity among the trials (P = 0.52 I<SUP>2 </SUP>= 0%). A total of 11.3% of participants on PPI and 14.7% of participants on control treatment had active bleeding at index endoscopy. PPI treatment had no significant effect on the proportion of participants with active bleeding (OR 0.74, 95% CI (fixed-effect model) 0.54 to 1.02; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). When sensitivity analysis was performed by sequentially excluding each individual trial, the results remained robust to the exclusion of two studies (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) but a marginally significant result was obtained in favour of PPI treatment if either the Hulagu study (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) or the Wallner study (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) was excluded.</P>
<P>The Lau study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported this outcome only in participants with peptic ulcer disease and hence could not be included in the main analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Need for endoscopic haemostatic treatment at index endoscopy</HEADING>
<P>Three trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported the proportions of participants who received endoscopic haemostatic treatment at index endoscopy. These three trials comprised a total of 985 participants in the PPI group and 998 participants in the control group. A total of 8.6% of participants on PPI and 11.7% of participants on control treatment required endoscopic haemostatic treatment at index endoscopy. There was no statistically significant heterogeneity amongst the trials (P = 0.41, I<SUP>2 </SUP>= 0%). The rate for endoscopic haemostatic treatment was significantly lower in the PPI group (OR 0.68, 95% CI 0.50 to 0.93; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). This result was not robust to exclusion of the Lau study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) during sensitivity analysis, attributing the treatment effect to the results of this trial alone. However, considering current standards of care, the proportion of participants with high-risk stigmata treated with endoscopic therapy was low in both the studies, at 22.5% in the Daneshmend study (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) and 40% in the Hawkey study (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). In comparison, in the more recent study by Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>), all participants (100%) with high risk stigmata on endoscopy received endoscopic treatment amounting to 24% of all participants randomised. Hence, the results of this meta-analysis would appear to reflect a true treatment effect of PPI in reducing the need for haemostatic treatment during index endoscopy. Inspection of the funnel plot did not give any indication of publication bias (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of hospital stay</HEADING>
<P>Three trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) reported data on length of hospital stay for all randomised participants, but a quantitative analysis for pooled outcome was not possible as both the studies reported this outcome as a median. Daneshmend et al reported median time to discharge: five days in the PPI group and six days in the control group (not statistically significant); Wallner et al reported median time (range) to discharge: eight days (three to 26) in the PPI group and 7.6 (three to 20) in the control group (not statistically significant). Lau et al (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported a significantly reduced median (range) stay in the PPI group three (one to 43) days compared to three (one to 54) days in the placebo group. Also, the authors reported (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) a significant proportion had a hospital stay of fewer than three days in the PPI group 190 (60.5%) compared to 156 (49.2%) in the placebo group. The other study (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) measured and reported the duration of stay in the intensive care unit and concluded this to be significantly shorter in the PPI group. Due to the wide variation in the manner that length of stay was reported in the above studies, a pooled analysis for the outcome was not possible and hence, an overall conclusion on the effect of PPI treatment on hospital stay could not be reached.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis according to degree of adequate concealment (Comparison 02)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Only one of the trials reporting mortality rates for all randomised participants was classified as being grade A regarding concealment of allocation (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). There was no significant difference in the mortality rates between the PPI and placebo group (OR 1.16; 95% CI 0.41 to 3.23), P = 0.78; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>The other five trials that reported mortality rate for all randomised participants (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) were classified as being grade B regarding concealment of allocation. There was no statistically significant heterogeneity among the trials (P = 0.44, I<SUP>2</SUP> = 0%). Mortality was not significantly affected by PPI treatment (OR 1.12, 95% CI 0.72 to 1.73, P = 0.47; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>The pooled odds ratio was not statistically significant (OR 1.12; 95% CI 0.75 to 1.68; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rebleeding</HEADING>
<P>Of the five trials reporting rebleeding rates for all randomised participants, one (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) was grade A regarding concealment of allocation. The difference in rebleeding rates was not statistically significant (OR 1.40, 95% CI 0.56 to 3.53; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>Four trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) were grade B regarding concealment of allocation. There was no statistically significant heterogeneity among the trials (P = 0.53, I<SUP>2</SUP> = 0%) and the pooled effect on rebleeding was not significant (OR 0.77, 95% CI 0.58 to 1.02, P = 0.07; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Surgery</HEADING>
<P>One trial (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) of grade A concealment of allocation reported surgical intervention rates. The effect was not statistically significant (OR 0.67, 95% CI 0.19 to 2.39, P = 0.54; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). Four trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) with grade B concealment of allocation also found a non-significant result (OR 0.92, 95% CI 0.66 to 1.29, P = 0.63; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). There was no significant statistical heterogeneity between the trials (P = 0.46, I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis according to control treatment (Comparison 03)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Three trials compared PPI to placebo (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). There was no statistically significant heterogeneity between them (P = 0.38, I<SUP>2</SUP> = 0%). There was no statistically significant effect on mortality (OR 1.19, 95% CI (fixed-effect model) 0.78 to 1.81; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>Two trials (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) compared PPI to an H2RA. There was no statistically significant heterogeneity among them (P = 0.79, I<SUP>2</SUP> = 0%). They also found no significant effect on mortality (OR 0.66; 95% CI 0.18 to 2.44; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>One trial (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) compared IV PPI treatment with no treatment before endoscopy and demonstrated no mortality during the period of the study in either group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rebleeding</HEADING>
<P>Three trials compared PPI to placebo treatment (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). There was no statistically significant heterogeneity among the trials (P = 0.51, I<SUP>2</SUP> = 0%). The pooled effect was not significant (OR 0.87; 95% CI 0.66 to 1.16; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>One trial compared PPI to an H2RA (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>) and found no significant effect on rebleeding (OR 0.56, 95% CI 0.14 to 2.26; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>One trial (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) compared PPI treatment with no treatment prior to endoscopy. The OR for rebleeding was 0.39 (95%CI 0.14 to 1.12, P= 0.08; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Surgery</HEADING>
<P>Three trials compared PPI to placebo (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). There was no statistically significant heterogeneity among them (P = 0.59, I<SUP>2</SUP> = 0%). There was no statistically significant effect on surgery (OR 0.90, 95% CI (fixed-effect model) 0.64 to 1.27; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). One trial (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) compared PPI to H2RA and also found no significant effect on surgery (OR 1.53, 95% CI 0.45 to 5.18; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). Another trial (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) compared PPI treatment with no treatment prior to endoscopy and found no significant effect for PPI in reducing the requirement for surgery (OR 0.37, 95% CI 0.07,2.02, P = 0.25; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis according to route of PPI administration (Comparison 04)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Five trials used intravenous PPI treatment (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) with no statistically significant heterogeneity among them (P = 0.79, I<SUP>2</SUP> = 0%). The pooled effect on mortality was not statistically significant (OR 1.21; 95% CI 0.80 to 1.84; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). One trial (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) studied the effect of oral PPI treatment and also found no significant effect on mortality (OR 0.39, 95 % CI 0.07 to 2.07; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rebleeding</HEADING>
<P>Four trials used intravenous PPI (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) with no statistically significant heterogeneity among them (P = 0.33, I<SUP>2</SUP> = 13%). The pooled effect on rebleeding was not statistically significant (OR 0.79, 95 % CI (fixed-effect model) 0.60 to 1.05; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
<P>One other trial used oral PPI treatment (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) and also found a non-significant result (OR 1.01, 95% CI 0.40 to 2.54; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Surgery</HEADING>
<P>Four trials used intravenous PPI treatment (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) with no statistically significant heterogeneity between them (P = 0.56, I<SUP>2</SUP> = 0%). The pooled effect on surgery was not statistically significant (OR 0.93, 95 % CI (fixed-effect model) 0.67 to 1.30; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>). One trial (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) studied the effect of oral PPI treatment and also found no significant effect on surgery (OR 0.49, 95 % CI 0.12 to 2.01; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis according to the PPI used (Comparison 05)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Four trials used omeprazole (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) with no statistically significant heterogeneity among them (P = 0.79, I<SUP>2</SUP> = 0%). The pooled effect on mortality was not statistically significant (OR 1.21, 95 % CI (fixed-effect model) 0.80 to 1.84; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
<P>One trial (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) studied the effect of oral lansoprazole and also found no significant effect on mortality (OR 0.39, 95 % CI 0.07 to 2.07; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>)</P>
<P>The other trial (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) used intravenous pantoprazole and demonstrated no mortality between their treatment groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rebleeding</HEADING>
<P>Three trials used omeprazole (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>;) with no statistically significant heterogeneity between them (P = 0.46, I<SUP>2</SUP> = 0%). The pooled effect on rebleeding was not statistically significant (OR 0.84, 95 % CI (fixed-effect model) 0.63 to 1.13; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
<P>One other trial used oral lansoprazole treatment (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) and also found a non significant result (OR 1.01, 95% CI 0.40 to 2.54; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
<P>The other trial (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) used intravenous pantoprazole and found no significant difference in rebleeding rates between their treatment groups (OR 0.39, 95% CI 0.14 TO 1.12; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Surgery</HEADING>
<P>Three trials used omeprazole treatment (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) with no statistically significant heterogeneity among them (P = 0.65, I<SUP>2</SUP> = 0%). The pooled effect on surgery was not statistically significant (OR 0.97, 95 % CI (fixed-effect model) 0.69 to 1.37; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). One trial (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) studied the effect of lansoprazole and also found no significant effect on surgery (OR 0.49, 95 % CI 0.12 to 2.01; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis according to report of endoscopic haemostatic treatment (Comparison 06)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Three trials reported use of initial endoscopic haemostatic treatment (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) with no statistically significant heterogeneity among them (P = 0.60, I<SUP>2</SUP> = 0%). The pooled effect on mortality was not statistically significant (OR 1.19; 95% CI 0.78 to 1.81; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
<P>Three trials did not report use of initial endoscopic haemostatic treatment (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) with no statistical heterogeneity amongst them (P = 0.79, I<SUP>2</SUP> = 0%) and also found no significant effect on mortality (OR 0.66, 95 % CI 0.18 to 2.44; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rebleeding</HEADING>
<P>Three trials reported the use of initial endoscopic haemostatic treatment (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) with no statistically significant heterogeneity between them (P = 0.51, I<SUP>2</SUP> = 0%). The pooled effect on rebleeding was not statistically significant (OR 0.87, 95 % CI (fixed-effect model) 0.66 to 1.16; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
<P>Two trials did not report use of initial endoscopic haemostatic treatment (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) with no statistical heterogeneity among them ( P = 0.69, I<SUP>2</SUP> = 0%) and found no significant difference in rebleeding rates between their treatment groups (OR 0.45, 95% CI 0.20 to 1.03; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Surgery</HEADING>
<P>Three trials reported the use of initial endoscopic haemostatic treatment (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) with no statistically significant heterogeneity among them (P = 0.59, I<SUP>2</SUP> = 0%). The pooled effect on surgery was not statistically significant (OR 0.90, 95 % CI (fixed-effect model) 0.64 to 1.27; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
<P>Two trials did not report use of initial endoscopic haemostatic treatment (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) with no statistical heterogeneity amongst them (P = 0.59, I<SUP>2</SUP> = 0%) and found no significant difference in rebleeding rates between their treatment groups (OR 0.91, 95% CI 0.35 to 2.36; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes for participants with peptic ulcer bleeding (Comparison 07)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Two trials reported separate mortality rates for participants with peptic ulcer bleeding (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>). These trials comprised 282 participants in the PPI arm and 298 in the control arm in total. There was no statistically significant heterogeneity among the trials (P = 0.20, I<SUP>2</SUP> = 39%). The pooled effect on mortality was not significant (OR 1.59, 95 % CI 0.85 to 2.97; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
<P>Daneshmend et al also reported separate outcomes for participants bleeding from gastric and duodenal ulcers (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>). For participants with gastric ulcer bleeding, mortality was 7% in the PPI group and 5% in the control group. In participants with bleeding duodenal ulcer, mortality was 11% in the PPI group compared to 5% in the control group (differences were not statistically significant).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rebleeding</HEADING>
<P>Two trials reported separate rebleeding rates for participants with peptic ulcer bleeding (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). These trials comprised 433 participants in the PPI arm and 447 in the control arm. There was no statistically significant heterogeneity between the trials (P = 0.54, I<SUP>2</SUP> = 0%). The pooled effect on mortality was not significant (OR 0.86, 95 % CI 0.59 to 1.26; <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>). The Daneshmend study (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) reported rebleeding rates separately for gastric and duodenal ulcer. The rebleeding rates were 27% in the PPI group compared to 25% in the placebo group in participants with bleeding gastric ulcer, and 21% in the PPI group compared to 29% in the placebo group for participants with bleeding duodenal ulcer. The results were not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Surgery</HEADING>
<P>Two trials reported separate surgical intervention rates for participants with peptic ulcer bleeding (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). These trials comprised 433 participants in the PPI arm and 447 in the control arm. There was no statistically significant heterogeneity between the trials (P = 0.80, I<SUP>2</SUP> = 0%). The pooled effect for surgery was non-significant (OR 0.91, 95 % CI 0.59 to 1.40; <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>).</P>
<P>The Daneshmend study (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) reported this outcome separately for gastric and duodenal ulcer participants. In participants with bleeding gastric ulcer, 19% in the PPI group underwent surgery compared to 17% in the placebo group. In participants with bleeding duodenal ulcer, 18% in the PPI group underwent surgery compared to 21% in the placebo group. The results were not statistically significant.</P>
<P>Hawkey et al (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) provided outcomes on peptic ulcer participants (42.4% of total study population) but not per treatment group. The rates of rebleeding (13.9%), surgery (6.6%) and death (4.4%) in peptic ulcer participants did not differ significantly from the whole study population.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of participants with stigmata of recent haemorrhage at index endoscopy</HEADING>
<P>One trial reported the proportion of participants with stigmata of recent haemorrhage at index endoscopy for participants with peptic ulcer bleeding (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). In the PPI group, 67/187 participants were found to have stigmata of recent haemorrhage at index endoscopy compared with 100/190 participants in the placebo group (P = 0.001). The authors also observed that a significantly lower proportion of participants had actively bleeding ulcer in the PPI group (12/187) compared to the placebo group (28/190, P = 0.01).The proportion of non bleeding visible vessels, adherent clot or flat pigmented spots did not differ significantly between the groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Need for endoscopic haemostatic treatment at index endoscopy</HEADING>
<P>One trial reported the proportion of participants with peptic ulcer bleeding who received endoscopic haemostatic treatment at index endoscopy (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>). This was 42/187 (22.5%) participants in the PPI group versus 70/190 (36.8%) participants in the placebo group. The difference between the PPI and placebo groups was statistically significant (P = 0.002). The authors (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) also observed that the amount of adrenaline injected and the pulses of heater probe were significantly lesser in the PPI group in participants with peptic ulcer bleeding receiving endoscopic haemostatic treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood transfusion requirements</HEADING>
<P>None of the studies reported blood transfusion requirements in the subgroup of participants with peptic ulcer bleeding.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of hospital stay</HEADING>
<P>None of the studies reported length of stay in the subgroup of participants with peptic ulcer bleeding.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-11-10 09:02:38 -0500" MODIFIED_BY="Jan Lilleyman">
<P>Experimental data suggest that acid suppression and increased pH are important in clot stabilisation and hence potentially in reducing rebleeding (<LINK REF="REF-Green-1978" TYPE="REFERENCE">Green 1978</LINK>; <LINK REF="REF-Low-1980" TYPE="REFERENCE">Low 1980</LINK>). However, evidence from clinical trials would suggest an adjunctive role for PPI in supplementing endoscopic haemostasis which is the cornerstone in the management of non variceal upper gastrointestinal bleeding (<LINK REF="REF-Barkun-2003" TYPE="REFERENCE">Barkun 2003</LINK>; <LINK REF="REF-Cook-1992" TYPE="REFERENCE">Cook 1992</LINK>; <LINK REF="STD-Sung-2003" TYPE="STUDY">Sung 2003</LINK>).</P>
<P>The evidence for the use of PPI in acute upper GI bleeding has been evolving over the last decade. A meta-analysis of RCTs using acid suppressing drugs (either PPI or H2RA) compared to placebo for peptic ulcer bleeding showed a significant reduction in rates of rebleeding and surgery but no effect on mortality (<LINK REF="REF-Selby--2000" TYPE="REFERENCE">Selby 2000</LINK>). A meta-analysis of RCTs comparing PPI treatment to placebo found a significant reduction in rates of further bleeding but no effect on mortality or surgical intervention rates (<LINK REF="REF-Gisbert-2001" TYPE="REFERENCE">Gisbert 2001</LINK>).</P>
<P>More recently, several meta-analyses have studied the clinical effectiveness of PPIs compared to other available drug therapies in acute upper gastrointestinal haemorrhage (<LINK REF="REF-Khuroo-2005" TYPE="REFERENCE">Khuroo 2005</LINK>) or in acute peptic ulcer haemorrhage (<LINK REF="REF-Andriulli-2005" TYPE="REFERENCE">Andriulli 2005</LINK>; <LINK REF="REF-Bardou-2005" TYPE="REFERENCE">Bardou 2005</LINK>; <LINK REF="REF-Leontiadis-2005" TYPE="REFERENCE">Leontiadis 2005</LINK>)</P>
<P>Khuroo et al did not find a significant pooled effect of PPI treatment on clinical outcomes in patients with acute upper gastrointestinal bleeding (<LINK REF="REF-Khuroo-2005" TYPE="REFERENCE">Khuroo 2005</LINK>). However, the issue of time of initiation of PPI treatment was not addressed. Of the five trials included in that analysis, three (<LINK REF="STD-Orti-1995" TYPE="STUDY">Orti 1995</LINK>; <LINK REF="STD-Perez-Flores-1994" TYPE="STUDY">Perez Flores 1994</LINK>; <LINK REF="STD-Uribarrena-1994" TYPE="STUDY">Uribarrena 1994</LINK>) randomised patients and initiated treatment after endoscopy. For this reason, these trials have been excluded from our systematic review.</P>
<P>The other three meta-analyses assessed the effectiveness of PPI treatment in RCTs confined to patients with peptic ulcer bleeding (<LINK REF="REF-Andriulli-2005" TYPE="REFERENCE">Andriulli 2005</LINK>; <LINK REF="REF-Bardou-2005" TYPE="REFERENCE">Bardou 2005</LINK>; <LINK REF="REF-Leontiadis-2005" TYPE="REFERENCE">Leontiadis 2005</LINK>). These meta-analyses are in broad agreement that PPI treatment significantly reduces rebleeding and largely surgery, compared with H2RA or placebo in patients with peptic ulcer bleeding. A Cochrane meta-analysis found no evidence of an overall effect of PPI treatment on mortality, although a significant reduction in mortality was found among patients with active bleeding or a non-bleeding vessel (<LINK REF="REF-Leontiadis-2005" TYPE="REFERENCE">Leontiadis 2005</LINK>).The meta-analysis by Bardou et al (<LINK REF="REF-Bardou-2005" TYPE="REFERENCE">Bardou 2005</LINK>) was confined to patients with peptic ulcer bleeding and high-risk endoscopic stigmata (active bleeding, a non-bleeding vessel, adherent clot) and found a significant reduction in mortality in the groups of trials that studied high dose intravenous PPI treatment versus placebo and non-high dose oral or intravenous PPI treatment versus placebo, but found no effect in mortality in trials that studied high dose oral PPI treatment versus placebo. Andriulli et al (<LINK REF="REF-Andriulli-2005" TYPE="REFERENCE">Andriulli 2005</LINK>) found no evidence of an overall effect of PPIs on mortality.</P>
<P>To our knowledge, this is the first updated systematic review and meta-analysis assessing the clinical effectiveness of PPI therapy initiated prior to endoscopic diagnosis in unselected patients with acute upper gastrointestinal haemorrhage.</P>
<P>Mortality is the single most important outcome of the present analysis. We found no evidence that initiation of PPI treatment prior to endoscopy had an effect on the 30 day all-cause mortality in unselected patients with acute upper gastrointestinal bleeding. The confidence interval of the pooled result is wide and is compatible with no difference in mortality rates between PPI and control groups, or may also suggest inadequate power to rule out clinically important differences in mortality. The quality of evidence regarding mortality is low due to an important inconsistency in the direction of the results among studies and also due to the wide confidence intervals to be consistent with conflicting clinical recommendations.</P>
<P>Rebleeding is a clinically important outcome that is related to poor prognosis. We found no evidence of an effect of PPI treatment initiated prior to endoscopy on rebleeding rates in unselected patients with upper gastrointestinal bleeding. The confidence interval for this result is consistent with no effect or a clinically insignificant reduction in rebleeding rates with PPI.</P>
<P>Surgery in patients with upper gastrointestinal bleeding can be associated with high mortality and is of considerable cost (<LINK REF="REF-Barkun-2003" TYPE="REFERENCE">Barkun 2003</LINK>; <LINK REF="REF-Rockall-1995" TYPE="REFERENCE">Rockall 1995</LINK>). Again, we found no evidence of an effect of PPI treatment initiated prior to endoscopy on surgical intervention rates in such patients. The confidence interval of this result is compatible with no difference in the requirement for surgery with PPI or control treatment.</P>
<P>An interesting observation is the effect of PPI treatment on findings at index endoscopy performed up to 24 hours (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) or 48 hours (<LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) following admission. As first described by Daneshmend et al (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>), an unexpected, but statistically significant reduction in stigmata of haemorrhage at index endoscopy was reported in patients treated with PPI (omeprazole) compared to placebo. Subsequent but smaller trials did not confirm this (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>), although one of these found that PPI treatment started prior to endoscopy significantly reduced the amount of blood in the stomach (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>).</P>
<P>Our meta-analysis of these trials showed a significant reduction in the proportion of patients with stigmata of haemorrhage (active spurting or bleeding, non bleeding visible vessel and adherent clot) at index endoscopy with PPI treatment, but the above analysis was dominated by one trial (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>) and was not robust to its exclusion. Furthermore, this analysis became non-significant when a random effects model was used. There was no demonstrable effect on the proportion of patients with blood in the stomach or the proportion with active bleeding. However, the most recent of the trials (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) found that PPIs prior to endoscopy significantly reduced both stigmata of haemorrhage at index endoscopy and rates of endoscopic haemostatic treatment, in patients with peptic ulcer bleeding. The authors did not report these outcomes for all randomised patients and hence this study could not be included in our meta analysis for this outcome.</P>
<P>Of note, <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK> was the only study to have administered high dose intravenous PPI. None of the other studies (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>) used high dose intra venous PPI infusion. The biological rationale of high dose PPI infusion achieving sustained acid suppression (prolonged period of pH around 6) has been shown in gastric pH studies (<LINK REF="REF-Brunner-1996" TYPE="REFERENCE">Brunner 1996</LINK>; <LINK REF="STD-Hasselgren-1998" TYPE="STUDY">Hasselgren 1998</LINK>; <LINK REF="REF-Van-Rensburg-2003" TYPE="REFERENCE">Van Rensburg 2003</LINK>) using 80mg bolus followed by 8mg/hr infusion of omeprazole or pantoprazole. However, a recent clinical trial in the US (<LINK REF="STD-Jensen-2006" TYPE="STUDY">Jensen 2006</LINK>) was stopped prematurely due to slow recruitment of patients. This trial (<LINK REF="STD-Jensen-2006" TYPE="STUDY">Jensen 2006</LINK>) was not powered to show significant differences between the groups and showed a trend for rebleeding rates to be lower in the high dose PPI group. A further multicentre trial (<LINK REF="REF-Sung-2009" TYPE="REFERENCE">Sung 2009</LINK>) has shown that high dose esomeprazole given after haemostatic treatment reduces rebleeding and endoscopic retreatment rates in patients with peptic ulcer bleeding</P>
<P>The rate of reduction of stigmata of haemorrhage seems plausible considering the findings of a study by Lau et al (<LINK REF="REF-Lau-1998" TYPE="REFERENCE">Lau 1998</LINK>). They found a significant rate of reduction of stigmata per day for the first three days in patients treated with intravenous H2RA for acid suppression. Our meta-analysis showed a significant reduction in stigmata of recent haemorrhage and a reduced requirement for endoscopic haemostatic treatment in the PPI group. It is plausible that the overall costs of treatment and the need for experienced endoscopy personnel could be reduced if the need for endoscopic therapy is reduced. This might also reduce exposure of patients to the risks of interventional treatment. However, the clinical significance of the above effects of PPIs on endoscopic stigmata of haemorrhage and requirement for endoscopic treatment are unclear. The current meta-analysis found no evidence of an effect on mortality, rebleeding or surgery. In the Lau study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>), among patients who did not have haemostatic treatment due to low risk stigmata on index endoscopy, 6/127 patients had rebleeding in the PPI group compared to 0/100 patients in the placebo group. Although not statistically significant, this increased rebleeding rate in the PPI group would raise concerns of spurious downstaging in ulcer stigmata at index endoscopy and could potentially lead to withholding of haemostatic treatment.</P>
<P>In this systematic review, planned subgroup analyses according to degree of allocation concealment, control treatment, route of PPI administration and application of initial endoscopic haemostatic treatment found no significant differences between pre-endoscopic initiation of PPI or control treatment regarding mortality, rebleeding or surgery. Based on the separate data for patients with peptic ulcer bleeding reported by three of the trials (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>), there was no evidence of an effect of PPI treatment initiated prior to endoscopy on mortality, rebleeding or surgery.</P>
<P>Two studies (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>; <LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) demonstrated a shorter hospital and ICU stay and the latter study (<LINK REF="STD-Naumovski-2005" TYPE="STUDY">Naumovski 2005</LINK>) observed lower blood transfusion requirements in the PPI group. However, the other studies included in this review found no significant difference between the groups for this outcome (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>; <LINK REF="STD-Wallner-1996" TYPE="STUDY">Wallner 1996</LINK>). Also the presence of variation in the reporting of this outcome precluded a meaningful meta-analysis to estimate a pooled effect among the trials.</P>
<SUMMARY_OF_RESULTS MODIFIED="2009-10-14 18:14:24 -0400" MODIFIED_BY="[Empty name]">
<P>In conclusion, PPI treatment initiated prior to endoscopy for upper gastrointestinal bleeding may reduce the proportion of patients with stigmata of recent haemorrhage. PPI treatment significantly reduces the need for haemostatic treatment at index endoscopy. However, we found no evidence that this improves mortality, rebleeding or the need for surgery.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-10-28 13:49:18 -0400" MODIFIED_BY="Cathy Bennett">
<P>This systematic review and meta-analysis was designed to include trials performed all around the world and regardless of publication status or language of publication. Only three of the 127 studies identified by the search could not be retrieved in full. Hence, we believe this review is comprehensive and the results reflect the available evidence for the use of PPI before endoscopy in acute upper gastrointestinal bleeding.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-11-10 08:57:43 -0500" MODIFIED_BY="Jan Lilleyman">
<P>Of the six trials included, only one (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) was assessed to be of methodologically high quality with a low risk of bias. However, this could be attributed to incomplete reporting of methodological data in the manuscript rather than methodology or design of the trials. The absence of statistical heterogeneity and the robustness of the results of all the analyses (with the exception of the analysis of the effect on stigmata of recent haemorrhage at index endoscopy) during sensitivity analysis excluding each study would support the quality and reliability of the evidence and conclusions reached by this review. The quality of the evidence could have been better if further details for outcomes such as blood transfusion requirement and stay in hospital had been available, to allow comparison of the pooled outcomes between the treatment groups.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-11-10 08:59:04 -0500" MODIFIED_BY="Jan Lilleyman">
<P>Based on the available data, it is difficult to address several key issues which remain to be answered including the optimal duration of PPI treatment and time to endoscopy. Only the Lau study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) reported these data and the information was not available from the other studies included in this review to perform <I>post hoc</I> analyses.</P>
<P>An important limitation of the studies included in this review is the small proportion of patients receiving endoscopic haemostatic treatment (EHT). In the two studies that reported the proportion of patients undergoing EHT (<LINK REF="STD-Daneshmend-1992" TYPE="STUDY">Daneshmend 1992</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>), this was only applied in around 30% of patients with active bleeding or with other stigmata of recent haemorrhage. However, it is uncertain if the combination of high dose PPI in conjunction with a more aggressive endoscopic therapy would influence the outcome positively or negatively. <LINK REF="STD-Sung-2003" TYPE="STUDY">Sung 2003</LINK> included patients with ulcers containing non-bleeding visible vessels or adherent clots and showed that combination therapy with endoscopic haemostasis and continuous intravenous omeprazole produced a lower rebleeding rate (1.1%) than intravenous omeprazole alone (11.6%). It would be difficult without individual patient data to determine confidently whether particular patient subgroups do benefit (for example based on 'severity' of initial bleed, likelihood of peptic ulcer, etc).</P>
<P>Another potential source of bias in the review would be the selection of the primary outcome. Although mortality is clinically the most important and significant outcome, the risk of mortality in most unselected patients with upper gastrointestinal bleeding is low (<LINK REF="REF-Longstreth-1998" TYPE="REFERENCE">Longstreth 1998</LINK>; <LINK REF="REF-Rockall-1996" TYPE="REFERENCE">Rockall 1996</LINK>). Also, most RCTs reported rebleeding or requirement for retreatment as the primary outcome and hence would be inadequately powered to show a significant difference in mortality between the PPI and control groups. In our meta-analyses, a trend was observed for reduced rebleeding and active bleeding in the PPI group, with an adequate number of patients these results may have become statistically significant in favour of PPI for some of the clinically relevant outcomes.</P>
<P>Finally, cost effectiveness of PPI therapy in upper gastrointestinal haemorrhage was not considered in this review. In clinical practice, empirical PPI therapy is considered acceptable by many treating physicians (<LINK REF="REF-Andrews-2002" TYPE="REFERENCE">Andrews 2002</LINK>; <LINK REF="REF-Andrews-2002a" TYPE="REFERENCE">Andrews 2002a</LINK>; <LINK REF="REF-Zandieh-2002" TYPE="REFERENCE">Zandieh 2002</LINK>), despite the lack of robust clinical evidence to support this practice. However, there is some evidence to suggest that this approach might be cost effective. A recent study utilised a decision analytical model to estimate the incremental cost-effectiveness of empirical intravenous PPI treatment for upper gastrointestinal haemorrhage for the first 24 hours in 1000 hypothetical patients. Based on the expected reductions in rates of rebleeding and surgery over a period of 60 days, the authors concluded that this approach is cost effective with a potential saving of $20,700 resulting from the prevention of 37 rebleeding episodes (<LINK REF="REF-Enns-2003" TYPE="REFERENCE">Enns 2003</LINK>). More recent evidence on the cost effectiveness of PPI prior to endoscopy raises uncertainty. Sung et al (<LINK REF="STD-Sung-2008" TYPE="STUDY">Sung 2008</LINK>) used a decision analysis model based on the data from the Lau study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>) and found preemptive PPI treatment to be a cost effective strategy. However, another study (<LINK REF="STD-Al_x002d_Sabah-2008" TYPE="STUDY">Al-Sabah 2008</LINK>) found this strategy to be slightly more costly and effective. This strategy was found to be cost effective in Canada if high risk patents stay more than 6 days and low risk patients stay less than 3 days in hospital.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-10-14 18:23:13 -0400" MODIFIED_BY="[Empty name]">
<P>Recent consensus recommendations (<LINK REF="REF-Barkun-2003" TYPE="REFERENCE">Barkun 2003</LINK>; <LINK REF="REF-Barkun-2010" TYPE="REFERENCE">Barkun 2010</LINK>) support the use of PPI before endoscopy based on the cost effectiveness studies. However, our review has not found any evidence to support reduction in clinically significant adverse outcomes with the use of PPI before endoscopy in acute upper gastrointestinal bleeding.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-10-28 07:55:06 -0400" MODIFIED_BY="Cathy Bennett">
<IMPLICATIONS_PRACTICE MODIFIED="2009-10-14 18:27:36 -0400" MODIFIED_BY="[Empty name]">
<P>PPI therapy is already widely initiated before endoscopy in patients with upper gastrointestinal bleeding. The present analysis did not find significant improvement with PPI treatment for clinically important outcomes including rebleeding, surgery or mortality. The reduced rate of serious endoscopic stigmata of bleeding found at endoscopy among patients given PPI therapy before endoscopy and the reduced requirement for endoscopic haemostatic treatment are of uncertain clinical significance. However, PPI therapy may have a role if prompt endoscopy is not readily available. Among such patients in whom PPI therapy is initiated before endoscopy, therapy can obviously be discontinued if endoscopy finds no evidence of bleeding or evidence of bleeding from an alternate source (for example, oesophageal or gastric varices).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-10-28 07:55:06 -0400" MODIFIED_BY="Cathy Bennett">
<P>There is a need for further large trials using high dose PPI treatment prior to endoscopy in patients with upper gastrointestinal bleeding and concentrating on clinical outcomes. The comparator could be either post-endoscopic initiation of PPI treatment (among patients found to have had ulcer bleeding) or pre-endoscopic initiation of a control treatment (placebo or an H2RA).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-11-10 09:00:40 -0500" MODIFIED_BY="Jan Lilleyman">
<P>Iris Gordon, Trial Search Coordinator for Cochrane Upper Gastrointestinal and Pancreatic Disease group, for conducting the initial literature searches.</P>
<P>We acknowledge Racquel Simpson, Trial Search Coordinator for Cochrane Upper Gastrointestinal and Pancreatic Disease group for conducting the updated literature searches in October 2008.</P>
<P>We thank Jan Lilleyman and Cathy Bennett for coordinating the update of this review and for administrative and logistical support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-11-04 17:17:42 -0500" MODIFIED_BY="[Empty name]">
<P>A Sreedharan - Has received speaker fees from Astra Zeneca and has accepted honoraria from Abbott for attending scientific meetings</P>
<P>Janet Martin - co-investigator in a partner grant between industry (Astra Zeneca) and CIHR, but does not receive any payment from this grant.</P>
<P>G Leontiadis - Has received speaker fees and reimbursement for expenses to attend scientific meetings from AstraZeneca, Sanofi-Aventis, Janssen-Cilag and GlaxoSmithKline.</P>
<P>D Forman - Has received speaker fees from Astra Zeneca</P>
<P>P Moayyedi - Chair is partly funded by an unrestricted donation from AstraZeneca to McMaster University.</P>
<P>Has been on the speaker's bureau for AstraZeneca, Altana and Janssen-Ortho</P>
<P>Has been on the advisory boards of AstraZeneca and Janssen-Ortho</P>
<P>C Howden - Previously consulted for TAP Pharmaceutical Products Inc, Takeda Chemical Industries, and Altana Pharma</P>
<P>Currently consults for Santarus Inc., Takeda Pharmaceuticals North America, Procter &amp; Gamble, Xenoport</P>
<P>Speaker's bureau for Santarus Inc, AstraZeneca and Takeda Pharmaceuticals North America</P>
<P>Previous research grant support from AstraZeneca</P>
<P>Was previously an investigator and speaker for Merck.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-11-06 15:26:54 -0500" MODIFIED_BY="[Empty name]">
<P>All review authors were responsible for conception of the review and protocol design. AS and SD performed eligibility checks on the search results, data extraction and contributed to the writing up of the initial version of the review. SD did not take any further part in this update. AS and JM performed eligibility checks on the search results. AS and JM carried out the data extraction. Statistical analyses were performed by AS. The manuscript was updated by AS, GL and JM; all review authors provided critical review. All review authors contributed to final editing of the review and gave final approval.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-10-28 14:06:32 -0400" MODIFIED_BY="Cathy Bennett">
<P>A post hoc decision was made to include a third author to independently data extract. Two post hoc analyses were conducted; concerning blood transfusion requirements and proportion of participants with presence of blood in the stomach.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-10-28 08:58:07 -0400" MODIFIED_BY="Cathy Bennett">
<P>Protocol Published as 'Proton Pump Inhibitors (before endoscopic diagnosis) in upper gastrointestinal bleeding'. Dorward S, Forman D, Howden CW, Leontiadis GI, Sreedharan A <I>The Cochrane Database of Systematic Reviews</I> Published in Issue 2, 2006. Copyright  2005 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-11-10 09:16:30 -0500" MODIFIED_BY="Jan Lilleyman">
<STUDIES MODIFIED="2009-11-10 07:46:04 -0500" MODIFIED_BY="Jan Lilleyman">
<INCLUDED_STUDIES MODIFIED="2009-11-10 07:37:29 -0500" MODIFIED_BY="Jan Lilleyman">
<STUDY DATA_SOURCE="PUB" ID="STD-Daneshmend-1992" MODIFIED="2009-11-10 07:37:29 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Daneshmend 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-11-10 07:37:29 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daneshmand TK, Hawkey CJ, Langman MJ, Logan RG, Walt RP</AU>
<TI>Omeprazole versus placebo for acute upper gastrointestinal bleeding: Randomised double blind controlled trial</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>304</VL>
<PG>143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawkey-2001" NAME="Hawkey 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkey GM, Cole AT, McIntyre AS, Long RG, Hawkey CJ</AU>
<TI>Drug Treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points</TI>
<SO>Gut</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>372-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulagu-1995" NAME="Hulagu 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulagu S, Demirturk L, Gul S, Yazgan Y, Altin M, Danaci M</AU>
<TI>The effect of omeprazole or ranitidine intravenous on upper gastrointestinal bleeding</TI>
<SO>Endoskopi Journal</SO>
<YR>1995</YR>
<VL>2</VL>
<PG>35-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Lau-2007" MODIFIED="2009-11-10 07:34:43 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Lau 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-10 07:34:43 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau JY, Leung WK, Wu JCY, Chan FKL, Wong VWS, Chiu PWY et al</AU>
<TI>Omeprazole before endoscopy in patients with gastrointestinal bleeding</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>356</VL>
<PG>1631-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-07-22 08:55:52 -0400" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naumovski-2005" MODIFIED="2009-07-22 08:49:30 -0400" MODIFIED_BY="[Empty name]" NAME="Naumovski 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-22 08:49:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naumovski-Mihalic S, Katicic M, Colic-Cvlje V, Bozek T, Prskalo M, Sabaric B, et al</AU>
<TI>Intravenous proton pump inhibitor in ulcer bleeding in patients admitted to an intensive care unit</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>128 suppl 4</VL>
<PG>W1578</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallner-1996" NAME="Wallner 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallner G, Ciechanski A, Wesolowski M, Sory A, Misiuna P</AU>
<TI>Treatment of acute upper gastrointestinal bleeding with intravenous omeprazole or ranitidine</TI>
<SO>European Journal of Clinical Research</SO>
<YR>1996</YR>
<VL>8</VL>
<PG>235-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-11-10 07:46:04 -0500" MODIFIED_BY="Jan Lilleyman">
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Sabah-2008" MODIFIED="2009-11-10 07:36:09 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Al-Sabah 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-10 07:36:09 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Sabah S, Barkun AN, Herba K, Adam V, Fallone C, Mayrand S et al</AU>
<TI>Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding</TI>
<SO>Gastroenterology</SO>
<YR>2008</YR>
<VL>135</VL>
<NO>5</NO>
<PG>1790-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrews-2005" MODIFIED="2009-11-10 07:36:20 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Andrews 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-10 07:36:20 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrews CN, Levy A, Fishman M, Hahn M, Atkinson K, Kwan P et al</AU>
<TI>Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high risk stigmata: a multicentre comparative study</TI>
<SO>Canadian Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>11</NO>
<PG>667-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Avgerinos-2005" MODIFIED="2009-11-10 07:35:51 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Avgerinos 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-10 07:35:51 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avgerinos A, Sgouros S, Viazis N, Vlachogiannakos J, Papaxoinis K, Bergele C et al</AU>
<TI>Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: A prospective randomized placebo controlled trial</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>5</NO>
<PG>515-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bai-1995" MODIFIED="2009-11-10 07:35:33 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Bai 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-11-10 07:35:33 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bai G, Hu FL, Lu DH, Qin J</AU>
<TI>Efficacy of intravenous administration of omeprazole in the treatment of upper gastrointestinal haemorrhage caused by peptic ulcer and acute gastric mucosal lesion</TI>
<SO>The Chinese Journal of Clinical Pharmacology</SO>
<YR>1995</YR>
<VL>11</VL>
<PG>206-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bajaj-2007" MODIFIED="2009-11-10 07:36:44 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Bajaj 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-10 07:36:44 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Dua KS, Hanson K, Presberg K</AU>
<TI>Prospective randomized trial comparing effect of oral versus intravenous pantoprazole on rebleeding after nonvariceal upper gastrointestinal bleeding: A pilot study</TI>
<SO>Digestive Diseases &amp; Sciences</SO>
<YR>2007</YR>
<VL>52</VL>
<NO>9</NO>
<PG>2190-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brunner-1990" MODIFIED="2009-10-28 09:21:07 -0400" MODIFIED_BY="Cathy Bennett" NAME="Brunner 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-10-28 09:21:07 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brunner G, Chang J</AU>
<TI>Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: An open randomised controlled trial</TI>
<SO>Digestion</SO>
<YR>1990</YR>
<VL>45</VL>
<NO>4</NO>
<PG>217-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2005" MODIFIED="2009-08-03 18:08:51 -0400" MODIFIED_BY="[Empty name]" NAME="Cheng 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-03 18:08:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng HC, Kao AW, Chuang CH, Sheu BS</AU>
<TI>The efficacy of high and low dose intravenous omeprazole in preventing rebleeding for patients with bleeding peptic ulcers and comorbid illnesses</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2005</YR>
<VL>50</VL>
<NO>7</NO>
<PG>1194-1201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chu-1993" NAME="Chu 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chu XQ, Jia LS</AU>
<TI>Effects of omeprazole and ranitidine on the treatment of peptic ulcer hemorrhage</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>S239</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colin-1993" MODIFIED="2009-10-28 14:06:49 -0400" MODIFIED_BY="Cathy Bennett" NAME="Colin 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-10-28 14:06:49 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colin R, Michel P, Sallerin V</AU>
<TI>Comparison of the efficacy of lansoprazole and ranitidine in the prevention of early relapse in people with upper gastrointestinal ulcerative haemorrhage with a high risk of early recurrence of rebleeding. A double blind multi centre study</TI>
<SO>Gastroenterolgie Clinique et Biologique</SO>
<YR>1993</YR>
<VL>17</VL>
<PG>A105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costamagna-1998" MODIFIED="2009-10-28 14:07:08 -0400" MODIFIED_BY="Cathy Bennett" NAME="Costamagna 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-10-28 14:07:08 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costamagna G, Mutignani M, Perri V, Colombo GM, Bruni A, Gabbrielli A, D Pietro C, Cruciiti F</AU>
<TI>Lansoprazole in preventing bleeding relapse in upper gastrointestinal non variceal bleeding</TI>
<SO>Gatroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<NO>Suppl.</NO>
<PG>A95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dovas-1992" MODIFIED="2009-10-28 14:10:41 -0400" MODIFIED_BY="Cathy Bennett" NAME="Dovas 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-10-28 14:10:41 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dovas A</AU>
<TI>Medical treatment of active bleeding of upper gastrointestinal tract: Omeprazole or H2 antagonists? A comparative study</TI>
<SO>Annales Medicales</SO>
<YR>1992</YR>
<PG>169-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elphick-2007" MODIFIED="2009-10-28 13:57:02 -0400" MODIFIED_BY="Cathy Bennett" NAME="Elphick 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-10-28 13:57:02 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="YES" TYPE="CORRESPONDENCE">
<AU>Elphick DA, Riley SA</AU>
<TI>Omeprazole before endoscopy in patients with gastrointestinal bleeding</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<PG>303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fasseas-2001" NAME="Fasseas 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fasseas P, Leybishkis B, Rocca G</AU>
<TI>Omeprazole versus ranitidine in the medical treatment of acute upper gastrointestinal bleeding: assessment by repeat early endoscopy</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2001</YR>
<VL>55</VL>
<PG>661-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Felder-1998" NAME="Felder 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Felder LR, Barkin JS</AU>
<TI>A comparison of omeprazole and placebo for bleeding peptic ulcer</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>5</NO>
<PG>428-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fried-1999" MODIFIED="2009-11-10 07:38:12 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Fried 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-11-10 07:38:12 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fried R, Beglinger C, Meier R, Stumpf J, Adler G, Schepp W et al</AU>
<TI>Comparison on intravenous Pantoprazole with intravenous ranitidine in peptic ulcer bleeding</TI>
<SO>Gut</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>Suppl V</NO>
<PG>A100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-1995" NAME="Gao 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao Z, Deng C, Yi J</AU>
<TI>The effect of omeprazole on upper gastrointestinal haemorrhage</TI>
<SO>Acta Academaie Medicinae Hubei</SO>
<YR>1995</YR>
<VL>16</VL>
<PG>223-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goletti-1994" NAME="Goletti 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goletti O, Sidoti F, Lippolis PV, De Negri F, Cavina E</AU>
<TI>Omeprazole versus ranitidine plus somatostatin in the treatment of severe gastroduodenal bleeding: A prospective, randomised controlled trial</TI>
<SO>Italian Journal of Gastroenterology</SO>
<YR>1994</YR>
<VL>26</VL>
<PG>72-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasselgren-1998" MODIFIED="2009-10-28 13:53:23 -0400" MODIFIED_BY="Cathy Bennett" NAME="Hasselgren 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-10-28 13:53:23 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasselgren G</AU>
<TI>Optimisation of acid suppression for patients with peptic ulcer bleeding. An intra gastric pH-metry study with omeprazole</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>1998</YR>
<VL>10</VL>
<PG>601-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hulagu-1994" NAME="Hulagu 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulagu S, Demirturk L, Gul S, Yazgan Y, Altin M, Danaci M</AU>
<TI>The effect of omeprazole or ranitidine intravenous on upper gastrointestinal bleeding</TI>
<SO>Endoscopy</SO>
<YR>1994</YR>
<VL>26</VL>
<PG>404</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hung-2007" MODIFIED="2009-11-10 07:39:04 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Hung 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-10 07:39:04 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hung WK, Li VKM, Chung CK, Ying MW, Loo CK, Liu CKT et al</AU>
<TI>Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric PH and recurrent bleeding in peptic ulcers</TI>
<SO>Australian and New Zealand Journal of Surgery</SO>
<YR>2007</YR>
<VL>77</VL>
<NO>8</NO>
<PG>677-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-2006" MODIFIED="2009-10-28 13:51:04 -0400" MODIFIED_BY="Cathy Bennett" NAME="Jensen 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-10-28 13:51:04 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen DM, Pace SC, Soffer E, Comer GM</AU>
<TI>Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: A US multicenter randomized double-blind study</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>9</NO>
<PG>1991-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keyvani-2006" MODIFIED="2009-10-28 13:52:52 -0400" MODIFIED_BY="Cathy Bennett" NAME="Keyvani 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-10-28 13:52:52 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keyvani L, Murthy S, Leeson S, Targownik LE</AU>
<TI>Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>8</NO>
<PG>1247-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2007" MODIFIED="2009-11-10 07:40:09 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Kim 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-10 07:40:09 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim JI, Cheung DY, Cho SH, Park SH, Han JY, Kim JK et al</AU>
<TI>Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized controlled trial</TI>
<SO>Digestive Diseases &amp; Sciences</SO>
<YR>2007</YR>
<VL>52</VL>
<NO>12</NO>
<PG>3371-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-2005" MODIFIED="2009-11-10 07:40:33 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Lau 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-10 07:40:33 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lau JY, Leung WK, Wu JC, Chan FK, Wong V, Hung LC et al</AU>
<TI>Early administration of high dose intravenous omeprazole prior to endoscopy in patients with upper gastrointestinal bleeding: A double blind placebo controlled randomized trial</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>128 (suppl 4)</VL>
<NO>Suppl 4</NO>
<PG>A 347</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2003" MODIFIED="2009-08-03 19:11:20 -0400" MODIFIED_BY="[Empty name]" NAME="Lee 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-03 19:11:20 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee KK, You JH, Wong IC</AU>
<TI>Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2003</YR>
<VL>57</VL>
<PG>160-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2007" MODIFIED="2009-08-03 17:19:50 -0400" MODIFIED_BY="[Empty name]" NAME="Lin 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-03 17:19:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin HJ</AU>
<TI>Pre-endoscopic PPI therapy reduces recurrent adverse outcomes in acute non-variceal upper gastrointestinal bleeding [comment]</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>3</NO>
<PG>343-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2002" NAME="Liu 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu RH, Wei CM, Wang XP, Yin ZZ</AU>
<TI>The efficacy of Losec versus famotidine in the treatment of bleeding duodenal ulcer</TI>
<SO>Shanghai Medical and Pharmaceutical Journal</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>7</NO>
<PG>199-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maculotti-1995" NAME="Maculotti 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maculotti L, Pradella P</AU>
<TI>Comparison between ranitidine, famotidine and omeprazole in the treatment of bleeding duodenal ulcer</TI>
<SO>Minerva Chirurgica</SO>
<YR>1995</YR>
<VL>50</VL>
<NO>3</NO>
<PG>279-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munkel-1997" NAME="Munkel 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munkel L, French L</AU>
<TI>Treatment of bleeding peptic ulcers with omeprazole</TI>
<SO>Journal of Family Practice</SO>
<YR>1997</YR>
<VL>45</VL>
<NO>1</NO>
<PG>20-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murthy-2007" MODIFIED="2009-08-03 18:37:06 -0400" MODIFIED_BY="[Empty name]" NAME="Murthy 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-03 18:36:59 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murthy S, Keyvani L, Leeson S, Targownik LE</AU>
<TI>Intravenous versus high-dose oral proton pump inhibitor therapy after endoscopic haemostasis of high risk lesions in patients with acute nonvariceal upper gastrointestinal bleeding</TI>
<SO>Digestive Diseases &amp; Sciences</SO>
<YR>2007</YR>
<VL>52</VL>
<NO>7</NO>
<PG>1685-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nehme-2001" NAME="Nehme 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nehme O, Barkin JS</AU>
<TI>Recurrent ulcer bleeding: Is intravenous omeprazole the solution</TI>
<SO>American journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>96</VL>
<NO>2</NO>
<PG>594-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orti-1995" MODIFIED="2009-11-10 07:41:36 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Orti 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-11-10 07:41:36 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orti E, Canelles P, Quiles F, Zapater R, Cuquerella J, Ariete V et al</AU>
<TI>Is upper gastrointestinal bleeding evolution influenced by the used antisecretory</TI>
<SO>Revista Espanola De Enfermedades Digestivas</SO>
<YR>1995</YR>
<VL>87</VL>
<PG>427-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez-Flores-1994" MODIFIED="2009-11-10 07:41:53 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Perez Flores 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-11-10 07:41:53 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez Flores R, Garcia Molinero MJ, Herrero Quiros C, Blasco Colmenarejo MM, Caneiro Alcubilla E, Garcia-Rayo Somoza M et al</AU>
<TI>The treatment of upper digestive hemorrhage of peptic origin: intravenous ranitidine versus intravenous omeprazole</TI>
<SO>Revista Espaola de Enfermedades Digestivas</SO>
<YR>1994</YR>
<VL>86</VL>
<NO>3</NO>
<PG>637-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Savides-2001" NAME="Savides 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Savides TJ, Pratha V</AU>
<TI>Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>1</NO>
<PG>130-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaffalitzky-2007" MODIFIED="2009-10-28 13:59:05 -0400" MODIFIED_BY="Cathy Bennett" NAME="Schaffalitzky 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-10-28 13:59:05 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaffalitzky de Muckadell OB</AU>
<TI>Acid pump inhibitor before gastroscopy for upper gastrointestinal bleeding</TI>
<SO>Ugeskrift for Lger</SO>
<YR>2007</YR>
<VL>169</VL>
<NO>35</NO>
<PG>2903</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scheurlen-2000" NAME="Scheurlen 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheurlen M</AU>
<TI>Peptic ulcer hemorrhage: IV antacid prevents recurrence</TI>
<SO>Fortschritte der Medzin</SO>
<YR>2000</YR>
<VL>142</VL>
<NO>45</NO>
<PG>30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schonekas-1999" MODIFIED="2009-11-10 07:42:39 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Schonekas 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-11-10 07:42:39 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schonekas H, Ahrens H, Pannewick U, Ell C, Koop H, Petritsch W et al</AU>
<TI>Comparison of two doses of intravenous pantoprazole in peptic ulcer bleeding</TI>
<SO>Gut</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>Suppl V</NO>
<PG>A104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Srinath-1997" NAME="Srinath 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Srinath C</AU>
<TI>Comparison of omeprazole and placebo for bleeding peptic ulcer</TI>
<SO>Tropical Gastroenterology</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>3</NO>
<PG>115-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sung-2003" MODIFIED="2009-10-28 13:57:54 -0400" MODIFIED_BY="Cathy Bennett" NAME="Sung 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-10-28 13:57:54 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sung JY, Chan FK, Lau JWW</AU>
<TI>The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with non bleeding visible vessels or adherent clots: A randomised comparison</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>139</VL>
<PG>237-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sung-2008" MODIFIED="2009-11-10 07:43:24 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Sung 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-10 07:43:24 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sung JJY, Mossner J, Barkun A, Kuipers EJ, Lau J, Jensen D et al</AU>
<TI>Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: Rationale/design of peptic ulcer bleed study</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>8</NO>
<PG>666-7</PG>
<IDENTIFIERS MODIFIED="2009-11-10 07:43:24 -0500" MODIFIED_BY="Jan Lilleyman">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran-2007" MODIFIED="2009-11-10 07:46:04 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Tran 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-10 07:46:04 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Tran HA, Kang E, Becker D</AU>
<TI>Omeprazole before endoscopy in patients with gastrointestinal bleeding [comment]</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007;357(3):303-304</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsoi-2008" MODIFIED="2009-08-03 17:09:24 -0400" MODIFIED_BY="[Empty name]" NAME="Tsoi 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-03 17:09:24 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsoi KKF, Lau JYW, Sung JJY</AU>
<TI>Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding</TI>
<SO>Gastrointestinal endoscopy</SO>
<YR>2008</YR>
<VL>67</VL>
<PG>1056-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Udd-2001" NAME="Udd 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Udd M, Miettinen P, Janatuinen E, Heikkinen M, Tarvainen R, Pasanen P, et al</AU>
<TI>Regular versus high dose omeprazole for peptic ulcer bleeding - prospective randomised double blind study</TI>
<SO>Annales Chirurgiae et Gynaecologiae</SO>
<YR>1999</YR>
<VL>88</VL>
<NO>2</NO>
<PG>169</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uribarrena-1994" MODIFIED="2009-10-28 13:54:56 -0400" MODIFIED_BY="Cathy Bennett" NAME="Uribarrena 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-10-28 13:54:56 -0400" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uribarrena R, Bajador E, Simon MA, Sebastian JJ, Gomollon F</AU>
<TI>Omeprazole and cimetidine in the treatment of upper digestive haemorrhage</TI>
<SO>Revista Espanola de Enfermedades Digestivas</SO>
<YR>1994</YR>
<VL>86</VL>
<PG>878-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2007" MODIFIED="2009-11-10 07:44:15 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Wei 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-10 07:44:15 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei KL, Tung SY, Sheen CH, Chang TS, Lee IL, Wu CS</AU>
<TI>Effect of oral esomeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>1</NO>
<PG>43-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2001" NAME="Wu 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu N, Wang SJ, Wang SG, Pan GH</AU>
<TI>Therapeutic efficacy of pantoprazole on upper gastrointestinal hemorrhage</TI>
<SO>Chinese New Medicine</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>12</NO>
<PG>1091-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xuan-2003" NAME="Xuan 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xuan JL</AU>
<TI>Loseco compared with famotisine in the treatment of upper gastrointestinal bleeding: clinical analysis of 90 cases</TI>
<SO>Guangxi Medical Journal</SO>
<YR>2003</YR>
<VL>25</VL>
<PG>529-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yilmaz-2006" MODIFIED="2009-08-03 18:55:31 -0400" MODIFIED_BY="[Empty name]" NAME="Yilmaz 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-03 18:55:25 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yilmaz S, Bayan K, Tuzun Y, Dursun M, Canoruc F</AU>
<TI>A head to head comparison of oral vs intravenous omeprazole for patients with bleeding peptic ulcers with a clean base, flat spots and adherent clots</TI>
<SO>World Journal of Gastroenterology.</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>48</NO>
<PG>7837-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zargar-2006" MODIFIED="2009-11-10 07:44:31 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Zargar 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-10 07:44:31 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zargar SA, Javid G, Khan BA, Yattoo GN, Shah AH, Gulzar GM et al</AU>
<TI>Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: Prospective randomized controlled trial</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>4</NO>
<PG>716-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-11-10 09:16:30 -0500" MODIFIED_BY="Jan Lilleyman">
<ADDITIONAL_REFERENCES MODIFIED="2009-11-10 09:16:30 -0500" MODIFIED_BY="Jan Lilleyman">
<REFERENCE ID="REF-Andrews-2002" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Andrews 2002" TYPE="JOURNAL_ARTICLE">
<AU>Andrews C, Zandieh I, Brodie M</AU>
<TI>Appropriateness of discontinuation of intravenous proton pump inhibitor (IV PPI) in bleeding peptic ulcer patients without high risk ulcer stigmata at endoscopy: preliminary results of multicenter evaluation</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2002</YR>
<VL>55</VL>
<NO>5</NO>
<PG>A592</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andrews-2002a" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Andrews 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Andrews C, Zandieh I, Levy AR</AU>
<TI>Comparison of intravenous proton pump inhibitor (IV PPI) use between hospitals:preliminary results</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2002</YR>
<VL>55</VL>
<NO>5</NO>
<PG>T1874</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andriulli-2005" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Andriulli 2005" TYPE="JOURNAL_ARTICLE">
<AU>Andriulli A, Annese V, Caruso N, Pilotto A, Accadia L, Niro AG, Quitadamo M, Merla A, Fiorella S, Leandro G</AU>
<TI>Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>9</NO>
<PG>2133</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bardou-2005" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Bardou 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bardou M, Toubouti Y. Benhaberou-Brun D, Rahme E and Barkun AN</AU>
<TI>Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2005</YR>
<VL>21</VL>
<PG>677-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barkun-2003" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Barkun 2003" TYPE="JOURNAL_ARTICLE">
<AU>Barkun AN, Bardou M, Marshall JK</AU>
<TI>Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding Conference Group</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>169</VL>
<PG>843-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barkun-2004" MODIFIED="2009-10-28 14:00:10 -0400" MODIFIED_BY="Cathy Bennett" NAME="Barkun 2004" TYPE="JOURNAL_ARTICLE">
<AU>Barkun A N, Herba K, Adam V, Kenedy W, Fallone C A, Bardou M</AU>
<TI>High dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcer in the USA and Canada : A Cost-effective analysis</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>19</VL>
<PG>591-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barkun-2006" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Barkun 2006" TYPE="OTHER">
<AU>Barkun A, Bardou M</AU>
<TI>The role of PPI therapy in upper GI tract bleeding</TI>
<SO>Gastroenterology and Hepatology Annual Review</SO>
<YR>2006</YR>
<VL>1</VL>
<PG>20-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barkun-2010" MODIFIED="2009-10-28 13:56:11 -0400" MODIFIED_BY="Cathy Bennett" NAME="Barkun 2010" TYPE="JOURNAL_ARTICLE">
<AU>Barkun A, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P, for the International Consensus Upper Gastrointestinal Bleeding Conference Group</AU>
<TI>International consensus recommendations on the management of patients with non-variceal upper gastrointestinal bleeding (ICON-UGIB)</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2010 (in press)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blatchford--1997" MODIFIED="2009-10-28 09:21:44 -0400" MODIFIED_BY="Cathy Bennett" NAME="Blatchford  1997" TYPE="JOURNAL_ARTICLE">
<AU>Blatchford O, Davidson LA, Murray WR, Blatchford M, Pell J</AU>
<TI>Acute upper gastrointestinal haemorrhage in west of Scotland: A case ascertainment study</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>510-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brunner-1996" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Brunner 1996" TYPE="JOURNAL_ARTICLE">
<AU>Brunner G, Luna P, Hartman M, Wurst W</AU>
<TI>Optimising the intra gastric PH as supportive therapy in upper GI bleeding</TI>
<SO>Yale J Biol Med</SO>
<YR>1996</YR>
<VL>69</VL>
<PG>225-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cook-1992" MODIFIED="2009-10-28 13:56:22 -0400" MODIFIED_BY="Cathy Bennett" NAME="Cook 1992" TYPE="JOURNAL_ARTICLE">
<AU>Cook DJ, Guyatt GH, Salena BJ, Laine LA.</AU>
<TI>Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage:a meta-analysis</TI>
<SO>Gastroenterology</SO>
<YR>1992</YR>
<VL>102</VL>
<PG>139-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enns-2003" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Enns 2003" TYPE="JOURNAL_ARTICLE">
<AU>Enns RA, Gagnon YM, Rioux KP, Levy AR</AU>
<TI>Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>225-233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gagnon-2003" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Gagnon 2003" TYPE="JOURNAL_ARTICLE">
<AU>Gagnon YM, Levy AR, Eloubeidi MA</AU>
<TI>Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding</TI>
<SO>Value Health</SO>
<YR>2003</YR>
<VL>6</VL>
<PG>457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-1990" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Gilbert 1990" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert DA</AU>
<TI>Epidemiology of upper gastrointestinal bleeding</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1990</YR>
<VL>36</VL>
<PG>S8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gisbert-2001" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Gisbert 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM</AU>
<TI>Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer</TI>
<SO>Alimentaryt Pharmacology and Therapeutics.</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>7</NO>
<PG>917-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gralnek-1997" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Gralnek 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gralnek IM, Jensen DM, Kovacs TP</AU>
<TI>An economic analysis of patients with active arterial peptic ulcer hemorrhage treated with endoscopic heater probe, injection sclerosis or surgery in a prospective randomised trial</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1997</YR>
<VL>46</VL>
<PG>105-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gralnek-1998" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Gralnek 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gralnek IM, Jensen DM, Gornbein J</AU>
<TI>Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and nonbleeding visible vessel: An analysis of two prospective clinical trials</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>93</VL>
<PG>2047-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-1978" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Green 1978" TYPE="JOURNAL_ARTICLE">
<AU>Green FW, Kaplan MM, Curtis LE</AU>
<TI>Effect of acid and pepsin on blood coagulation and platelet aggregation: A possible contributor to prolonged gastroduodenal mucosal hemorrhage</TI>
<SO>Gastroenterology</SO>
<YR>1978</YR>
<VL>74</VL>
<NO>Suppl 1</NO>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-10-28 08:03:58 -0400" MODIFIED_BY="Cathy Bennett" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<VL>Version 5.0.1 [updated September 2008]</VL>
<EN>The Cochrane Collaboration</EN>
<PB>Available from www.cochrane-handbook.org.</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higham-2002" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Higham 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higham J, Kang JY, Majeed A</AU>
<TI>Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects</TI>
<SO>Gut</SO>
<YR>2002</YR>
<VL>50</VL>
<PG>460-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jiranek-1996" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Jiranek 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jiranek GC, Kozarek RA</AU>
<TI>A cost effective approach to the patient with peptic ulcer bleeding</TI>
<SO>Surgery Clinics of North America</SO>
<YR>1996</YR>
<VL>76</VL>
<PG>83-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khuroo-2005" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Khuroo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE</AU>
<TI>Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>11-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kolkman-1996" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Kolkman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kolkman JJ, Meuwissen SGM</AU>
<TI>A review on treatment of bleeding peptic ulcer. A collaborative task of gastroenterologist and surgeon</TI>
<SO>Scan J Gasteroenterol</SO>
<YR>1996</YR>
<VL>31</VL>
<NO>Suppl 218</NO>
<PG>16-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laine-1994" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Laine 1994" TYPE="JOURNAL_ARTICLE">
<AU>Laine L, Peterson WL</AU>
<TI>Bleeding peptic ulcer</TI>
<SO>New Eng J Med</SO>
<YR>1994</YR>
<VL>331</VL>
<PG>717-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lau-1998" MODIFIED="2009-10-28 09:22:06 -0400" MODIFIED_BY="Cathy Bennett" NAME="Lau 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lau JY, Chung SCS, Leung JW, Lo KK, Yung Y, Li AKC</AU>
<TI>The evolution of stigmata of hemorrhage in bleeding peptic ulcers: A sequential endoscopic study</TI>
<SO>Endoscopy</SO>
<YR>1998</YR>
<VL>30</VL>
<NO>6</NO>
<PG>513-518</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1999" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Lee 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lee JG, Turnipseed S, Romano PS</AU>
<TI>Endoscopy based triage significantly reduces hospitalisation rates and costs of treating upper GI bleeding: A randomised controlled trial</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1999</YR>
<VL>50</VL>
<PG>755-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leontiadis-2005" MODIFIED="2009-11-10 09:16:30 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Leontiadis 2005" TYPE="COCHRANE_REVIEW">
<AU>Leontiadis GI, Sharma VK, Howden CW</AU>
<TI>Proton pump inhibitor treatment for acute peptic ulcer bleeding</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>Issue 4. Art. No.: CD002094</NO>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<IDENTIFIERS MODIFIED="2009-10-28 14:14:15 -0400" MODIFIED_BY="Cathy Bennett">
<IDENTIFIER MODIFIED="2009-10-28 14:14:15 -0400" MODIFIED_BY="Cathy Bennett" TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD002094.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Longstreth-1995" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Longstreth 1995" TYPE="JOURNAL_ARTICLE">
<AU>Longstreth GF, Feitelberg SP</AU>
<TI>Outpatient care of selected patients with acute non-variceal upper gastrointestinal haemorrhage</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<PG>108-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Longstreth-1997" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Longstreth 1997" TYPE="JOURNAL_ARTICLE">
<AU>Longstreth GF</AU>
<TI>Epidemiology and outcome of patients hospitalized with</TI>
<SO>American Journal Gastroenterology</SO>
<YR>1997</YR>
<VL>92</VL>
<PG>419-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Longstreth-1998" MODIFIED="2009-11-08 16:45:33 -0500" MODIFIED_BY="[Empty name]" NAME="Longstreth 1998" TYPE="JOURNAL_ARTICLE">
<AU>Longstreth GF, Feitelberg SP</AU>
<TI>Successful outpatient management of acute upper gastrointestinal hemorrhage: use of practice guidelines in a large patient series</TI>
<SO>Gastrointest Endosc</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>219-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Low-1980" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Low 1980" TYPE="JOURNAL_ARTICLE">
<AU>Low J, Dodds AJ, Biggs JC</AU>
<TI>Fibrinolytic activity of gastroduodenal secretions-a possible role in upper gastrointestinal haemorrhage</TI>
<SO>Thrombosis Research</SO>
<YR>1980</YR>
<VL>17</VL>
<PG>819-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paimela-2002" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Paimela 2002" TYPE="JOURNAL_ARTICLE">
<AU>Paimela H, Paimela R, Luosujarvi E. Kivilaakso E</AU>
<TI>Current features of peptic ulcer disease in Finland. Incidence of surgery, hospital admissions and mortality for the disease during the past twenty- five years</TI>
<SO>Scandanavian Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>37</VL>
<PG>399-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmer--2002" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Palmer  2002" TYPE="JOURNAL_ARTICLE">
<AU>Palmer</AU>
<TI>Non-variceal upper gastrointestinal haemorrhage: guidelines. British Society of Gastroenterology Endoscopy Committee</TI>
<SO>Gut</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>Suppl 4</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rockall-1995" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Rockall 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rockall TA, Logan RFA, Devlin HB, Northfield TC</AU>
<TI>Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>222-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rockall-1996" MODIFIED="2009-08-04 19:23:54 -0400" MODIFIED_BY="[Empty name]" NAME="Rockall 1996" TYPE="JOURNAL_ARTICLE">
<AU>Rockall TA, Logan RF, Devlin HB, Northfield TC.</AU>
<TI>Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage: National Audit of Acute Upper Gastrointestinal Haemorrhage.</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<PG>1138-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Selby--2000" MODIFIED="2009-10-28 14:00:43 -0400" MODIFIED_BY="Cathy Bennett" NAME="Selby  2000" TYPE="JOURNAL_ARTICLE">
<AU>Selby NM, Kubba AK, Hawkey CJ</AU>
<TI>Acid suppression in peptic ulcer haemorrhage: a 'meta-analysis'</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>9</NO>
<PG>1119-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silverstein-1981" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Silverstein 1981" TYPE="JOURNAL_ARTICLE">
<AU>Silverstein FE, Gilbert DA, Tedesco FJ, Buenger NK, Persing J</AU>
<TI>The national ASGE survey on upper gastrointestinal bleeding. I. Study design and baseline data.</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1981</YR>
<VL>27</VL>
<NO>2</NO>
<PG>73-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spiegel-2003" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Spiegel 2003" TYPE="JOURNAL_ARTICLE">
<AU>Spiegel BM, Ofman JJ, Woods K, Vakil NB</AU>
<TI>Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost-effectiveness of competing strategies</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>86-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sung-2009" MODIFIED="2009-11-08 15:17:44 -0500" MODIFIED_BY="[Empty name]" NAME="Sung 2009" TYPE="JOURNAL_ARTICLE">
<AU>Sung JJ, Barkun A, Kuipers EJ, Mssner J, Jensen DM, Stuart R et al</AU>
<TI>Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2009</YR>
<VL>150</VL>
<NO>7</NO>
<PG>455-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Leerdam-2003" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="van Leerdam 2003" TYPE="JOURNAL_ARTICLE">
<AU>van Leerdam ME, Vreeburg EM, Rauws EAJ, Geraedts AM, Tijssen JGP, Reitsma JB, Tytgat GNJ</AU>
<TI>Acute upper GI bleeding: Did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>1494-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Rensburg-2003" MODIFIED="2009-10-28 14:01:19 -0400" MODIFIED_BY="Cathy Bennett" NAME="Van Rensburg 2003" TYPE="JOURNAL_ARTICLE">
<AU>Van Rensburg CJ, Hartman M, Thorpe A</AU>
<TI>Intragastric PH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>2635-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zandieh-2002" MODIFIED="2008-10-30 12:42:31 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Zandieh 2002" TYPE="JOURNAL_ARTICLE">
<AU>Zandieh I, Andrews C, Brodie M</AU>
<TI>Prescribing practices and indications for the use of intravenous proton pump inhibitors (IV PPI) in six urban tertiary care centres</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2002</YR>
<VL>55</VL>
<NO>5</NO>
<PG>T1883</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-10-28 09:22:24 -0400" MODIFIED_BY="Cathy Bennett">
<REFERENCE ID="REF-Dorward-2006" MODIFIED="2009-10-28 09:22:24 -0400" MODIFIED_BY="Cathy Bennett" NAME="Dorward 2006" TYPE="COCHRANE_REVIEW">
<AU>Dorward S, Sreedharan A, Leontiadis G, Howden C, Moayyedi P, Forman D</AU>
<TI>Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4:CD005415</NO>
<IDENTIFIERS MODIFIED="2009-08-03 19:29:07 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-11-10 09:01:25 -0500" MODIFIED_BY="Jan Lilleyman">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-11-10 09:01:25 -0500" MODIFIED_BY="Jan Lilleyman" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-11-10 09:01:25 -0500" MODIFIED_BY="Jan Lilleyman" STUDY_ID="STD-Daneshmend-1992">
<CHAR_METHODS>
<P>Large multicentre (two centres) double blind RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-28 14:06:35 -0400" MODIFIED_BY="Cathy Bennett">
<P>Country: UK. Included 1147 participants (578 on PPI; 569 on control treatment). PU 43.9%; oesophageal varices 2.5% of total. Excluded severe bleeding (that required surgery) and bleeding that developed in patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-10 09:01:25 -0500" MODIFIED_BY="Jan Lilleyman">
<P>1. Omeprazole 80 mgs IV immediately, then 3 doses of 40 mg IV at eight-hourly intervals, then 40 mg oral every 12 hours for 101 hours or until surgery, discharge, or death. 2.Identical regimen with mannitol. Post-intervention drug treatment at discretion of physician. Initial endoscopic treatment at discretion of endoscopist (received by a minority of high risk participants).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 09:02:10 -0400" MODIFIED_BY="Cathy Bennett">
<P>40-day mortality; rebleeding; surgery; stigmata of recent haemorrhage at index endoscopy; number of participants requiring blood transfusion. First three outcomes also reported by peptic ulcer site.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-28 09:02:11 -0400" MODIFIED_BY="Cathy Bennett">
<P>Only a few of the high-risk participants with PU received initial endoscopic treatment. Timing of assessment of rebleeding and surgery not clear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 09:20:00 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Hawkey-2001">
<CHAR_METHODS>
<P>Multicentre (two centres) double blind RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-28 09:02:21 -0400" MODIFIED_BY="Cathy Bennett">
<P>Country: UK. 414 participants in total (102 on PPI; 103 on placebo; 103 on tranexamic acid; 106 on tranexamic acid plus PPI). PU 42.4%; 3.9% oesophageal varices 2.5% of total. Excluded severe bleeding (that required immediate surgery).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-28 09:19:53 -0400" MODIFIED_BY="Cathy Bennett">
<P>1. Lansoprazole 60 mg orally (start), followed by 30 mg plus dummy medication four times daily for four days. 2. Placebo - double dummy technique. 3.Tranexamic acid 2g orally (start), followed by 1g orally plus dummy medication four times daily for four days. 4.Tranexamic acid and lansoprazole - both active drugs as above for four days. Post-intervention drug treatment not mentioned. Initial endoscopic haemostatic treatment offered for participants with active bleeding.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 09:02:23 -0400" MODIFIED_BY="Cathy Bennett">
<P>30 day mortality; 30 day surgery; rebleeding (timing unclear); stigmata of recent haemorrhage at index endoscopy; number of participants requiring blood transfusion.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-28 09:20:00 -0400" MODIFIED_BY="Cathy Bennett">
<P>For the current meta-analysis we included only group 1 (lansoprazole alone) as active treatment group and group 2 (placebo) as control group. participants that received tranexamic acid or the combination of PPI and tranexamic acid were not included. Timing of assessment of rebleeding not clear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 14:02:50 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Hulagu-1995">
<CHAR_METHODS>
<P>Single centred, open RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-28 14:02:50 -0400" MODIFIED_BY="Cathy Bennett">
<P>Country: Turkey. Included 58 participants (30 omeprazole group, 28 control treatment group).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Omeprazole 80mg IV as soon as possible after admission, followed by 40 mg IV once a day and 100mg IV 3 times a day for 6 days. Omeprazole 20mg once a day at end of 4 weeks. 2. Rantidine 100 mg as soon as possible after admission, followed by 100 mg IV 3 times a day for 6 days. Famotidine 40mg once a day at end of 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 09:02:32 -0400" MODIFIED_BY="Cathy Bennett">
<P>Mortality, rebleeding, stigmata of recent haemorrhage at index endoscopy, number of participants requiring blood transfusion.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 14:03:07 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Lau-2007">
<CHAR_METHODS MODIFIED="2009-10-28 14:03:07 -0400" MODIFIED_BY="Cathy Bennett">
<P>Single centre double blind randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-28 09:20:26 -0400" MODIFIED_BY="Cathy Bennett">
<P>Setting: Hongkong, Asia, 631 participants randomised (314 in the PPI group and 317 in the placebo group) 187 participants with Peptic ulcer disease in the PPI group and 190 in the placebo group. 3.8% participants with variceal bleed. Excluded long term aspirin users and participants with continued shock requiring emergency surgery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-28 09:20:36 -0400" MODIFIED_BY="Cathy Bennett">
<P>Intravenous omeprazole 80mg at randomisation and continuous infusion at 8mg/hour until endoscopy. Intravenous placebo 80mg bolus followed by infusion 8mg/hr until endoscopy. participants with high risk stigmata requiring endoscopic treatment were treated with PPI 8mg/hour infusion for 72 hours followed by 8 weeks of oral omeprazole 40mg. Omeprazole based standard Helicobacter eradication treatment for 7 days used as appropriate.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 09:02:45 -0400" MODIFIED_BY="Cathy Bennett">
<P>30 day mortality, rebleeding, surgery, proportion of participants requiring endoscopic therapy, length of hospital stay and mean units of blood transfusion reported according to treatment group. Stigmata of haemorrhage reported only in peptic ulcer disease participants.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 14:03:28 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Naumovski-2005">
<CHAR_METHODS MODIFIED="2009-10-28 14:03:20 -0400" MODIFIED_BY="Cathy Bennett">
<P>Single centre. Open RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-28 14:03:25 -0400" MODIFIED_BY="Cathy Bennett">
<P>participants with acute UGI bleeding admitted to intensive care unit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-28 14:03:28 -0400" MODIFIED_BY="Cathy Bennett">
<P>IV Pantoprazole 80mg bolus after randomisation and 40mg tid for 5 days. control group received no treatment until endoscopy and then treated with pantoprazole 40mg iv bolus followed by 40mg tid for 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-28 07:50:25 -0400" MODIFIED_BY="[Empty name]">
<P>mortality, rebleeding, surgery, length of stay in ICU, mean number of blood units transfused and lesion stabilisation on repeat endoscopy at 5 days. No mention of follow up duration and time of outcome measurement. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 09:03:26 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Wallner-1996">
<CHAR_METHODS>
<P>Single centred, open RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-28 09:03:24 -0400" MODIFIED_BY="Cathy Bennett">
<P>Country: Poland. Included 102 participants (50 on PPI and 52 on placebo group). PU 75.5% of total; no participants with oesophageal varices (hepatic insufficiency was an exclusion criterion).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-28 09:03:25 -0400" MODIFIED_BY="Cathy Bennett">
<P>1. Omeprazole IV bolus delivery, dosing regime unclear: stated as "40 mg" or "80 mg" or "120 mg" (presumably representing total daily doses). 2. Ranitidine IV bolus delivery, dosing regime unclear: stated as "150 mg" or "200 mg" or "300-400 mg" (presumably representing total daily doses). Unclear if participants within each treatment arm were allocated to each dosing group by a random method or not. Duration of treatment depending on continuation of bleeding. Initial endoscopic haemostatic treatment not mentioned.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 09:03:26 -0400" MODIFIED_BY="Cathy Bennett">
<P>Mortality; surgery; stigmata of recent haemorrhage at index endoscopy; number of participants requiring blood transfusion. Timing of outcome assessment not clear.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Timing of assessment of rebleeding not clear. Initial endoscopic haemostatic treatment not mentioned. Dosing of pharmacological treatments not clear. Rebleeding rates could be extracted because the study was designed to assess time needed for bleeding cessation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-10-29 05:50:47 -0400" MODIFIED_BY="Cathy Bennett" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-08-03 17:10:05 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x002d_Sabah-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 17:10:05 -0400" MODIFIED_BY="[Empty name]">
<P>Cost effectiveness study. Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 14:03:50 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Andrews-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 14:03:50 -0400" MODIFIED_BY="Cathy Bennett">
<P>Not an RCT. Retrospective observation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 14:03:50 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Avgerinos-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 14:03:50 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomised controlled trial in participants with Peptic ulcer bleeding with outcome being serial gastric PH measurements over 24 hours, in response to treatment with somatostatin, PPI and placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:29 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Bai-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:29 -0400" MODIFIED_BY="Cathy Bennett">
<P>Restricted to participants with bleeding from peptic ulcer and acute gastric mucosal lesions. Randomised after endoscopy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 18:02:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bajaj-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 18:02:07 -0400" MODIFIED_BY="[Empty name]">
<P>RCT comparing oral and IV PPI in NVUGIB. Does not satisfy the inclusion criteria of this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 19:17:36 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brunner-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 19:17:36 -0400" MODIFIED_BY="[Empty name]">
<P>Limited to peptic ulcer bleeding. Randomisation after endoscopy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:30 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Cheng-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:30 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomised after endoscopy. Comparison between low and high dose IV PPI. participants with peptic ulcer bleeding and comorbid illness.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:32 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Chu-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:32 -0400" MODIFIED_BY="Cathy Bennett">
<P>Restricted to peptic ulcer bleeding participants only and randomisation after endoscopy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Colin-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Costamagna-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised after endoscopy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dovas-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to gain copy of publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 17:21:22 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elphick-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 17:21:22 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT. Letter to the editor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:33 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Fasseas-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:33 -0400" MODIFIED_BY="Cathy Bennett">
<P>Restricted to endoscopically verified participants and only gastric ulcers, duodenal ulcers and erosions were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 14:03:58 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Felder-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 14:03:58 -0400" MODIFIED_BY="Cathy Bennett">
<P>Restricted to peptic ulcer bleeding participants only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:34 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Fried-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:34 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomised after endoscopy. Restricted to peptic ulcer bleeding participants only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gao-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear when randomisation took place.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:35 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Goletti-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:35 -0400" MODIFIED_BY="Cathy Bennett">
<P>Control group not being either placebo or H2RA alone; compared omeprazole alone versus the combination of ranitidine and endoscopic haemostatic therapy. Restricted to participants with ulcers or haemorrhagic gastritis. Randomisation post endoscopic diagnosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 19:16:55 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hasselgren-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 19:16:55 -0400" MODIFIED_BY="[Empty name]">
<P>Study with main outcome of intra gastric PH studies. Limited to Peptic ulcer bleeding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 07:50:34 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Hulagu-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 07:50:34 -0400" MODIFIED_BY="Cathy Bennett">
<P>Abstract publication, the trial was subsequently published in full (<LINK REF="STD-Hulagu-1995" TYPE="STUDY">Hulagu 1995</LINK>).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 14:04:03 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Hung-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 14:04:03 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomized post endoscopy in peptic ulcer bleeding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:35 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Jensen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:35 -0400" MODIFIED_BY="Cathy Bennett">
<P>RCT on bleeding peptic ulcer participants. Randomized post endoscopic haemostasis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 17:35:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keyvani-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 17:35:51 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT. Retrospective observation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 18:28:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 18:28:38 -0400" MODIFIED_BY="[Empty name]">
<P>Randomisation post endoscopy. RCT comparing oral PPI to endoscopic haemoclipping in peptic ulcer bleeding. Does not satisfy the inclusion criteria of this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:37 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Lau-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:37 -0400" MODIFIED_BY="Cathy Bennett">
<P>Abstract publication with results for Peptic ulcer disease participants only. The trial was subsequently published in full (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 19:15:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 19:15:52 -0400" MODIFIED_BY="[Empty name]">
<P>Cost effectiveness study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 17:20:17 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 17:20:17 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT. Letter to the Editor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:37 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Liu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:37 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomised after endoscopy. Restricted to duodenal ulcer participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maculotti-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Designed to assess healing rates. Not reporting any of the outcomes pre-determined in this systematic review. Randomisation post endoscopy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:38 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Munkel-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:38 -0400" MODIFIED_BY="Cathy Bennett">
<P>Restricted to peptic ulcer bleeding participants only. Randomisation post endoscopy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 18:38:16 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murthy-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 18:38:16 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT. Retrospective review of oral PPI versus IV PPI in peptic ulcer bleeding post endoscopic haemostasis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nehme-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised after endoscopy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:39 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Orti-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:39 -0400" MODIFIED_BY="Cathy Bennett">
<P>Restricted to participants suspected to have bleeding from peptic origin. It was not clear from the paper if the authors ascertained this before randomisation. Communications to obtain further details are ongoing.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:40 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Perez-Flores-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:40 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomisation post endoscopy, restricted to participants with peptic ulcer bleeding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Savides-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised after endoscopy, restricted to peptic ulcer bleeding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 17:25:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schaffalitzky-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 17:25:47 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT. Letter to the editor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:40 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Scheurlen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:40 -0400" MODIFIED_BY="Cathy Bennett">
<P>Restricted to peptic ulcer bleeding participants only, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:41 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Schonekas-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:41 -0400" MODIFIED_BY="Cathy Bennett">
<P>Restricted to peptic ulcer bleeding participants only; control group not either placebo or H2RA alone; compared two different regimens of PPI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Srinath-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. This article was a comment on another RCT (Khuroo 1997).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-29 05:50:43 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Sung-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-29 05:50:43 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomisation post endoscopy. participants with visible vessel and adherent clot.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:42 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Sung-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:42 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomisation post endoscopy. participants with Peptic ulcer bleeding only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 17:21:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tran-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 17:21:49 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT. Letter to the editor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-29 05:50:47 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Tsoi-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-29 05:50:47 -0400" MODIFIED_BY="Cathy Bennett">
<P>Not an RCT. Cost effectiveness study based on the data from the Lau study (<LINK REF="STD-Lau-2007" TYPE="STUDY">Lau 2007</LINK>).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Udd-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Control group not being either placebo or H2RA alone; compared to intravenous regimens of omeprazole at different doses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:43 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Uribarrena-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:43 -0400" MODIFIED_BY="Cathy Bennett">
<P>Selected participants with bleeding from gastric ulcer, duodenal ulcer, erosions and peptic oesophagitis only. Participants with bleeding from non-peptic sources were excluded from the analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:43 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Wei-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:43 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomization post endoscopic haemostasis. participants with peptic ulcer bleeding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wu-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to gain copy of publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xuan-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomisation after endoscopy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:44 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Yilmaz-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:44 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomization post endoscopy. participants with peptic ulcer bleeding with low risk stigmata.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-28 09:03:44 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Zargar-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-28 09:03:44 -0400" MODIFIED_BY="Cathy Bennett">
<P>Randomization post endoscopy. participants with peptic ulcer bleeding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-10-28 14:03:45 -0400" MODIFIED_BY="Cathy Bennett">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-10-28 14:03:44 -0400" MODIFIED_BY="Cathy Bennett" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:02:27 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Daneshmend-1992">
<DESCRIPTION>
<P>The treatments were randomized in blocks of 10. No further description of sequence generation provided by authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:02:39 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Authors report no method for sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:02:57 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Hulagu-1995">
<DESCRIPTION>
<P>Authors report no details of sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:03:13 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Lau-2007">
<DESCRIPTION>
<P>Consecutive participants randomised according to computer generated random numbers in blocks of 20.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:03:30 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Naumovski-2005">
<DESCRIPTION>
<P>Authors do not provide details of sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:03:44 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Wallner-1996">
<DESCRIPTION>
<P>Series of random odd and even numbers generated by the computer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-10-28 14:03:31 -0400" MODIFIED_BY="Cathy Bennett" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:02:28 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Daneshmend-1992">
<DESCRIPTION>
<P>No report from the authors on the methods to use adequate concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:02:40 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Authors report no method for allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:02:58 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Hulagu-1995">
<DESCRIPTION>
<P>Authors report no details of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 09:02:46 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Lau-2007">
<DESCRIPTION>
<P>Sealed packs generated centrally in the pharmacy and sent to the wards with lowest numbered pack to be opened by the resident treating the participant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:03:31 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Naumovski-2005">
<DESCRIPTION>
<P>Authors do not provide details of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-13 19:43:11 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wallner-1996">
<DESCRIPTION>
<P>No details of allocation concealment reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-10-28 14:03:45 -0400" MODIFIED_BY="Cathy Bennett" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-28 07:07:23 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daneshmend-1992">
<DESCRIPTION>
<P>Authors report that this study was double blind and that mortality assessors were blinded, but does not report who else was blinded. Authors also report that the appearances of study treatment and placebo were identical.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-28 07:21:26 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Authors mention double blind, double dummy comparison.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-28 14:02:58 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Hulagu-1995">
<DESCRIPTION>
<P>Authors report no details of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-28 09:02:54 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Lau-2007">
<DESCRIPTION>
<P>Participants and all investigators were blinded to the treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-28 14:03:32 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Naumovski-2005">
<DESCRIPTION>
<P>Authors do not provide details of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-28 14:03:45 -0400" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Wallner-1996">
<DESCRIPTION>
<P>Open study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-10-28 14:02:42 -0400" MODIFIED_BY="Cathy Bennett" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-28 14:02:30 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Daneshmend-1992">
<DESCRIPTION>
<P>Initially 1154 participants randomised. Authors reported 4 participants were not given the study treatment ( one omeprazole group and three placebo group) and in 3 the treatment given could not subsequently be clearly identified. Hence 1147 were successfully randomised (578 in omeprazole group and 569 to placebo group) Authors clearly reported protocol violations in 98 participants, (62 participants were prescribed concomitant H2RA, 18 more than 12 hours after admission, 3 were under age or pregnant). Authors have also reported Intention to treat and per protocol analysis separately. The results for each of the outcomes were comparable between the two analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-28 14:02:42 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Authors provide a clear disposition of participants at each stage after randomisation. Of the 414 participants enrolled, 55 not endoscoped. Of the 298 endoscoped, 61 were not Gi bleed. 248 participants were eligible and 50 not eligible for further evaluation due to protocol violations (39 more than 72 hours after start of bleeding, 9 more than 8 hours from 1st dose to endoscopy, 2 participants with no trial data). 20 further participants were not evaluable (14 participants missed 2 or more doses, 4 endoscopy received before trial treatment, 3 prohibited drugs during trial and 1 previously in trial). The authors also report the withdrawals and dropouts within each treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-28 09:20:15 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Hulagu-1995">
<DESCRIPTION>
<P>Authors provide clear disposition for all randomised participants. Among the 6 omeprazole group participants who were not endoscoped in the 1<SUP>st</SUP> month; one participant died of massive upper gastrointestinal haemorrhage due to end stage liver disease, two participants moved to another city and could not come to control, one participant had appendicitis and operated at control date, and two participants refused control endoscopy. For the 1<SUP>st</SUP> month endoscopy of ranitidine group, 20 of 28 participants(71%) were reexamined. Among the 8 ranitidine group participants who were not endoscoped in the 1<SUP>st</SUP> month; one participant died of pancreas carcinoma with massive upper gastrointestinal bleeding, one participant had coronary by-pass surgery, one participant had unstable heart disease, 3 participants refused the endoscopy procedure and 2 participants with unknown reasons could not be reexamined. Authors report that these participants were omitted from the rest of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-28 09:02:58 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Lau-2007">
<DESCRIPTION>
<P>Clear reporting of disposition of participants at each stage of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-28 09:03:10 -0400" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Naumovski-2005">
<DESCRIPTION>
<P>Abstract publication. Authors do not provide disposition of participants at each stage of study. Hence difficult to ascertain the robustness of assessment of incomplete data. The authors do not report withdrawal or dropout data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-28 09:20:44 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Wallner-1996">
<DESCRIPTION>
<P>Reported disposition of all randomised participants and outcomes for all participants randomised. No withdrawal or dropouts were observed during the study period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-10-28 14:03:01 -0400" MODIFIED_BY="Cathy Bennett" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:02:31 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Daneshmend-1992">
<DESCRIPTION>
<P>No evidence of imputation or last observation carried forward.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:02:21 -0400" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>No evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:03:01 -0400" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Hulagu-1995">
<DESCRIPTION>
<P>No data regarding requirement for surgery. No data per treatment group for stigmata of recent haemorrhage.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 09:20:41 -0400" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Lau-2007">
<DESCRIPTION>
<P>Stigmata of the recent haemorrhage reported only for peptic ulcer patients. The absence of this data for all randomised patients precluded the inclusion of this study from the main analysis which might have influenced the overall results for this outcome. The authors report that 5 patients in the omeprazole group excluded from analyses, (3 received the wrong diagnosis, 1 had small-bowel obstruction, 1 had a history of total gastrectomy, 1 had cholangitis, 2 withdrew voluntarily). 2 of the 314 patients did not undergo endoscopy. Of the 319 patients in the placebo group, 2 were excluded from the analysis, 1 because of wrong diagnosis and the other withdrew voluntarily.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-13 19:34:28 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naumovski-2005">
<DESCRIPTION>
<P>Length of stay limited to the intensive care unit. No stigmata of recent haemorrhage per treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-13 19:54:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wallner-1996">
<DESCRIPTION>
<P>No evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-10-28 14:03:34 -0400" MODIFIED_BY="Cathy Bennett" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:02:31 -0400" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Daneshmend-1992">
<DESCRIPTION>
<P>Authors do not describe whether length of stay ended by discharge or death. Authors do not describe in detail the criteria for requirement of repeat endoscopy offered for participants with rebleeding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:02:48 -0400" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Authors report the decision to offer repeat endoscopy for rebleeding was left to the discretion of treating physician and do not describe in detail the criteria for requirement of repeat endoscopy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-13 19:18:22 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hulagu-1995">
<DESCRIPTION>
<P>No definition of rebleeding. Indications for surgery not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-28 07:54:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lau-2007">
<DESCRIPTION>
<P>In the publication the authors did not distinguish length of stay ended by mortality or discharge; however, they provided separated data when requested.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 14:03:34 -0400" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Naumovski-2005">
<DESCRIPTION>
<P>Included participants admitted to ICU only. Authors do not report indications for surgery, timing of endoscopy, time period for assessment of any of the outcomes including mortality.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-13 19:53:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wallner-1996">
<DESCRIPTION>
<P>Did not distinguish length of stay ended by mortality or discharge. Rebleeding not reported as an outcome although the study was designed to assess cessation of bleeding at day 5 depending on clinical and laboratory criteria. No data reported on the requirement for repeat endoscopy for persistence of bleeding. Authors did not report time of assessment of mortality.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-10-28 14:08:44 -0400" MODIFIED_BY="Cathy Bennett">
<COMPARISON ID="CMP-001" MODIFIED="2009-10-28 14:08:44 -0400" MODIFIED_BY="Cathy Bennett" NO="1">
<NAME>Main analysis</NAME>
<DICH_OUTCOME CHI2="2.7255153155878773" CI_END="1.6767440843290449" CI_START="0.7538316087003808" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1242698477094415" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.22446678279394178" LOG_CI_START="-0.12272565622529703" LOG_EFFECT_SIZE="0.05087056328432236" METHOD="MH" MODIFIED="2009-07-22 10:02:35 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6047574186744682" P_Q="0.0" P_Z="0.5657329973649374" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1114" TOTAL_2="1109" WEIGHT="100.0" Z="0.5743470231793416">
<NAME>Mortality - 30 days or at point closest to 30 days</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1765749708022533" CI_START="0.8198168145279421" EFFECT_SIZE="1.335811648079306" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="30" LOG_CI_END="0.3377736307605761" LOG_CI_START="-0.08628317850327714" LOG_EFFECT_SIZE="0.1257452261286495" ORDER="3389" O_E="0.0" SE="0.24909306887664734" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.06204735696238617" WEIGHT="61.96424665644995"/>
<DICH_DATA CI_END="2.0685064627039456" CI_START="0.07428741595476132" EFFECT_SIZE="0.392" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31565688211443027" LOG_CI_START="-1.1290847480735158" LOG_EFFECT_SIZE="-0.4067139329795427" ORDER="3390" O_E="0.0" SE="0.8486483851588082" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.720204081632653" WEIGHT="10.74031959907941"/>
<DICH_DATA CI_END="15.634392732993957" CI_START="0.055443484303442904" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1940810171535208" LOG_CI_START="-1.2561494846334584" LOG_EFFECT_SIZE="-0.031034233739968786" ORDER="3391" O_E="0.0" SE="1.4392775255862666" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="2.0715197956577267" WEIGHT="2.201765517811279"/>
<DICH_DATA CI_END="3.232056727275432" CI_START="0.4147491016331538" EFFECT_SIZE="1.157796451914099" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5094789746664379" LOG_CI_START="-0.38221454600567906" LOG_EFFECT_SIZE="0.06363221433037947" MODIFIED="2009-07-22 10:02:18 -0400" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.5237851879969162" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.2743509231649649" WEIGHT="14.948278095568178"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 10:02:35 -0400" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.0" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.655242328144004" CI_START="0.1355808455537983" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.42410416269553297" LOG_CI_START="-0.8678016619282457" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="3392" O_E="0.0" SE="0.7588718764209773" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.5758865248226951" WEIGHT="10.145390131091187"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6724309543439166" CI_END="1.0594002121013408" CI_START="0.620671945853987" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8108883961946094" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.025060055549203885" LOG_CI_START="-0.2071378841234713" LOG_EFFECT_SIZE="-0.09103891428713369" METHOD="MH" MODIFIED="2009-07-29 07:24:25 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4521484532964474" P_Q="0.0" P_Z="0.12431677331278083" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1064" TOTAL_2="1057" WEIGHT="100.0" Z="1.536904189985014">
<NAME>Rebleeding within 30 days</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.108663278907071" CI_START="0.5897799919764587" EFFECT_SIZE="0.8086206896551724" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="100" LOG_CI_END="0.04479966308547388" LOG_CI_START="-0.22930996478118193" LOG_EFFECT_SIZE="-0.09225515084785402" ORDER="3393" O_E="0.0" SE="0.1610133522734148" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.02592529961032277" WEIGHT="71.90498968138817"/>
<DICH_DATA CI_END="2.5433922140598235" CI_START="0.4017694448516396" EFFECT_SIZE="1.0108695652173914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.40541333747320196" LOG_CI_START="-0.39602309505644223" LOG_EFFECT_SIZE="0.004695121208379869" ORDER="3394" O_E="0.0" SE="0.4707677276422358" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.2216222533894343" WEIGHT="7.507744650609812"/>
<DICH_DATA CI_END="2.2573510693807823" CI_START="0.1409668647218337" EFFECT_SIZE="0.5641025641025641" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.35359910699009894" LOG_CI_START="-0.850882959398685" LOG_EFFECT_SIZE="-0.24864192620429296" ORDER="3395" O_E="0.0" SE="0.7075187280791587" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="0.5005827505827505" WEIGHT="4.499581595324246"/>
<DICH_DATA CI_END="3.534113457517098" CI_START="0.556360912049642" EFFECT_SIZE="1.4022277227722773" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5482804877804406" LOG_CI_START="-0.25464338960281846" LOG_EFFECT_SIZE="0.1468185490888111" MODIFIED="2009-07-29 07:24:06 -0400" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="0.47164146011221997" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.22244566689678677" WEIGHT="6.426563205024853"/>
<DICH_DATA CI_END="1.1176084054356956" CI_START="0.13885744357554058" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.04828965940946592" LOG_CI_START="-0.8574308345515673" LOG_EFFECT_SIZE="-0.40457058757105074" MODIFIED="2009-07-29 07:24:25 -0400" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.5320247015414632" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.283050283050283" WEIGHT="9.661120867652926"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.838193711307172" CI_END="1.245382730232835" CI_START="0.651896398434506" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9010330274253642" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.09530283904991806" LOG_CI_START="-0.18582141832220142" LOG_EFFECT_SIZE="-0.045259289636141696" METHOD="MH" MODIFIED="2009-07-29 07:27:58 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5852579898159942" P_Q="0.0" P_Z="0.5279852931221429" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1084" TOTAL_2="1081" WEIGHT="100.00000000000001" Z="0.6310844783151192">
<NAME>Surgery for continued or recurrent bleeding within 30 days of randomisation</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3991628762431882" CI_START="0.6656342141531407" EFFECT_SIZE="0.9650547557524302" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="63" LOG_CI_END="0.14586827355994353" LOG_CI_START="-0.17676436304542364" LOG_EFFECT_SIZE="-0.015448044742740074" ORDER="3396" O_E="0.0" SE="0.18951600779930086" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.03591631721218466" WEIGHT="73.2915913678001"/>
<DICH_DATA CI_END="2.0144607562988814" CI_START="0.11913908948268542" EFFECT_SIZE="0.4898989898989899" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3041588113179163" LOG_CI_START="-0.9239457233084888" LOG_EFFECT_SIZE="-0.3098934559952863" ORDER="3397" O_E="0.0" SE="0.7213946828550412" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.5204102884515255" WEIGHT="7.493071941394812"/>
<DICH_DATA CI_END="2.3932404567576198" CI_START="0.1869082780654368" EFFECT_SIZE="0.6688172043010753" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.37898633580383845" LOG_CI_START="-0.7283714635300713" LOG_EFFECT_SIZE="-0.1746925638631164" MODIFIED="2009-07-29 07:27:43 -0400" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.6504674528382499" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.4231079072018809" WEIGHT="7.622736427278175"/>
<DICH_DATA CI_END="2.0225742821979127" CI_START="0.06710956092779925" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30590448072003007" LOG_CI_START="-1.1732156025971743" LOG_EFFECT_SIZE="-0.43365556093857216" MODIFIED="2009-07-29 07:27:58 -0400" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.8688424587030222" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.7548872180451128" WEIGHT="6.141732999102019"/>
<DICH_DATA CI_END="5.1826348025658096" CI_START="0.4518187700262005" EFFECT_SIZE="1.5302325581395348" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7145506070995392" LOG_CI_START="-0.3450357310308014" LOG_EFFECT_SIZE="0.18475743803436895" ORDER="3398" O_E="0.0" SE="0.6224062600547267" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.38738955255531204" WEIGHT="5.450867264424908"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.196431771627155" CI_END="1.1642661790558453" CI_START="0.7753254317867274" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.950097457101721" ESTIMABLE="YES" EVENTS_1="404" EVENTS_2="410" I2="6.145345361999102" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.06605228175688797" LOG_CI_START="-0.11051597031464755" LOG_EFFECT_SIZE="-0.022231844278879788" METHOD="MH" NO="4" P_CHI2="0.36231951231296355" P_Q="0.0" P_Z="0.6216161508548012" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="760" TOTAL_2="752" WEIGHT="99.99999999999999" Z="0.49356114233779297">
<NAME>Patients requiring blood transfusion (post hoc analysis)</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1863681086590776" CI_START="0.7462865912391691" EFFECT_SIZE="0.9409413434247871" ESTIMABLE="YES" EVENTS_1="298" EVENTS_2="302" LOG_CI_END="0.07421946369502312" LOG_CI_START="-0.12709436141210192" LOG_EFFECT_SIZE="-0.02643744885853942" ORDER="3399" O_E="0.0" SE="0.1182527373874312" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.013983709899620769" WEIGHT="77.30157962184683"/>
<DICH_DATA CI_END="2.4164141357287217" CI_START="0.778890773691558" EFFECT_SIZE="1.371904761904762" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="60" LOG_CI_END="0.38317136763474424" LOG_CI_START="-0.10852344054175687" LOG_EFFECT_SIZE="0.1373239635464937" ORDER="3400" O_E="0.0" SE="0.28882396425143114" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.08341928232591196" WEIGHT="10.741186217039854"/>
<DICH_DATA CI_END="1.6854538165218313" CI_START="0.19373453549664105" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.2267168568246458" LOG_CI_START="-0.7127929541972348" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="3401" O_E="0.0" SE="0.5518727136428219" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="0.30456349206349204" WEIGHT="4.555744498951387"/>
<DICH_DATA CI_END="1.5086067640940046" CI_START="0.2946058940093352" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="36" LOG_CI_END="0.1785760506171754" LOG_CI_START="-0.5307585687285379" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="3402" O_E="0.0" SE="0.4166666666666667" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.1736111111111111" WEIGHT="7.401489662161916"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.584060791841087" CI_END="0.8415814010049829" CI_START="0.5360593662471118" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6716677694128903" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="307" I2="34.555841725756956" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.07490387101609679" LOG_CI_START="-0.27078711141575057" LOG_EFFECT_SIZE="-0.17284549121592369" METHOD="MH" MODIFIED="2009-10-28 14:08:44 -0400" MODIFIED_BY="Cathy Bennett" NO="5" P_CHI2="0.2049137583902495" P_Q="0.0" P_Z="5.423725139095299E-4" Q="0.0" RANDOM="NO" SCALE="4.38" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="672" TOTAL_2="660" WEIGHT="100.00000000000001" Z="3.4589068159395584">
<NAME>Proportion of patients with stigmata of recent haemorrhage</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7724388767225088" CI_START="0.46920954502136736" EFFECT_SIZE="0.6020263232648423" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="236" LOG_CI_END="-0.1121358763722263" LOG_CI_START="-0.3286331617143403" LOG_EFFECT_SIZE="-0.22038451904328327" ORDER="3403" O_E="0.0" SE="0.12717157708880403" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="534" TOTAL_2="525" VAR="0.016172610019253627" WEIGHT="86.51578077505285"/>
<DICH_DATA CI_END="2.6366611554089805" CI_START="0.5787438988749127" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" LOG_CI_END="0.4210543209987589" LOG_CI_START="-0.23751357428746822" LOG_EFFECT_SIZE="0.09177037335564536" ORDER="3404" O_E="0.0" SE="0.3868460416547875" STUDY_ID="STD-Hawkey-2001" TOTAL_1="58" TOTAL_2="55" VAR="0.1496498599439776" WEIGHT="6.525694391090262"/>
<DICH_DATA CI_END="4.09402810597494" CI_START="0.40377378505957784" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.6121508198184082" LOG_CI_START="-0.3938618809682721" LOG_EFFECT_SIZE="0.10914446942506809" ORDER="3405" O_E="0.0" SE="0.5909368402852788" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="0.3492063492063492" WEIGHT="2.7484358400202926"/>
<DICH_DATA CI_END="2.350615262478174" CI_START="0.2918607968642726" EFFECT_SIZE="0.8282828282828283" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="44" LOG_CI_END="0.3711815516871845" LOG_CI_START="-0.534824236114851" LOG_EFFECT_SIZE="-0.08182134221383322" ORDER="3406" O_E="0.0" SE="0.5321922845558952" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.28322862774082286" WEIGHT="4.210088993836607"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.39702348952632" CI_END="1.2965152576715822" CI_START="0.31567404887950307" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6397469975101412" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="164" I2="62.94253668005559" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.11277763200670826" LOG_CI_START="-0.5007611193801342" LOG_EFFECT_SIZE="-0.19399174368671293" METHOD="MH" NO="6" P_CHI2="0.06730578714125879" P_Q="0.0" P_Z="0.21518913991810618" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.23794439836640308" TOTALS="YES" TOTAL_1="622" TOTAL_2="608" WEIGHT="99.99999999999999" Z="1.2394223838824885">
<NAME>Proportion of patients with blood in stomach (post hoc analysis)</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0070018318040619" CI_START="0.5640679149558365" EFFECT_SIZE="0.7536693065412875" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="131" LOG_CI_END="0.0030302605652093003" LOG_CI_START="-0.24866860290521803" LOG_EFFECT_SIZE="-0.12281917117000438" ORDER="3407" O_E="0.0" SE="0.14784915833199733" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="534" TOTAL_2="525" VAR="0.021859373619480014" WEIGHT="49.99352369647886"/>
<DICH_DATA CI_END="0.6897877632205698" CI_START="0.14180149883576804" EFFECT_SIZE="0.31275060144346434" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="29" LOG_CI_END="-0.1612845142494642" LOG_CI_START="-0.8483191786546227" LOG_EFFECT_SIZE="-0.5048018464520434" ORDER="3408" O_E="0.0" SE="0.4035675627480276" STUDY_ID="STD-Hawkey-2001" TOTAL_1="58" TOTAL_2="55" VAR="0.16286677770238317" WEIGHT="32.40554856429897"/>
<DICH_DATA CI_END="5.997657236876073" CI_START="0.37514647988985955" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.77798164241936" LOG_CI_START="-0.4257991243079975" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="3409" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="0.5" WEIGHT="17.600927739222165"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.284924104866084" CI_END="1.0206216626554123" CI_START="0.5360555569323282" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7396687865470233" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="97" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.00886478197766113" LOG_CI_START="-0.2707901975856276" LOG_EFFECT_SIZE="-0.13096270780398325" METHOD="MH" NO="7" P_CHI2="0.5154153196126019" P_Q="0.0" P_Z="0.0664011197753999" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="672" TOTAL_2="660" WEIGHT="100.0" Z="1.835706204942151">
<NAME>Proportion of patients with active bleeding</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9939479543284695" CI_START="0.4683053201898073" EFFECT_SIZE="0.6822544356790932" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="73" LOG_CI_END="-0.0026363557834933296" LOG_CI_START="-0.3294709083807397" LOG_EFFECT_SIZE="-0.16605363208211654" ORDER="3410" O_E="0.0" SE="0.1919842340527504" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="534" TOTAL_2="525" VAR="0.03685794612482124" WEIGHT="76.5252129083958"/>
<DICH_DATA CI_END="1.5323518803749134" CI_START="0.21451411736492723" EFFECT_SIZE="0.5733333333333334" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.18535850560824146" LOG_CI_START="-0.6685441212324685" LOG_EFFECT_SIZE="-0.24159280781211348" ORDER="3411" O_E="0.0" SE="0.5015866298924062" STUDY_ID="STD-Hawkey-2001" TOTAL_1="58" TOTAL_2="55" VAR="0.2515891472868217" WEIGHT="12.254775991746168"/>
<DICH_DATA CI_END="5.010013597137996" CI_START="0.2874243696309746" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6998389045406964" LOG_CI_START="-0.5414764124454468" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="3412" O_E="0.0" SE="0.7291547618075785" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="0.5316666666666666" WEIGHT="3.979280709963554"/>
<DICH_DATA CI_END="3.8267333945731496" CI_START="0.4940571513764648" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5828282063324256" LOG_CI_START="-0.30622280999986284" LOG_EFFECT_SIZE="0.13830269816628143" ORDER="3413" O_E="0.0" SE="0.5222329678670935" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.2727272727272727" WEIGHT="7.240730389894467"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7691747960200184" CI_END="0.9315331708090218" CI_START="0.501997911944923" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6838330985361576" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="117" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.03080167577275548" LOG_CI_START="-0.29929808929458984" LOG_EFFECT_SIZE="-0.1650498825336727" METHOD="MH" MODIFIED="2009-07-29 08:04:12 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.41288453137884107" P_Q="0.0" P_Z="0.015967623967181946" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="985" TOTAL_2="998" WEIGHT="100.0" Z="2.409654722574224">
<NAME>Endoscopic haemostatic therapy at index endoscopy</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.806799605458931" CI_START="0.44185612683496567" EFFECT_SIZE="0.8935018050541517" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.2569099870548271" LOG_CI_START="-0.3547191186445491" LOG_EFFECT_SIZE="-0.04890456579486101" ORDER="3414" O_E="0.0" SE="0.3592739643007155" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="569" TOTAL_2="578" VAR="0.1290777814243518" WEIGHT="16.782114793138412"/>
<DICH_DATA CI_END="2.5433922140598235" CI_START="0.4017694448516396" EFFECT_SIZE="1.0108695652173914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.40541333747320196" LOG_CI_START="-0.39602309505644223" LOG_EFFECT_SIZE="0.004695121208379869" ORDER="3415" O_E="0.0" SE="0.4707677276422358" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.2216222533894343" WEIGHT="9.172450685667497"/>
<DICH_DATA CI_END="0.8647172642395144" CI_START="0.4105136790859337" EFFECT_SIZE="0.5958005249343832" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="90" LOG_CI_END="-0.06312587016846467" LOG_CI_START="-0.3866723667965285" LOG_EFFECT_SIZE="-0.22489911848249658" MODIFIED="2009-07-29 08:04:12 -0400" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.19005281370031293" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.03612007199540586" WEIGHT="74.04543452119408"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-09-28 06:15:05 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Analysis according to degree of allocation concealment</NAME>
<DICH_OUTCOME CHI2="2.7255153155878773" CI_END="1.6767440843290449" CI_START="0.7538316087003808" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1242698477094415" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.22446678279394178" LOG_CI_START="-0.12272565622529703" LOG_EFFECT_SIZE="0.05087056328432236" METHOD="MH" MODIFIED="2009-09-28 06:10:38 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6047574186744682" P_Q="0.0" P_Z="0.5657329973649374" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1114" TOTAL_2="1109" WEIGHT="100.0" Z="0.5743470231793416">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2320567272754324" CI_START="0.41474910163315376" DF="0" EFFECT_SIZE="1.157796451914099" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.509478974666438" LOG_CI_START="-0.38221454600567906" LOG_EFFECT_SIZE="0.06363221433037947" MODIFIED="2009-09-28 06:08:10 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7796844297129596" STUDIES="1" TAU2="0.0" TOTAL_1="314" TOTAL_2="317" WEIGHT="14.948278095568178" Z="0.2797303007205245">
<NAME>Degree of allocation concealment: A</NAME>
<DICH_DATA CI_END="3.232056727275432" CI_START="0.4147491016331538" EFFECT_SIZE="1.157796451914099" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5094789746664379" LOG_CI_START="-0.38221454600567906" LOG_EFFECT_SIZE="0.06363221433037947" MODIFIED="2009-09-28 06:04:41 -0400" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.5237851879969162" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.2743509231649649" WEIGHT="14.948278095568178"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7243229945087624" CI_END="1.7260794735037663" CI_START="0.724629410590298" DF="3" EFFECT_SIZE="1.118377374376398" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="41" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.23706078796641555" LOG_CI_START="-0.1398840431998177" LOG_EFFECT_SIZE="0.04858837238329892" MODIFIED="2009-09-28 06:10:38 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4361097423292337" P_Z="0.6133617510511425" STUDIES="5" TAU2="0.0" TOTAL_1="800" TOTAL_2="792" WEIGHT="85.05172190443183" Z="0.5052806249872108">
<NAME>Degree of allocation concealment: non-A</NAME>
<DICH_DATA CI_END="2.1765749708022533" CI_START="0.8198168145279421" EFFECT_SIZE="1.335811648079306" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="30" LOG_CI_END="0.3377736307605761" LOG_CI_START="-0.08628317850327714" LOG_EFFECT_SIZE="0.1257452261286495" MODIFIED="2009-09-28 06:10:38 -0400" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.24909306887664734" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.06204735696238617" WEIGHT="61.96424665644995"/>
<DICH_DATA CI_END="2.0685064627039456" CI_START="0.07428741595476132" EFFECT_SIZE="0.392" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31565688211443027" LOG_CI_START="-1.1290847480735158" LOG_EFFECT_SIZE="-0.4067139329795427" ORDER="3418" O_E="0.0" SE="0.8486483851588082" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.720204081632653" WEIGHT="10.74031959907941"/>
<DICH_DATA CI_END="15.634392732993957" CI_START="0.055443484303442904" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1940810171535208" LOG_CI_START="-1.2561494846334584" LOG_EFFECT_SIZE="-0.031034233739968786" ORDER="3419" O_E="0.0" SE="1.4392775255862666" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="2.0715197956577267" WEIGHT="2.201765517811279"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-29 08:09:37 -0400" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.0" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.655242328144004" CI_START="0.1355808455537983" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.42410416269553297" LOG_CI_START="-0.8678016619282457" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2009-09-28 06:08:00 -0400" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.7588718764209773" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.5758865248226951" WEIGHT="10.145390131091187"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6724309543439166" CI_END="1.059400212101341" CI_START="0.6206719458539871" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8108883961946095" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.02506005554920398" LOG_CI_START="-0.20713788412347123" LOG_EFFECT_SIZE="-0.09103891428713363" METHOD="MH" MODIFIED="2009-09-28 06:12:26 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4521484532964474" P_Q="0.0" P_Z="0.12431677331278106" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1064" TOTAL_2="1057" WEIGHT="99.99999999999999" Z="1.536904189985013">
<NAME>Rebleeding within 30 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.534113457517098" CI_START="0.556360912049642" DF="0" EFFECT_SIZE="1.4022277227722773" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.5482804877804406" LOG_CI_START="-0.25464338960281846" LOG_EFFECT_SIZE="0.1468185490888111" MODIFIED="2009-09-28 06:11:26 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4735111198990819" STUDIES="1" TAU2="0.0" TOTAL_1="314" TOTAL_2="317" WEIGHT="6.426563205024852" Z="0.7167779576173692">
<NAME>Degree of concealment: A</NAME>
<DICH_DATA CI_END="3.534113457517098" CI_START="0.556360912049642" EFFECT_SIZE="1.4022277227722773" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5482804877804406" LOG_CI_START="-0.25464338960281846" LOG_EFFECT_SIZE="0.1468185490888111" MODIFIED="2009-07-29 08:13:52 -0400" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.47164146011221997" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.22244566689678677" WEIGHT="6.426563205024852"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2068217188350636" CI_END="1.0192944224588303" CI_START="0.5820933347069854" DF="3" EFFECT_SIZE="0.7702755931595466" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="130" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.008299647775250744" LOG_CI_START="-0.23500737360044735" LOG_EFFECT_SIZE="-0.11335386291259826" MODIFIED="2009-09-28 06:12:26 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5306060421298016" P_Z="0.06781290389618246" STUDIES="4" TAU2="0.0" TOTAL_1="750" TOTAL_2="740" WEIGHT="93.57343679497514" Z="1.8262480676554276">
<NAME>Degree of concealment : non-A</NAME>
<DICH_DATA CI_END="1.108663278907071" CI_START="0.5897799919764587" EFFECT_SIZE="0.8086206896551724" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="100" LOG_CI_END="0.04479966308547388" LOG_CI_START="-0.22930996478118193" LOG_EFFECT_SIZE="-0.09225515084785402" MODIFIED="2009-09-28 06:12:26 -0400" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.1610133522734148" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.02592529961032277" WEIGHT="71.90498968138816"/>
<DICH_DATA CI_END="2.5433922140598235" CI_START="0.4017694448516396" EFFECT_SIZE="1.0108695652173914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.40541333747320196" LOG_CI_START="-0.39602309505644223" LOG_EFFECT_SIZE="0.004695121208379869" ORDER="3421" O_E="0.0" SE="0.4707677276422358" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.2216222533894343" WEIGHT="7.507744650609811"/>
<DICH_DATA CI_END="2.2573510693807823" CI_START="0.1409668647218337" EFFECT_SIZE="0.5641025641025641" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.35359910699009894" LOG_CI_START="-0.850882959398685" LOG_EFFECT_SIZE="-0.24864192620429296" ORDER="3422" O_E="0.0" SE="0.7075187280791587" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="0.5005827505827505" WEIGHT="4.499581595324246"/>
<DICH_DATA CI_END="1.1176084054356956" CI_START="0.13885744357554058" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.04828965940946592" LOG_CI_START="-0.8574308345515673" LOG_EFFECT_SIZE="-0.40457058757105074" MODIFIED="2009-07-29 08:11:48 -0400" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.5320247015414632" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.283050283050283" WEIGHT="9.661120867652924"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.838193711307172" CI_END="1.245382730232835" CI_START="0.651896398434506" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9010330274253642" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.09530283904991806" LOG_CI_START="-0.18582141832220142" LOG_EFFECT_SIZE="-0.045259289636141696" METHOD="MH" MODIFIED="2009-09-28 06:15:05 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5852579898159942" P_Q="0.0" P_Z="0.5279852931221429" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1084" TOTAL_2="1081" WEIGHT="100.0" Z="0.6310844783151192">
<NAME>Surgery for continued or recurrent bleeding within 30 days of randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3932404567576198" CI_START="0.1869082780654368" DF="0" EFFECT_SIZE="0.6688172043010753" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.37898633580383845" LOG_CI_START="-0.7283714635300713" LOG_EFFECT_SIZE="-0.1746925638631164" MODIFIED="2009-09-28 06:14:13 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5363163409211088" STUDIES="1" TAU2="0.0" TOTAL_1="314" TOTAL_2="317" WEIGHT="7.622736427278175" Z="0.6183929597906374">
<NAME>Degree of concealment: A</NAME>
<DICH_DATA CI_END="2.3932404567576198" CI_START="0.1869082780654368" EFFECT_SIZE="0.6688172043010753" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.37898633580383845" LOG_CI_START="-0.7283714635300713" LOG_EFFECT_SIZE="-0.1746925638631164" MODIFIED="2009-07-29 08:18:44 -0400" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.6504674528382499" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.4231079072018809" WEIGHT="7.622736427278175"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.604337675071595" CI_END="1.2862568655833708" CI_START="0.6583122313727283" DF="3" EFFECT_SIZE="0.9201948855001751" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="79" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.10932770588673066" LOG_CI_START="-0.18156807568669478" LOG_EFFECT_SIZE="-0.03612018489998204" MODIFIED="2009-09-28 06:15:05 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.456729649999847" P_Z="0.6264476880085592" STUDIES="4" TAU2="0.0" TOTAL_1="770" TOTAL_2="764" WEIGHT="92.37726357272183" Z="0.4867328163782466">
<NAME>Degree of concealment: non-A</NAME>
<DICH_DATA CI_END="1.3991628762431882" CI_START="0.6656342141531407" EFFECT_SIZE="0.9650547557524302" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="63" LOG_CI_END="0.14586827355994353" LOG_CI_START="-0.17676436304542364" LOG_EFFECT_SIZE="-0.015448044742740074" MODIFIED="2009-09-28 06:13:26 -0400" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.18951600779930086" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.03591631721218466" WEIGHT="73.2915913678001"/>
<DICH_DATA CI_END="2.0144607562988814" CI_START="0.11913908948268542" EFFECT_SIZE="0.4898989898989899" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3041588113179163" LOG_CI_START="-0.9239457233084888" LOG_EFFECT_SIZE="-0.3098934559952863" ORDER="3425" O_E="0.0" SE="0.7213946828550412" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.5204102884515255" WEIGHT="7.493071941394812"/>
<DICH_DATA CI_END="2.0225742821979127" CI_START="0.06710956092779925" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30590448072003007" LOG_CI_START="-1.1732156025971743" LOG_EFFECT_SIZE="-0.43365556093857216" MODIFIED="2009-07-29 08:30:23 -0400" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.8688424587030222" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.7548872180451128" WEIGHT="6.141732999102019"/>
<DICH_DATA CI_END="5.1826348025658096" CI_START="0.4518187700262005" EFFECT_SIZE="1.5302325581395348" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7145506070995392" LOG_CI_START="-0.3450357310308014" LOG_EFFECT_SIZE="0.18475743803436895" MODIFIED="2009-09-28 06:15:05 -0400" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.6224062600547267" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.38738955255531204" WEIGHT="5.450867264424908"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-07-29 08:28:33 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Analysis according to control treatment</NAME>
<DICH_OUTCOME CHI2="2.7255153155878773" CI_END="1.6767440843290444" CI_START="0.7538316087003807" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1242698477094413" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.2244667827939417" LOG_CI_START="-0.12272565622529709" LOG_EFFECT_SIZE="0.050870563284322275" METHOD="MH" MODIFIED="2009-07-29 08:24:11 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6047574186744682" P_Q="0.0" P_Z="0.5657329973649381" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1114" TOTAL_2="1109" WEIGHT="99.99999999999997" Z="0.5743470231793407">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9302792794451291" CI_END="1.8131951303779241" CI_START="0.7807416654726931" DF="2" EFFECT_SIZE="1.1898054403633551" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="42" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.2584445440217504" LOG_CI_START="-0.10749264322781654" LOG_EFFECT_SIZE="0.07547595039696692" MODIFIED="2009-07-29 08:24:11 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.38093008370338866" P_Z="0.4188026985942863" STUDIES="3" TAU2="0.0" TOTAL_1="994" TOTAL_2="989" WEIGHT="87.65284435109751" Z="0.8085001996591252">
<NAME>PPI versus placebo</NAME>
<DICH_DATA CI_END="2.1765749708022533" CI_START="0.8198168145279421" EFFECT_SIZE="1.335811648079306" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="30" LOG_CI_END="0.3377736307605761" LOG_CI_START="-0.08628317850327714" LOG_EFFECT_SIZE="0.1257452261286495" ORDER="3426" O_E="0.0" SE="0.24909306887664734" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.06204735696238617" WEIGHT="61.96424665644994"/>
<DICH_DATA CI_END="2.0685064627039456" CI_START="0.07428741595476132" EFFECT_SIZE="0.392" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31565688211443027" LOG_CI_START="-1.1290847480735158" LOG_EFFECT_SIZE="-0.4067139329795427" ORDER="3427" O_E="0.0" SE="0.8486483851588082" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.720204081632653" WEIGHT="10.740319599079408"/>
<DICH_DATA CI_END="3.232056727275432" CI_START="0.4147491016331538" EFFECT_SIZE="1.157796451914099" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5094789746664379" LOG_CI_START="-0.38221454600567906" LOG_EFFECT_SIZE="0.06363221433037947" MODIFIED="2009-07-29 08:24:11 -0400" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.5237851879969162" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.2743509231649649" WEIGHT="14.948278095568174"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07292448253136971" CI_END="2.4427250803245912" CI_START="0.1778019833628749" DF="1" EFFECT_SIZE="0.6590306245478659" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.38787459148570064" LOG_CI_START="-0.7500633988284151" LOG_EFFECT_SIZE="-0.18109440367135726" NO="2" P_CHI2="0.7871253833164573" P_Z="0.5327408773043953" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="80" WEIGHT="12.347155648902463" Z="0.6238275055737288">
<NAME>PPI versus H2RA</NAME>
<DICH_DATA CI_END="15.634392732993957" CI_START="0.055443484303442904" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1940810171535208" LOG_CI_START="-1.2561494846334584" LOG_EFFECT_SIZE="-0.031034233739968786" ORDER="3428" O_E="0.0" SE="1.4392775255862666" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="2.0715197956577267" WEIGHT="2.2017655178112787"/>
<DICH_DATA CI_END="2.655242328144004" CI_START="0.1355808455537983" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.42410416269553297" LOG_CI_START="-0.8678016619282457" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="3429" O_E="0.0" SE="0.7588718764209773" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.5758865248226951" WEIGHT="10.145390131091185"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-29 08:23:20 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>PPI versus No Treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-29 08:23:20 -0400" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.0" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6724309543439158" CI_END="1.0594002121013406" CI_START="0.6206719458539869" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8108883961946092" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.025060055549203795" LOG_CI_START="-0.2071378841234714" LOG_EFFECT_SIZE="-0.09103891428713382" METHOD="MH" MODIFIED="2009-07-29 08:26:37 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4521484532964475" P_Q="0.0" P_Z="0.12431677331278036" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1064" TOTAL_2="1057" WEIGHT="99.99999999999999" Z="1.536904189985016">
<NAME>Rebleeding within 30 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3323726713784232" CI_END="1.1559692451992196" CI_START="0.6559072416787392" DF="2" EFFECT_SIZE="0.87075174365836" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="118" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.06294627974372524" LOG_CI_START="-0.183157574153988" LOG_EFFECT_SIZE="-0.060105647205131396" MODIFIED="2009-07-29 08:26:02 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5136638275921181" P_Z="0.3383859574452074" STUDIES="3" TAU2="0.0" TOTAL_1="994" TOTAL_2="989" WEIGHT="85.83929753702282" Z="0.9573592767750049">
<NAME>PPI versus placebo</NAME>
<DICH_DATA CI_END="1.108663278907071" CI_START="0.5897799919764587" EFFECT_SIZE="0.8086206896551724" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="100" LOG_CI_END="0.04479966308547388" LOG_CI_START="-0.22930996478118193" LOG_EFFECT_SIZE="-0.09225515084785402" ORDER="3430" O_E="0.0" SE="0.1610133522734148" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.02592529961032277" WEIGHT="71.90498968138816"/>
<DICH_DATA CI_END="2.5433922140598235" CI_START="0.4017694448516396" EFFECT_SIZE="1.0108695652173914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.40541333747320196" LOG_CI_START="-0.39602309505644223" LOG_EFFECT_SIZE="0.004695121208379869" ORDER="3431" O_E="0.0" SE="0.4707677276422358" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.2216222533894343" WEIGHT="7.507744650609811"/>
<DICH_DATA CI_END="3.534113457517098" CI_START="0.556360912049642" EFFECT_SIZE="1.4022277227722773" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5482804877804406" LOG_CI_START="-0.25464338960281846" LOG_EFFECT_SIZE="0.1468185490888111" MODIFIED="2009-07-29 08:26:02 -0400" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.47164146011221997" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.22244566689678677" WEIGHT="6.426563205024852"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2573510693807823" CI_START="0.1409668647218337" DF="0" EFFECT_SIZE="0.5641025641025641" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.35359910699009894" LOG_CI_START="-0.850882959398685" LOG_EFFECT_SIZE="-0.24864192620429296" NO="2" P_CHI2="1.0" P_Z="0.4184041557744943" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="28" WEIGHT="4.499581595324246" Z="0.8091929867717592">
<NAME>PPI versus H2RA</NAME>
<DICH_DATA CI_END="2.2573510693807823" CI_START="0.1409668647218337" EFFECT_SIZE="0.5641025641025641" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.35359910699009894" LOG_CI_START="-0.850882959398685" LOG_EFFECT_SIZE="-0.24864192620429296" ORDER="3432" O_E="0.0" SE="0.7075187280791587" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="0.5005827505827505" WEIGHT="4.499581595324246"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1176084054356956" CI_START="0.13885744357554058" DF="0" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.04828965940946592" LOG_CI_START="-0.8574308345515673" LOG_EFFECT_SIZE="-0.40457058757105074" MODIFIED="2009-07-29 08:26:37 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.07995142990415065" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="9.661120867652924" Z="1.7509679556341855">
<NAME>PPI versus No Treatment</NAME>
<DICH_DATA CI_END="1.1176084054356956" CI_START="0.13885744357554058" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.04828965940946592" LOG_CI_START="-0.8574308345515673" LOG_EFFECT_SIZE="-0.40457058757105074" MODIFIED="2009-07-29 08:26:37 -0400" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.5320247015414632" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.283050283050283" WEIGHT="9.661120867652924"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.838193711307172" CI_END="1.245382730232835" CI_START="0.651896398434506" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9010330274253642" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.09530283904991806" LOG_CI_START="-0.18582141832220142" LOG_EFFECT_SIZE="-0.045259289636141696" METHOD="MH" MODIFIED="2009-07-29 08:28:33 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5852579898159942" P_Q="0.0" P_Z="0.5279852931221429" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1084" TOTAL_2="1081" WEIGHT="100.00000000000001" Z="0.6310844783151192">
<NAME>Surgery for continued or recurrent bleeding within 30 days of randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0548617935375448" CI_END="1.2689326600956186" CI_START="0.6372540381804552" DF="2" EFFECT_SIZE="0.8992399356261931" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="75" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.10343857550300323" LOG_CI_START="-0.1956874037928934" LOG_EFFECT_SIZE="-0.04612441414494511" MODIFIED="2009-07-29 08:28:21 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5901191938239148" P_Z="0.5455496539364588" STUDIES="3" TAU2="0.0" TOTAL_1="994" TOTAL_2="989" WEIGHT="88.40739973647308" Z="0.6044422536945615">
<NAME>PPI versus placebo</NAME>
<DICH_DATA CI_END="1.3991628762431882" CI_START="0.6656342141531407" EFFECT_SIZE="0.9650547557524302" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="63" LOG_CI_END="0.14586827355994353" LOG_CI_START="-0.17676436304542364" LOG_EFFECT_SIZE="-0.015448044742740074" ORDER="3433" O_E="0.0" SE="0.18951600779930086" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.03591631721218466" WEIGHT="73.2915913678001"/>
<DICH_DATA CI_END="2.0144607562988814" CI_START="0.11913908948268542" EFFECT_SIZE="0.4898989898989899" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3041588113179163" LOG_CI_START="-0.9239457233084888" LOG_EFFECT_SIZE="-0.3098934559952863" ORDER="3434" O_E="0.0" SE="0.7213946828550412" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.5204102884515255" WEIGHT="7.493071941394812"/>
<DICH_DATA CI_END="2.3932404567576198" CI_START="0.1869082780654368" EFFECT_SIZE="0.6688172043010753" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.37898633580383845" LOG_CI_START="-0.7283714635300713" LOG_EFFECT_SIZE="-0.1746925638631164" MODIFIED="2009-07-29 08:28:21 -0400" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.6504674528382499" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.4231079072018809" WEIGHT="7.622736427278175"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.1826348025658096" CI_START="0.4518187700262005" DF="0" EFFECT_SIZE="1.5302325581395348" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.7145506070995392" LOG_CI_START="-0.3450357310308014" LOG_EFFECT_SIZE="0.18475743803436895" NO="2" P_CHI2="1.0" P_Z="0.4942858358012432" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="52" WEIGHT="5.450867264424908" Z="0.6835081038553547">
<NAME>PPI versus H2RA</NAME>
<DICH_DATA CI_END="5.1826348025658096" CI_START="0.4518187700262005" EFFECT_SIZE="1.5302325581395348" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7145506070995392" LOG_CI_START="-0.3450357310308014" LOG_EFFECT_SIZE="0.18475743803436895" ORDER="3435" O_E="0.0" SE="0.6224062600547267" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.38738955255531204" WEIGHT="5.450867264424908"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0225742821979127" CI_START="0.06710956092779925" DF="0" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.30590448072003007" LOG_CI_START="-1.1732156025971743" LOG_EFFECT_SIZE="-0.43365556093857216" MODIFIED="2009-07-29 08:28:33 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2504474083854512" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="6.141732999102019" Z="1.1492633907436987">
<NAME>PPI versus No Treatment</NAME>
<DICH_DATA CI_END="2.0225742821979127" CI_START="0.06710956092779925" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30590448072003007" LOG_CI_START="-1.1732156025971743" LOG_EFFECT_SIZE="-0.43365556093857216" MODIFIED="2009-07-29 08:28:33 -0400" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.8688424587030222" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.7548872180451128" WEIGHT="6.141732999102019"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-07-29 08:48:44 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Analysis according to route of PPI administration</NAME>
<DICH_OUTCOME CHI2="2.7255153155878773" CI_END="1.6767440843290449" CI_START="0.7538316087003808" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1242698477094415" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.22446678279394178" LOG_CI_START="-0.12272565622529703" LOG_EFFECT_SIZE="0.05087056328432236" METHOD="MH" MODIFIED="2009-07-29 08:42:20 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6047574186744682" P_Q="0.0" P_Z="0.5657329973649374" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1114" TOTAL_2="1109" WEIGHT="200.0" Z="0.5743470231793416">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.068506462703946" CI_START="0.07428741595476132" DF="0" EFFECT_SIZE="0.392" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.3156568821144304" LOG_CI_START="-1.1290847480735158" LOG_EFFECT_SIZE="-0.4067139329795427" NO="1" P_CHI2="1.0" P_Z="0.2698050222594257" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="103" WEIGHT="100.0" Z="1.1035117200116131">
<NAME>Oral PPI</NAME>
<DICH_DATA CI_END="2.0685064627039456" CI_START="0.07428741595476132" EFFECT_SIZE="0.392" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31565688211443027" LOG_CI_START="-1.1290847480735158" LOG_EFFECT_SIZE="-0.4067139329795427" ORDER="3436" O_E="0.0" SE="0.8486483851588082" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.720204081632653" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0520632810674901" CI_END="1.8373048524234359" CI_START="0.8000135328975571" DF="3" EFFECT_SIZE="1.212381435851398" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="43" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.26418122203302175" LOG_CI_START="-0.09690266649177703" LOG_EFFECT_SIZE="0.08363927777062233" MODIFIED="2009-07-29 08:42:20 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7886569625810207" P_Z="0.3638844162057837" STUDIES="5" TAU2="0.0" TOTAL_1="1012" TOTAL_2="1006" WEIGHT="99.99999999999999" Z="0.9079882948701702">
<NAME>Intravenous PPI</NAME>
<DICH_DATA CI_END="2.1765749708022533" CI_START="0.8198168145279421" EFFECT_SIZE="1.335811648079306" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="30" LOG_CI_END="0.3377736307605761" LOG_CI_START="-0.08628317850327714" LOG_EFFECT_SIZE="0.1257452261286495" ORDER="3437" O_E="0.0" SE="0.24909306887664734" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.06204735696238617" WEIGHT="69.42019776245006"/>
<DICH_DATA CI_END="15.634392732993957" CI_START="0.055443484303442904" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1940810171535208" LOG_CI_START="-1.2561494846334584" LOG_EFFECT_SIZE="-0.031034233739968786" ORDER="3438" O_E="0.0" SE="1.4392775255862666" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="2.0715197956577267" WEIGHT="2.466696618139102"/>
<DICH_DATA CI_END="3.232056727275432" CI_START="0.4147491016331538" EFFECT_SIZE="1.157796451914099" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5094789746664379" LOG_CI_START="-0.38221454600567906" LOG_EFFECT_SIZE="0.06363221433037947" MODIFIED="2009-07-29 08:42:12 -0400" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.5237851879969162" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.2743509231649649" WEIGHT="16.746954535828703"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-29 08:42:20 -0400" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.0" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.655242328144004" CI_START="0.1355808455537983" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.42410416269553297" LOG_CI_START="-0.8678016619282457" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="3439" O_E="0.0" SE="0.7588718764209773" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.5758865248226951" WEIGHT="11.366151083582135"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.672430954343917" CI_END="1.059400212101341" CI_START="0.6206719458539871" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8108883961946095" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.02506005554920398" LOG_CI_START="-0.20713788412347123" LOG_EFFECT_SIZE="-0.09103891428713363" METHOD="MH" MODIFIED="2009-07-29 08:44:55 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.45214845329644726" P_Q="0.0" P_Z="0.12431677331278106" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1064" TOTAL_2="1057" WEIGHT="99.99999999999999" Z="1.536904189985013">
<NAME>Rebleeding within 30 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.543392214059824" CI_START="0.40176944485163957" DF="0" EFFECT_SIZE="1.0108695652173914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.4054133374732021" LOG_CI_START="-0.3960230950564423" LOG_EFFECT_SIZE="0.004695121208379869" NO="1" P_CHI2="1.0" P_Z="0.9816786401479377" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="103" WEIGHT="7.507744650609811" Z="0.0229644375971998">
<NAME>Oral PPI</NAME>
<DICH_DATA CI_END="2.5433922140598235" CI_START="0.4017694448516396" EFFECT_SIZE="1.0108695652173914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.40541333747320196" LOG_CI_START="-0.39602309505644223" LOG_EFFECT_SIZE="0.004695121208379869" ORDER="3440" O_E="0.0" SE="0.4707677276422358" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.2216222533894343" WEIGHT="7.507744650609811"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4357836232722443" CI_END="1.0508120755181316" CI_START="0.6009423985801513" DF="3" EFFECT_SIZE="0.7946556040945367" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="128" I2="12.683674848452867" ID="CMP-004.02.02" LOG_CI_END="0.021525054883691667" LOG_CI_START="-0.2211671539168366" LOG_EFFECT_SIZE="-0.09982104951657247" MODIFIED="2009-07-29 08:44:55 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.32918687420448045" P_Z="0.10689786021577699" STUDIES="4" TAU2="0.0" TOTAL_1="962" TOTAL_2="954" WEIGHT="92.49225534939018" Z="1.612294543103977">
<NAME>Intravenous PPI</NAME>
<DICH_DATA CI_END="1.108663278907071" CI_START="0.5897799919764587" EFFECT_SIZE="0.8086206896551724" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="100" LOG_CI_END="0.04479966308547388" LOG_CI_START="-0.22930996478118193" LOG_EFFECT_SIZE="-0.09225515084785402" ORDER="3441" O_E="0.0" SE="0.1610133522734148" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.02592529961032277" WEIGHT="71.90498968138816"/>
<DICH_DATA CI_END="2.2573510693807823" CI_START="0.1409668647218337" EFFECT_SIZE="0.5641025641025641" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.35359910699009894" LOG_CI_START="-0.850882959398685" LOG_EFFECT_SIZE="-0.24864192620429296" ORDER="3442" O_E="0.0" SE="0.7075187280791587" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="0.5005827505827505" WEIGHT="4.499581595324246"/>
<DICH_DATA CI_END="3.534113457517098" CI_START="0.556360912049642" EFFECT_SIZE="1.4022277227722773" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5482804877804406" LOG_CI_START="-0.25464338960281846" LOG_EFFECT_SIZE="0.1468185490888111" MODIFIED="2009-07-29 08:44:55 -0400" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.47164146011221997" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.22244566689678677" WEIGHT="6.426563205024852"/>
<DICH_DATA CI_END="1.1176084054356956" CI_START="0.13885744357554058" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.04828965940946592" LOG_CI_START="-0.8574308345515673" LOG_EFFECT_SIZE="-0.40457058757105074" MODIFIED="2009-07-29 08:43:53 -0400" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="0.5320247015414632" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.283050283050283" WEIGHT="9.661120867652924"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.838193711307172" CI_END="1.245382730232835" CI_START="0.651896398434506" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9010330274253642" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.09530283904991806" LOG_CI_START="-0.18582141832220142" LOG_EFFECT_SIZE="-0.045259289636141696" METHOD="MH" MODIFIED="2009-07-29 08:48:44 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5852579898159942" P_Q="0.0" P_Z="0.5279852931221429" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1084" TOTAL_2="1081" WEIGHT="100.00000000000001" Z="0.6310844783151192">
<NAME>Surgery for continued or recurrent bleeding within 30 days of randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.014460756298882" CI_START="0.11913908948268537" DF="0" EFFECT_SIZE="0.4898989898989899" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.3041588113179164" LOG_CI_START="-0.923945723308489" LOG_EFFECT_SIZE="-0.3098934559952863" NO="1" P_CHI2="1.0" P_Z="0.32259756775220183" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="103" WEIGHT="7.493071941394812" Z="0.9891340609375355">
<NAME>Oral PPI</NAME>
<DICH_DATA CI_END="2.0144607562988814" CI_START="0.11913908948268542" EFFECT_SIZE="0.4898989898989899" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3041588113179163" LOG_CI_START="-0.9239457233084888" LOG_EFFECT_SIZE="-0.3098934559952863" ORDER="3443" O_E="0.0" SE="0.7213946828550412" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.5204102884515255" WEIGHT="7.493071941394812"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0688098748606336" CI_END="1.3040152500171598" CI_START="0.669456715134882" DF="3" EFFECT_SIZE="0.9343349323247417" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="79" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.11528267035263023" LOG_CI_START="-0.1742774977942846" LOG_EFFECT_SIZE="-0.02949741372082719" MODIFIED="2009-07-29 08:48:44 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5582485102511416" P_Z="0.68965598112379" STUDIES="4" TAU2="0.0" TOTAL_1="982" TOTAL_2="978" WEIGHT="92.5069280586052" Z="0.3993219709733403">
<NAME>Intravenous PPI</NAME>
<DICH_DATA CI_END="1.3991628762431882" CI_START="0.6656342141531407" EFFECT_SIZE="0.9650547557524302" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="63" LOG_CI_END="0.14586827355994353" LOG_CI_START="-0.17676436304542364" LOG_EFFECT_SIZE="-0.015448044742740074" ORDER="3444" O_E="0.0" SE="0.18951600779930086" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.03591631721218466" WEIGHT="73.2915913678001"/>
<DICH_DATA CI_END="2.3932404567576198" CI_START="0.1869082780654368" EFFECT_SIZE="0.6688172043010753" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.37898633580383845" LOG_CI_START="-0.7283714635300713" LOG_EFFECT_SIZE="-0.1746925638631164" MODIFIED="2009-07-29 08:48:34 -0400" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="0.6504674528382499" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.4231079072018809" WEIGHT="7.622736427278175"/>
<DICH_DATA CI_END="2.0225742821979127" CI_START="0.06710956092779925" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30590448072003007" LOG_CI_START="-1.1732156025971743" LOG_EFFECT_SIZE="-0.43365556093857216" MODIFIED="2009-07-29 08:48:44 -0400" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.8688424587030222" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.7548872180451128" WEIGHT="6.141732999102019"/>
<DICH_DATA CI_END="5.1826348025658096" CI_START="0.4518187700262005" EFFECT_SIZE="1.5302325581395348" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7145506070995392" LOG_CI_START="-0.3450357310308014" LOG_EFFECT_SIZE="0.18475743803436895" ORDER="3445" O_E="0.0" SE="0.6224062600547267" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.38738955255531204" WEIGHT="5.450867264424908"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-08-03 04:53:01 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Analysis according to the PPI used</NAME>
<DICH_OUTCOME CHI2="2.7255153155878773" CI_END="1.6767440843290449" CI_START="0.7538316087003808" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1242698477094415" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.22446678279394178" LOG_CI_START="-0.12272565622529703" LOG_EFFECT_SIZE="0.05087056328432236" METHOD="MH" MODIFIED="2009-08-02 17:44:10 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6047574186744682" P_Q="0.0" P_Z="0.5657329973649374" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1114" TOTAL_2="1109" WEIGHT="100.0" Z="0.5743470231793416">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.05206328106749" CI_END="1.8373048524234363" CI_START="0.8000135328975572" DF="3" EFFECT_SIZE="1.2123814358513982" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="43" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.2641812220330218" LOG_CI_START="-0.09690266649177696" LOG_EFFECT_SIZE="0.08363927777062241" MODIFIED="2009-08-02 17:44:10 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7886569625810207" P_Z="0.36388441620578327" STUDIES="4" TAU2="0.0" TOTAL_1="972" TOTAL_2="966" WEIGHT="89.25968040092059" Z="0.9079882948701711">
<NAME>IV Omeprazole</NAME>
<DICH_DATA CI_END="2.1765749708022533" CI_START="0.8198168145279421" EFFECT_SIZE="1.335811648079306" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="30" LOG_CI_END="0.3377736307605761" LOG_CI_START="-0.08628317850327714" LOG_EFFECT_SIZE="0.1257452261286495" MODIFIED="2009-08-02 17:42:32 -0400" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.24909306887664734" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.06204735696238617" WEIGHT="61.96424665644995"/>
<DICH_DATA CI_END="15.634392732993957" CI_START="0.055443484303442904" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1940810171535208" LOG_CI_START="-1.2561494846334584" LOG_EFFECT_SIZE="-0.031034233739968786" MODIFIED="2009-08-02 17:42:49 -0400" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="1.4392775255862666" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="2.0715197956577267" WEIGHT="2.201765517811279"/>
<DICH_DATA CI_END="3.232056727275432" CI_START="0.4147491016331538" EFFECT_SIZE="1.157796451914099" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5094789746664379" LOG_CI_START="-0.38221454600567906" LOG_EFFECT_SIZE="0.06363221433037947" MODIFIED="2009-08-02 17:43:04 -0400" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.5237851879969162" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.2743509231649649" WEIGHT="14.948278095568178"/>
<DICH_DATA CI_END="2.655242328144004" CI_START="0.1355808455537983" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.42410416269553297" LOG_CI_START="-0.8678016619282457" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2009-08-02 17:44:10 -0400" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.7588718764209773" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.5758865248226951" WEIGHT="10.145390131091187"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-08-02 17:42:18 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>IV Pantoprazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-02 17:42:18 -0400" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.0" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.068506462703946" CI_START="0.07428741595476132" DF="0" EFFECT_SIZE="0.392" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="0.3156568821144304" LOG_CI_START="-1.1290847480735158" LOG_EFFECT_SIZE="-0.4067139329795427" MODIFIED="2009-08-02 17:41:59 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2698050222594257" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="103" WEIGHT="10.74031959907941" Z="1.1035117200116131">
<NAME>Oral Lansoprazole</NAME>
<DICH_DATA CI_END="2.0685064627039456" CI_START="0.07428741595476132" EFFECT_SIZE="0.392" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31565688211443027" LOG_CI_START="-1.1290847480735158" LOG_EFFECT_SIZE="-0.4067139329795427" MODIFIED="2009-08-02 17:41:59 -0400" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.8486483851588082" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.720204081632653" WEIGHT="10.74031959907941"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.672430954343916" CI_END="1.0594002121013408" CI_START="0.620671945853987" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8108883961946094" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.025060055549203885" LOG_CI_START="-0.2071378841234713" LOG_EFFECT_SIZE="-0.09103891428713369" METHOD="MH" MODIFIED="2009-08-02 17:50:10 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4521484532964476" P_Q="0.0" P_Z="0.12431677331278083" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1064" TOTAL_2="1057" WEIGHT="100.0" Z="1.536904189985014">
<NAME>Rebleeding within 30 days</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.552981919842897" CI_END="1.1255507818984758" CI_START="0.6289750172788457" DF="2" EFFECT_SIZE="0.841393678662261" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="114" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.051365094006254546" LOG_CI_START="-0.2013666042739904" LOG_EFFECT_SIZE="-0.07500075513386792" MODIFIED="2009-08-02 17:49:20 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.46001754288666963" P_Z="0.24471621398850907" STUDIES="3" TAU2="0.0" TOTAL_1="922" TOTAL_2="914" WEIGHT="82.83113448173727" Z="1.1632793185498018">
<NAME>IV Omeprazole</NAME>
<DICH_DATA CI_END="1.108663278907071" CI_START="0.5897799919764587" EFFECT_SIZE="0.8086206896551724" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="100" LOG_CI_END="0.04479966308547388" LOG_CI_START="-0.22930996478118193" LOG_EFFECT_SIZE="-0.09225515084785402" MODIFIED="2009-08-02 17:48:44 -0400" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="0.1610133522734148" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.02592529961032277" WEIGHT="71.90498968138817"/>
<DICH_DATA CI_END="2.2573510693807823" CI_START="0.1409668647218337" EFFECT_SIZE="0.5641025641025641" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.35359910699009894" LOG_CI_START="-0.850882959398685" LOG_EFFECT_SIZE="-0.24864192620429296" MODIFIED="2009-08-02 17:48:59 -0400" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.7075187280791587" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="0.5005827505827505" WEIGHT="4.499581595324246"/>
<DICH_DATA CI_END="3.534113457517098" CI_START="0.556360912049642" EFFECT_SIZE="1.4022277227722773" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5482804877804406" LOG_CI_START="-0.25464338960281846" LOG_EFFECT_SIZE="0.1468185490888111" MODIFIED="2009-08-02 17:49:20 -0400" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.47164146011221997" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.22244566689678677" WEIGHT="6.426563205024853"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1176084054356956" CI_START="0.13885744357554058" DF="0" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.04828965940946592" LOG_CI_START="-0.8574308345515673" LOG_EFFECT_SIZE="-0.40457058757105074" MODIFIED="2009-08-02 17:49:38 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07995142990415065" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="9.661120867652926" Z="1.7509679556341855">
<NAME>IV Pantoprazole</NAME>
<DICH_DATA CI_END="1.1176084054356956" CI_START="0.13885744357554058" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.04828965940946592" LOG_CI_START="-0.8574308345515673" LOG_EFFECT_SIZE="-0.40457058757105074" MODIFIED="2009-08-02 17:49:38 -0400" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.5320247015414632" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.283050283050283" WEIGHT="9.661120867652926"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.543392214059824" CI_START="0.40176944485163957" DF="0" EFFECT_SIZE="1.0108695652173914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="0.4054133374732021" LOG_CI_START="-0.3960230950564423" LOG_EFFECT_SIZE="0.004695121208379869" MODIFIED="2009-08-02 17:50:10 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9816786401479377" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="103" WEIGHT="7.507744650609812" Z="0.0229644375971998">
<NAME>Oral Lansoprazole</NAME>
<DICH_DATA CI_END="2.5433922140598235" CI_START="0.4017694448516396" EFFECT_SIZE="1.0108695652173914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.40541333747320196" LOG_CI_START="-0.39602309505644223" LOG_EFFECT_SIZE="0.004695121208379869" MODIFIED="2009-08-02 17:50:10 -0400" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.4707677276422358" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.2216222533894343" WEIGHT="7.507744650609812"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.838193711307172" CI_END="1.245382730232835" CI_START="0.651896398434506" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9010330274253642" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.09530283904991806" LOG_CI_START="-0.18582141832220142" LOG_EFFECT_SIZE="-0.045259289636141696" METHOD="MH" MODIFIED="2009-08-02 17:57:23 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5852579898159942" P_Q="0.0" P_Z="0.5279852931221429" Q="0.0" RANDOM="NO" SCALE="144.16731028426037" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1084" TOTAL_2="1081" WEIGHT="100.00000000000001" Z="0.6310844783151192">
<NAME>Surgery for continued or recurrent bleeding within 30 days of randomisation</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.863152312486102" CI_END="1.3710785060613302" CI_START="0.6927424945270544" DF="2" EFFECT_SIZE="0.9745790601492281" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="74" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.13706232260359283" LOG_CI_START="-0.15942817085521052" LOG_EFFECT_SIZE="-0.011182924125808872" MODIFIED="2009-08-02 17:56:25 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6494846187060692" P_Z="0.8824607824017917" STUDIES="3" TAU2="0.0" TOTAL_1="942" TOTAL_2="938" WEIGHT="86.36519505950318" Z="0.1478504640923668">
<NAME>IV Omeprazole</NAME>
<DICH_DATA CI_END="1.3991628762431882" CI_START="0.6656342141531407" EFFECT_SIZE="0.9650547557524302" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="63" LOG_CI_END="0.14586827355994353" LOG_CI_START="-0.17676436304542364" LOG_EFFECT_SIZE="-0.015448044742740074" MODIFIED="2009-08-02 17:55:11 -0400" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.18951600779930086" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.03591631721218466" WEIGHT="73.2915913678001"/>
<DICH_DATA CI_END="2.3932404567576198" CI_START="0.1869082780654368" EFFECT_SIZE="0.6688172043010753" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.37898633580383845" LOG_CI_START="-0.7283714635300713" LOG_EFFECT_SIZE="-0.1746925638631164" MODIFIED="2009-08-02 17:55:21 -0400" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.6504674528382499" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.4231079072018809" WEIGHT="7.622736427278175"/>
<DICH_DATA CI_END="5.1826348025658096" CI_START="0.4518187700262005" EFFECT_SIZE="1.5302325581395348" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7145506070995392" LOG_CI_START="-0.3450357310308014" LOG_EFFECT_SIZE="0.18475743803436895" MODIFIED="2009-08-02 17:56:25 -0400" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.6224062600547267" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.38738955255531204" WEIGHT="5.450867264424908"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0225742821979127" CI_START="0.06710956092779925" DF="0" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.30590448072003007" LOG_CI_START="-1.1732156025971743" LOG_EFFECT_SIZE="-0.43365556093857216" MODIFIED="2009-08-02 17:56:37 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2504474083854512" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="6.141732999102019" Z="1.1492633907436987">
<NAME>IV Pantoprazole</NAME>
<DICH_DATA CI_END="2.0225742821979127" CI_START="0.06710956092779925" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30590448072003007" LOG_CI_START="-1.1732156025971743" LOG_EFFECT_SIZE="-0.43365556093857216" MODIFIED="2009-08-02 17:56:37 -0400" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.8688424587030222" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.7548872180451128" WEIGHT="6.141732999102019"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.014460756298882" CI_START="0.11913908948268537" DF="0" EFFECT_SIZE="0.4898989898989899" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-005.03.03" LOG_CI_END="0.3041588113179164" LOG_CI_START="-0.923945723308489" LOG_EFFECT_SIZE="-0.3098934559952863" MODIFIED="2009-08-02 17:57:13 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.32259756775220183" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="103" WEIGHT="7.493071941394812" Z="0.9891340609375355">
<NAME>Oral Lansoprazole</NAME>
<DICH_DATA CI_END="2.0144607562988814" CI_START="0.11913908948268542" EFFECT_SIZE="0.4898989898989899" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3041588113179163" LOG_CI_START="-0.9239457233084888" LOG_EFFECT_SIZE="-0.3098934559952863" MODIFIED="2009-08-02 17:57:13 -0400" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.7213946828550412" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.5204102884515255" WEIGHT="7.493071941394812"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2009-08-03 05:24:21 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Analysis according to report of endoscopic haemostatic treatment</NAME>
<DICH_OUTCOME CHI2="2.7255153155878773" CI_END="1.6767440843290449" CI_START="0.7538316087003808" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1242698477094415" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.22446678279394178" LOG_CI_START="-0.12272565622529703" LOG_EFFECT_SIZE="0.05087056328432236" METHOD="MH" MODIFIED="2009-08-03 05:20:04 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6047574186744682" P_Q="0.0" P_Z="0.5657329973649374" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1114" TOTAL_2="1109" WEIGHT="100.0" Z="0.5743470231793416">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.930279279445129" CI_END="1.8131951303779248" CI_START="0.7807416654726932" DF="2" EFFECT_SIZE="1.1898054403633553" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="42" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.2584445440217505" LOG_CI_START="-0.10749264322781647" LOG_EFFECT_SIZE="0.075475950396967" MODIFIED="2009-08-03 05:19:17 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.38093008370338866" P_Z="0.418802698594286" STUDIES="3" TAU2="0.0" TOTAL_1="994" TOTAL_2="989" WEIGHT="87.65284435109754" Z="0.8085001996591259">
<NAME>Report of using Endoscopic Haemostatic treatment</NAME>
<DICH_DATA CI_END="2.1765749708022533" CI_START="0.8198168145279421" EFFECT_SIZE="1.335811648079306" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="30" LOG_CI_END="0.3377736307605761" LOG_CI_START="-0.08628317850327714" LOG_EFFECT_SIZE="0.1257452261286495" MODIFIED="2009-08-03 05:17:48 -0400" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.24909306887664734" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.06204735696238617" WEIGHT="61.96424665644995"/>
<DICH_DATA CI_END="2.0685064627039456" CI_START="0.07428741595476132" EFFECT_SIZE="0.392" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31565688211443027" LOG_CI_START="-1.1290847480735158" LOG_EFFECT_SIZE="-0.4067139329795427" MODIFIED="2009-08-03 05:18:07 -0400" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.8486483851588082" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.720204081632653" WEIGHT="10.74031959907941"/>
<DICH_DATA CI_END="3.232056727275432" CI_START="0.4147491016331538" EFFECT_SIZE="1.157796451914099" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5094789746664379" LOG_CI_START="-0.38221454600567906" LOG_EFFECT_SIZE="0.06363221433037947" MODIFIED="2009-08-03 05:19:17 -0400" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5237851879969162" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.2743509231649649" WEIGHT="14.948278095568178"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07292448253136971" CI_END="2.4427250803245912" CI_START="0.1778019833628749" DF="1" EFFECT_SIZE="0.6590306245478659" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.38787459148570064" LOG_CI_START="-0.7500633988284151" LOG_EFFECT_SIZE="-0.18109440367135726" MODIFIED="2009-08-03 05:20:04 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7871253833164573" P_Z="0.5327408773043953" STUDIES="3" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="12.347155648902465" Z="0.6238275055737288">
<NAME>No report of using endoscopic haemostatic treatment</NAME>
<DICH_DATA CI_END="15.634392732993957" CI_START="0.055443484303442904" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1940810171535208" LOG_CI_START="-1.2561494846334584" LOG_EFFECT_SIZE="-0.031034233739968786" MODIFIED="2009-08-03 05:19:30 -0400" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="1.4392775255862666" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="2.0715197956577267" WEIGHT="2.201765517811279"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-03 05:19:44 -0400" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.0" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.655242328144004" CI_START="0.1355808455537983" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.42410416269553297" LOG_CI_START="-0.8678016619282457" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2009-08-03 05:20:04 -0400" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.7588718764209773" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.5758865248226951" WEIGHT="10.145390131091187"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6724309543439166" CI_END="1.059400212101341" CI_START="0.6206719458539871" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8108883961946095" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.02506005554920398" LOG_CI_START="-0.20713788412347123" LOG_EFFECT_SIZE="-0.09103891428713363" METHOD="MH" MODIFIED="2009-08-03 05:22:03 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4521484532964474" P_Q="0.0" P_Z="0.12431677331278106" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1064" TOTAL_2="1057" WEIGHT="99.99999999999999" Z="1.536904189985013">
<NAME>Rebleeding</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3323726713784234" CI_END="1.1559692451992196" CI_START="0.6559072416787393" DF="2" EFFECT_SIZE="0.8707517436583601" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="118" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.06294627974372524" LOG_CI_START="-0.18315757415398792" LOG_EFFECT_SIZE="-0.06010564720513135" MODIFIED="2009-08-03 05:21:06 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5136638275921181" P_Z="0.33838595744520783" STUDIES="3" TAU2="0.0" TOTAL_1="994" TOTAL_2="989" WEIGHT="85.83929753702282" Z="0.9573592767750041">
<NAME>Report of using Endoscopic haemostatic treatment</NAME>
<DICH_DATA CI_END="1.108663278907071" CI_START="0.5897799919764587" EFFECT_SIZE="0.8086206896551724" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="100" LOG_CI_END="0.04479966308547388" LOG_CI_START="-0.22930996478118193" LOG_EFFECT_SIZE="-0.09225515084785402" MODIFIED="2009-08-03 05:20:41 -0400" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.1610133522734148" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.02592529961032277" WEIGHT="71.90498968138816"/>
<DICH_DATA CI_END="2.5433922140598235" CI_START="0.4017694448516396" EFFECT_SIZE="1.0108695652173914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.40541333747320196" LOG_CI_START="-0.39602309505644223" LOG_EFFECT_SIZE="0.004695121208379869" MODIFIED="2009-08-03 05:20:52 -0400" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.4707677276422358" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.2216222533894343" WEIGHT="7.507744650609811"/>
<DICH_DATA CI_END="3.534113457517098" CI_START="0.556360912049642" EFFECT_SIZE="1.4022277227722773" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5482804877804406" LOG_CI_START="-0.25464338960281846" LOG_EFFECT_SIZE="0.1468185490888111" MODIFIED="2009-08-03 05:21:06 -0400" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.47164146011221997" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.22244566689678677" WEIGHT="6.426563205024852"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1645080858759367" CI_END="1.029132110679977" CI_START="0.19503038350765398" DF="1" EFFECT_SIZE="0.4480089622161116" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="20" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.012471129141945815" LOG_CI_START="-0.7098977252435535" LOG_EFFECT_SIZE="-0.34871329805080387" MODIFIED="2009-08-03 05:22:03 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6850397294761312" P_Z="0.05845241696335137" STUDIES="2" TAU2="0.0" TOTAL_1="70" TOTAL_2="68" WEIGHT="14.16070246297717" Z="1.8922895165272973">
<NAME>No report of using endoscopic haemostatic treatment</NAME>
<DICH_DATA CI_END="2.2573510693807823" CI_START="0.1409668647218337" EFFECT_SIZE="0.5641025641025641" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.35359910699009894" LOG_CI_START="-0.850882959398685" LOG_EFFECT_SIZE="-0.24864192620429296" MODIFIED="2009-08-03 05:21:18 -0400" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.7075187280791587" STUDY_ID="STD-Hulagu-1995" TOTAL_1="30" TOTAL_2="28" VAR="0.5005827505827505" WEIGHT="4.499581595324246"/>
<DICH_DATA CI_END="1.1176084054356956" CI_START="0.13885744357554058" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.04828965940946592" LOG_CI_START="-0.8574308345515673" LOG_EFFECT_SIZE="-0.40457058757105074" MODIFIED="2009-08-03 05:21:32 -0400" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.5320247015414632" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.283050283050283" WEIGHT="9.661120867652924"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.838193711307172" CI_END="1.245382730232835" CI_START="0.651896398434506" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9010330274253642" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.09530283904991806" LOG_CI_START="-0.18582141832220142" LOG_EFFECT_SIZE="-0.045259289636141696" METHOD="MH" MODIFIED="2009-08-03 05:24:21 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5852579898159942" P_Q="0.0" P_Z="0.5279852931221429" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1084" TOTAL_2="1081" WEIGHT="100.00000000000001" Z="0.6310844783151192">
<NAME>Surgery</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0548617935375448" CI_END="1.2689326600956186" CI_START="0.6372540381804552" DF="2" EFFECT_SIZE="0.8992399356261931" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="75" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.10343857550300323" LOG_CI_START="-0.1956874037928934" LOG_EFFECT_SIZE="-0.04612441414494511" MODIFIED="2009-08-03 05:23:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5901191938239148" P_Z="0.5455496539364588" STUDIES="3" TAU2="0.0" TOTAL_1="994" TOTAL_2="989" WEIGHT="88.40739973647308" Z="0.6044422536945615">
<NAME>Report of using endoscopic haemostatic treatment</NAME>
<DICH_DATA CI_END="1.3991628762431882" CI_START="0.6656342141531407" EFFECT_SIZE="0.9650547557524302" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="63" LOG_CI_END="0.14586827355994353" LOG_CI_START="-0.17676436304542364" LOG_EFFECT_SIZE="-0.015448044742740074" MODIFIED="2009-08-03 05:23:17 -0400" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.18951600779930086" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="578" TOTAL_2="569" VAR="0.03591631721218466" WEIGHT="73.2915913678001"/>
<DICH_DATA CI_END="2.0144607562988814" CI_START="0.11913908948268542" EFFECT_SIZE="0.4898989898989899" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3041588113179163" LOG_CI_START="-0.9239457233084888" LOG_EFFECT_SIZE="-0.3098934559952863" MODIFIED="2009-08-03 05:23:29 -0400" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.7213946828550412" STUDY_ID="STD-Hawkey-2001" TOTAL_1="102" TOTAL_2="103" VAR="0.5204102884515255" WEIGHT="7.493071941394812"/>
<DICH_DATA CI_END="2.3932404567576198" CI_START="0.1869082780654368" EFFECT_SIZE="0.6688172043010753" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.37898633580383845" LOG_CI_START="-0.7283714635300713" LOG_EFFECT_SIZE="-0.1746925638631164" MODIFIED="2009-08-03 05:23:43 -0400" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.6504674528382499" STUDY_ID="STD-Lau-2007" TOTAL_1="314" TOTAL_2="317" VAR="0.4231079072018809" WEIGHT="7.622736427278175"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7789913934528023" CI_END="2.3586201021315216" CI_START="0.35473698892676686" DF="1" EFFECT_SIZE="0.9147074904319301" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="43.78837336255328" ID="CMP-006.03.02" LOG_CI_END="0.3726579956400048" LOG_CI_START="-0.4500935246680495" LOG_EFFECT_SIZE="-0.038717764514022306" MODIFIED="2009-08-03 05:24:21 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.18227335641991171" P_Z="0.8536467858360429" STUDIES="2" TAU2="0.0" TOTAL_1="90" TOTAL_2="92" WEIGHT="11.592600263526927" Z="0.18446741728529095">
<NAME>No report of using endoscopic haemostatic treatment</NAME>
<DICH_DATA CI_END="2.0225742821979127" CI_START="0.06710956092779925" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30590448072003007" LOG_CI_START="-1.1732156025971743" LOG_EFFECT_SIZE="-0.43365556093857216" MODIFIED="2009-08-03 05:24:02 -0400" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.8688424587030222" STUDY_ID="STD-Naumovski-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.7548872180451128" WEIGHT="6.141732999102019"/>
<DICH_DATA CI_END="5.1826348025658096" CI_START="0.4518187700262005" EFFECT_SIZE="1.5302325581395348" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7145506070995392" LOG_CI_START="-0.3450357310308014" LOG_EFFECT_SIZE="0.18475743803436895" MODIFIED="2009-08-03 05:24:21 -0400" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.6224062600547267" STUDY_ID="STD-Wallner-1996" TOTAL_1="50" TOTAL_2="52" VAR="0.38738955255531204" WEIGHT="5.450867264424908"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2009-08-03 05:07:55 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Analysis restricted to peptic ulcer patients</NAME>
<DICH_OUTCOME CHI2="1.6323101217592293" CI_END="2.9690964470877192" CI_START="0.849937728152416" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5885676217596612" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" I2="38.73713170863355" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.47262430529482286" LOG_CI_START="-0.07061289229803547" LOG_EFFECT_SIZE="0.2010057064983937" METHOD="MH" MODIFIED="2009-07-22 08:54:50 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.20138388515644934" P_Q="0.0" P_Z="0.1469384604229125" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="282" TOTAL_2="298" WEIGHT="100.0" Z="1.4504306670072535">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.913568041916718" CI_START="0.9575600198536512" EFFECT_SIZE="1.9358399448085546" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="13" LOG_CI_END="0.5925728889345105" LOG_CI_START="-0.01883399493186095" LOG_EFFECT_SIZE="0.28686944700132483" ORDER="3446" O_E="0.0" SE="0.3591434300959928" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="246" TOTAL_2="257" VAR="0.12898400338111526" WEIGHT="72.89675982470006"/>
<DICH_DATA CI_END="2.954902859486624" CI_START="0.14498945394792087" EFFECT_SIZE="0.6545454545454545" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.47054320830276797" LOG_CI_START="-0.8386635857566813" LOG_EFFECT_SIZE="-0.1840601887269566" ORDER="3448" O_E="0.0" SE="0.7690345515086702" STUDY_ID="STD-Wallner-1996" TOTAL_1="36" TOTAL_2="41" VAR="0.5914141414141415" WEIGHT="27.10324017529995"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.37935996703135605" CI_END="1.2552427663308632" CI_START="0.5932778056381208" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8629644685338435" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="77" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.09872772731653628" LOG_CI_START="-0.22674189819749538" LOG_EFFECT_SIZE="-0.06400708544047956" METHOD="MH" MODIFIED="2009-07-29 08:53:19 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5379462867870818" P_Q="0.0" P_Z="0.44076870859025696" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="433" TOTAL_2="447" WEIGHT="100.0" Z="0.7708957910931663">
<NAME>Rebleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2327079496108189" CI_START="0.5510198255438741" EFFECT_SIZE="0.8241641337386019" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="70" LOG_CI_END="0.09086019671243303" LOG_CI_START="-0.2588327750694338" LOG_EFFECT_SIZE="-0.0839862891785004" ORDER="3449" O_E="0.0" SE="0.20541138263279624" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="246" TOTAL_2="257" VAR="0.042193836115117025" WEIGHT="88.72842536964961"/>
<DICH_DATA CI_END="3.289459435005804" CI_START="0.4150070518202228" EFFECT_SIZE="1.1683958499600957" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.517124535128473" LOG_CI_START="-0.3819445236720269" LOG_EFFECT_SIZE="0.06759000572822303" MODIFIED="2009-07-29 08:53:19 -0400" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.5281176156030309" STUDY_ID="STD-Lau-2007" TOTAL_1="187" TOTAL_2="190" VAR="0.27890821591023074" WEIGHT="11.27157463035039"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.062477102210728844" CI_END="1.3996792552182864" CI_START="0.5940410241407131" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9118480675191353" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.14602852592965002" LOG_CI_START="-0.22618356184924143" LOG_EFFECT_SIZE="-0.0400775179597957" METHOD="MH" MODIFIED="2009-07-29 08:54:13 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8026227705958859" P_Q="0.0" P_Z="0.6729711259743263" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="433" TOTAL_2="447" WEIGHT="100.0" Z="0.42207383569777474">
<NAME>Surgery</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4493502805413114" CI_START="0.5927345409883484" EFFECT_SIZE="0.926865671641791" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="50" LOG_CI_END="0.1611733589162213" LOG_CI_START="-0.22713976396471386" LOG_EFFECT_SIZE="-0.03298320252424626" ORDER="3451" O_E="0.0" SE="0.22809705056122012" STUDY_ID="STD-Daneshmend-1992" TOTAL_1="246" TOTAL_2="257" VAR="0.05202826447472781" WEIGHT="91.09875361199579"/>
<DICH_DATA CI_END="3.4345438106642963" CI_START="0.16735693311709401" EFFECT_SIZE="0.7581521739130435" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5358690605605819" LOG_CI_START="-0.7763562913604221" LOG_EFFECT_SIZE="-0.12024361539992011" MODIFIED="2009-07-29 08:54:13 -0400" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.7708076673386498" STUDY_ID="STD-Lau-2007" TOTAL_1="187" TOTAL_2="190" VAR="0.5941444600280505" WEIGHT="8.901246388004205"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-10-28 14:08:45 -0400" MODIFIED_BY="Cathy Bennett">
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-07-29 09:33:36 -0400" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Main analysis, outcome: 1.1 Mortality - 30 days or at point closest to 30 days.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-07-29 09:33:57 -0400" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Main analysis, outcome: 1.2 Rebleeding within 30 days.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-07-29 09:34:27 -0400" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Main analysis, outcome: 1.3 Surgery for continued or recurrent bleeding within 30 days of randomisation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-10-28 14:08:45 -0400" MODIFIED_BY="Cathy Bennett" NO="4" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Main analysis, outcome: 1.5 Proportion of patients with stigmata of recent haemorrhage.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-07-29 09:35:14 -0400" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.08" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Main analysis, outcome: 1.8 Endoscopic haemostatic therapy at index endoscopy.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-11-06 15:37:41 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-11-06 15:37:41 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-10-28 07:58:51 -0400" MODIFIED_BY="Cathy Bennett">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-06 15:37:41 -0500" MODIFIED_BY="[Empty name]">
<P>1 randomized controlled trial.pt. (267272)</P>
<P>2 controlled clinical trial.pt. (80460)</P>
<P>3 randomized.ab. (175319)</P>
<P>4 placebo.ab. (110572)</P>
<P>5 drug therapy.fs. (1309262)</P>
<P>6 randomly.ab. (127249)</P>
<P>7 trial.ab. (182795)</P>
<P>8 groups.ab. (882077)</P>
<P>9 or/1-8 (2367276)</P>
<P>10 (animals not (humans and animals)).sh. (3277268)</P>
<P>11 9 not 10 (2008270)</P>
<P>12 exp stomach/ (96737)</P>
<P>13 stomach.tw. (73048)</P>
<P>14 gastr$.tw. (329679)</P>
<P>15 exp duodenum/ (35151)</P>
<P>16 duoden$.tw. (63673)</P>
<P>17 peptic$.tw. (22791)</P>
<P>18 exp esophagus/ (35405)</P>
<P>19 esophag$.tw. (77638)</P>
<P>20 oesophag$.tw. (22091)</P>
<P>21 or/12-20 (509656)</P>
<P>22 exp peptic ulcer/ (70077)</P>
<P>23 exp peptic ulcer hemorrhage/ (6406)</P>
<P>24 exp gastrointestinal hemorrhage/ (37564)</P>
<P>25 (peptic adj5 ulcer$).tw. (19919)</P>
<P>26 (stomach adj5 ulcer$).tw. (3840)</P>
<P>27 (duoden$ adj5 ulcer$).tw. (19848)</P>
<P>28 (gastroduoden$ adj5 ulcer$).tw. (3900)</P>
<P>29 (bleed$ adj5 ulcer$).tw. (4193)</P>
<P>30 (rebleed$ adj5 ulcer$).tw. (154)</P>
<P>31 (recurrent adj5 bleed$ adj5 ulcer$).tw. (136)</P>
<P>32 (acute adj5 bleed$ adj5 ulcer$).tw. (269)</P>
<P>33 (gastrointestinal adj5 bleed$).tw. (9453)</P>
<P>34 (gastrointestinal adj5 rebleed$).tw. (43)</P>
<P>35 (gastrointestinal adj5 hemorrhag$).tw. (4059)</P>
<P>36 (gastrointestinal adj5 haemorrhag$).tw. (1077)</P>
<P>37 (ulcer adj5 hemorrhag$).tw. (1229)</P>
<P>38 (ulcer adj5 haemorrhag$).tw. (272)</P>
<P>39 (haemorrhagic adj3 gastritis).tw. (69)</P>
<P>40 (hemorrhagic adj3 gastritis).tw. (279)</P>
<P>41 (haemorrhagic adj3 duodenitis).tw. (2)</P>
<P>42 (hemorrhagic adj3 duodenitis).tw. (14)</P>
<P>43 exp melena/ (1659)</P>
<P>44 melena.tw. (1167)</P>
<P>45 melaena.tw. (434)</P>
<P>46 exp hematemesis/ (1708)</P>
<P>47 haematemesis.tw. (630)</P>
<P>48 hematemesis.tw. (1379)</P>
<P>49 (coffee adj1 ground).tw. (87)</P>
<P>50 or/22-49 (113582)</P>
<P>51 exp omeprazole/ (7383)</P>
<P>52 omeprazole.tw. (5588)</P>
<P>53 lansoprazole.tw. (1395)</P>
<P>54 pantoprazole.tw. (713)</P>
<P>55 rabeprazole.tw. (509)</P>
<P>56 esomeprazole.tw. (440)</P>
<P>57 (proton adj5 pump adj5 inhibitor$).tw. (4880)</P>
<P>58 ppi$.tw. (6568)</P>
<P>59 or/51-58 (16898)</P>
<P>60 21 and 50 and 59 (4178)</P>
<P>61 60 and 11 (3255)</P>
<P>62 limit 61 to ed=20050301-20081010 (573)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>